{"PMC7362853": [["Dear Editor, Brain, Behavior and Immunity,", [["Brain", "ANATOMY", 13, 18]]]], "PMC7481799": [], "PMC7362315": [], "f0cd69cc5ce78e991615973043a3db23a29bab4a": [["C owpox virus (family Poxviridae, genus Orthopoxvirus[OPV]) was originally considered to infect milking cows and to have zoonotic potential.", [["C owpox virus", "ORGANISM", 0, 13], ["Orthopoxvirus[OPV]", "ORGANISM", 40, 58], ["cows", "ORGANISM", 104, 108], ["C owpox virus", "SPECIES", 0, 13], ["cows", "SPECIES", 104, 108], ["C owpox virus", "SPECIES", 0, 13], ["OPV", "SPECIES", 54, 57], ["C owpox virus (family Poxviridae", "TREATMENT", 0, 32]]], ["Because of its relationship to variola virus and immunologic crossreaction, cowpox virus was used to protect humans against smallpox (1) .", [["smallpox", "DISEASE", 124, 132], ["variola virus", "ORGANISM", 31, 44], ["cowpox virus", "ORGANISM", 76, 88], ["humans", "ORGANISM", 109, 115], ["humans", "SPECIES", 109, 115], ["variola virus", "SPECIES", 31, 44], ["cowpox virus", "SPECIES", 76, 88], ["humans", "SPECIES", 109, 115], ["variola virus", "PROBLEM", 31, 44], ["immunologic crossreaction", "TREATMENT", 49, 74], ["cowpox virus", "TREATMENT", 76, 88], ["variola virus", "OBSERVATION", 31, 44]]], ["Later, vaccinia virus, another OPV with unknown origin, was used as a vaccine virus through the global smallpox eradication campaign, and cowpox virus infections became less common in cattle, other animals, and humans.", [["vaccinia virus", "DISEASE", 7, 21], ["cowpox virus infections", "DISEASE", 138, 161], ["vaccinia virus", "ORGANISM", 7, 21], ["cowpox virus", "ORGANISM", 138, 150], ["humans", "ORGANISM", 211, 217], ["vaccinia virus", "SPECIES", 7, 21], ["cattle", "SPECIES", 184, 190], ["humans", "SPECIES", 211, 217], ["vaccinia virus", "SPECIES", 7, 21], ["OPV", "SPECIES", 31, 34], ["cowpox virus", "SPECIES", 138, 150], ["cattle", "SPECIES", 184, 190], ["humans", "SPECIES", 211, 217], ["vaccinia virus", "PROBLEM", 7, 21], ["a vaccine virus", "TREATMENT", 68, 83], ["the global smallpox eradication campaign", "TREATMENT", 92, 132], ["cowpox virus infections", "PROBLEM", 138, 161], ["vaccinia virus", "OBSERVATION", 7, 21], ["cowpox virus", "OBSERVATION", 138, 150]]], ["However, during recent decades, cowpox virus infections have reemerged in domestic cats and other animals, including wild animals in captivity (2) (3) (4) , and have increased in humans subsequent to transmission from cats, rodents, zoo animals, and circus animals (5) (6) (7) (8) (9) .", [["cowpox virus infections", "DISEASE", 32, 55], ["cowpox virus", "ORGANISM", 32, 44], ["cats", "ORGANISM", 83, 87], ["humans", "ORGANISM", 179, 185], ["cats", "ORGANISM", 218, 222], ["cats", "SPECIES", 83, 87], ["humans", "SPECIES", 179, 185], ["cats", "SPECIES", 218, 222], ["cowpox virus", "SPECIES", 32, 44], ["humans", "SPECIES", 179, 185], ["cowpox virus infections", "PROBLEM", 32, 55], ["cowpox virus infections", "OBSERVATION", 32, 55], ["increased", "OBSERVATION_MODIFIER", 166, 175]]], ["Cowpox virus seems to be restricted to Eurasia, but spread of poxviruses to new regions through relocation of their natural host species is possible (10) .C owpox virus (family Poxviridae, genus OrthopoxvirusCowpox virus was fi rst isolated from felid specieslions (Panthera leo), cheetahs (Acinonyx jubatus), black panthers (Panthera pardus), ocelots (Leopardus pardalis), jaguars (Panthera onca), pumas (Felis concolor), leopard cat (Prionailurus bengalensis), Pallas cat (Otocolobus manul), and domestic cat (Felis catus)-during an outbreak in the Moscow Zoo in 1973-1974 (11) and subsequently from 3 cheetahs in Whipsnade Park, England, in 1977 (12) .", [["Cowpox virus", "ORGANISM", 0, 12], ["C owpox virus", "ORGANISM", 155, 168], ["family Poxviridae", "ORGANISM", 170, 187], ["genus", "ORGANISM", 189, 194], ["OrthopoxvirusCowpox virus", "ORGANISM", 195, 220], ["felid specieslions", "ORGANISM", 246, 264], ["Panthera leo", "ORGANISM", 266, 278], ["Acinonyx jubatus", "ORGANISM", 291, 307], ["black panthers", "ORGANISM", 310, 324], ["Panthera pardus", "ORGANISM", 326, 341], ["ocelots", "ORGANISM_SUBDIVISION", 344, 351], ["Leopardus pardalis", "ORGANISM", 353, 371], ["jaguars", "ORGANISM", 374, 381], ["Panthera onca", "ORGANISM", 383, 396], ["pumas", "ORGANISM", 399, 404], ["Felis concolor", "ORGANISM", 406, 420], ["leopard cat", "ORGANISM", 423, 434], ["Prionailurus bengalensis", "ORGANISM", 436, 460], ["Pallas cat", "ORGANISM", 463, 473], ["Otocolobus manul", "ORGANISM", 475, 491], ["cat", "ORGANISM", 507, 510], ["Felis catus", "ORGANISM", 512, 523], ["C owpox virus", "SPECIES", 155, 168], ["OrthopoxvirusCowpox virus", "SPECIES", 195, 220], ["Panthera leo", "SPECIES", 266, 278], ["cheetahs", "SPECIES", 281, 289], ["Acinonyx jubatus", "SPECIES", 291, 307], ["black panthers", "SPECIES", 310, 324], ["Panthera pardus", "SPECIES", 326, 341], ["ocelots", "SPECIES", 344, 351], ["Leopardus pardalis", "SPECIES", 353, 371], ["jaguars", "SPECIES", 374, 381], ["Panthera onca", "SPECIES", 383, 396], ["pumas", "SPECIES", 399, 404], ["Felis concolor", "SPECIES", 406, 420], ["leopard cat", "SPECIES", 423, 434], ["Prionailurus bengalensis", "SPECIES", 436, 460], ["Pallas cat", "SPECIES", 463, 473], ["Otocolobus manul", "SPECIES", 475, 491], ["cat", "SPECIES", 507, 510], ["Felis catus", "SPECIES", 512, 523], ["Cowpox virus", "SPECIES", 0, 12], ["C owpox virus", "SPECIES", 155, 168], ["Panthera leo", "SPECIES", 266, 278], ["Acinonyx jubatus", "SPECIES", 291, 307], ["black panthers", "SPECIES", 310, 324], ["Panthera pardus", "SPECIES", 326, 341], ["Leopardus pardalis", "SPECIES", 353, 371], ["Panthera onca", "SPECIES", 383, 396], ["Felis concolor", "SPECIES", 406, 420], ["leopard cat", "SPECIES", 423, 434], ["Prionailurus bengalensis", "SPECIES", 436, 460], ["Pallas cat", "SPECIES", 463, 473], ["Otocolobus manul", "SPECIES", 475, 491], ["domestic cat", "SPECIES", 498, 510], ["Felis catus", "SPECIES", 512, 523], ["Cowpox virus", "PROBLEM", 0, 12], ["poxviruses", "PROBLEM", 62, 72], ["C owpox virus (family Poxviridae", "TREATMENT", 155, 187], ["genus OrthopoxvirusCowpox virus", "TREATMENT", 189, 220], ["cheetahs (Acinonyx jubatus", "TREATMENT", 281, 307], ["black panthers (Panthera pardus)", "TREATMENT", 310, 342], ["ocelots (Leopardus pardalis", "TREATMENT", 344, 371], ["leopard cat (Prionailurus bengalensis", "TREATMENT", 423, 460], ["Eurasia", "OBSERVATION", 39, 46], ["spread", "OBSERVATION_MODIFIER", 52, 58], ["poxviruses", "OBSERVATION", 62, 72], ["new", "OBSERVATION_MODIFIER", 76, 79], ["natural host species", "OBSERVATION", 116, 136]]], ["Since 1978, cowpox virus infections have been diagnosed in domestic cats in several European countries (13) (14) (15) (16) ; the cats were probably infected by contact with rodents, and in some cases infections were transmitted to humans (16) (17) (18) .", [["cowpox virus infections", "DISEASE", 12, 35], ["infections", "DISEASE", 200, 210], ["cowpox virus", "ORGANISM", 12, 24], ["cats", "ORGANISM", 68, 72], ["cats", "ORGANISM", 129, 133], ["humans", "ORGANISM", 231, 237], ["cowpox virus", "SPECIES", 12, 24], ["cats", "SPECIES", 68, 72], ["cats", "SPECIES", 129, 133], ["humans", "SPECIES", 231, 237], ["cowpox virus", "SPECIES", 12, 24], ["humans", "SPECIES", 231, 237], ["cowpox virus infections", "PROBLEM", 12, 35], ["some cases infections", "PROBLEM", 189, 210], ["virus infections", "OBSERVATION", 19, 35], ["probably", "UNCERTAINTY", 139, 147], ["infected", "OBSERVATION", 148, 156]]], ["Serologic surveys and detection of OPV DNA by PCR have indicated that wild rodents and shrews are likely reservoir hosts of cowpox virus in western Europe (19) (20) (21) (22) (23) , although infectious virus has never been isolated from these animals.C owpox virus (family Poxviridae, genus OrthopoxvirusAnti-OPV antibodies have been demonstrated in carnivores such as European lynx (Lynx lynx), red fox (Vulpes vulpes), and a brown bear (Ursus arctos) (24, 25) .", [["OPV", "ORGANISM", 35, 38], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["shrews", "ORGANISM_SUBDIVISION", 87, 93], ["cowpox virus", "ORGANISM", 124, 136], ["C owpox virus", "ORGANISM", 251, 264], ["family Poxviridae", "ORGANISM", 266, 283], ["OrthopoxvirusAnti-OPV antibodies", "ORGANISM", 291, 323], ["Lynx lynx", "ORGANISM", 384, 393], ["red fox", "ORGANISM", 396, 403], ["Vulpes vulpes", "ORGANISM", 405, 418], ["brown bear", "ORGANISM", 427, 437], ["Ursus arctos", "ORGANISM", 439, 451], ["OPV DNA", "DNA", 35, 42], ["OrthopoxvirusAnti-OPV antibodies", "PROTEIN", 291, 323], ["cowpox virus", "SPECIES", 124, 136], ["C owpox virus", "SPECIES", 251, 264], ["Lynx lynx", "SPECIES", 384, 393], ["red fox", "SPECIES", 396, 403], ["Vulpes vulpes", "SPECIES", 405, 418], ["Ursus arctos", "SPECIES", 439, 451], ["OPV", "SPECIES", 35, 38], ["cowpox virus", "SPECIES", 124, 136], ["C owpox virus", "SPECIES", 251, 264], ["European lynx", "SPECIES", 369, 382], ["Lynx lynx", "SPECIES", 384, 393], ["red fox", "SPECIES", 396, 403], ["Vulpes vulpes", "SPECIES", 405, 418], ["Ursus arctos", "SPECIES", 439, 451], ["Serologic surveys", "TEST", 0, 17], ["OPV DNA", "TEST", 35, 42], ["PCR", "TEST", 46, 49], ["cowpox virus", "PROBLEM", 124, 136], ["infectious virus", "PROBLEM", 191, 207], ["C owpox virus (family Poxviridae", "TREATMENT", 251, 283], ["genus OrthopoxvirusAnti-OPV antibodies", "TREATMENT", 285, 323], ["red fox (Vulpes vulpes", "PROBLEM", 396, 418], ["cowpox virus", "OBSERVATION", 124, 136], ["infectious", "OBSERVATION", 191, 201], ["brown bear", "OBSERVATION_MODIFIER", 427, 437]]], ["Taking into account the human cowpox virus cases reported from Finland, Sweden, and Norway (16, 23, 26) , OPV, presumably cowpox virus, is probably widespread among wildlife in Scandinavia, having small wild rodent populations as a reservoir.", [["cowpox virus", "DISEASE", 30, 42], ["cowpox virus", "DISEASE", 122, 134], ["human", "ORGANISM", 24, 29], ["cowpox virus", "ORGANISM", 30, 42], ["cowpox virus", "ORGANISM", 122, 134], ["human", "SPECIES", 24, 29], ["cowpox virus", "SPECIES", 30, 42], ["cowpox virus", "SPECIES", 122, 134], ["rodent", "SPECIES", 208, 214], ["human cowpox virus", "SPECIES", 24, 42], ["cowpox virus", "SPECIES", 122, 134], ["cowpox virus", "PROBLEM", 122, 134], ["a reservoir", "TREATMENT", 230, 241], ["presumably", "UNCERTAINTY", 111, 121], ["cowpox virus", "OBSERVATION", 122, 134], ["probably", "UNCERTAINTY", 139, 147], ["widespread", "OBSERVATION_MODIFIER", 148, 158], ["small", "OBSERVATION_MODIFIER", 197, 202]]], ["Because carnivores are exposed to OPV through predation on rodents, virus-specifi c DNA or antibodies in carnivores could serve as an indicator for the epizootiologic situation in rodent populations (25) .C owpox virus (family Poxviridae, genus OrthopoxvirusTo our knowledge, no cowpox virus case has been reported in free-ranging wild felids.", [["OPV", "CHEMICAL", 34, 37], ["specifi c", "GENE_OR_GENE_PRODUCT", 74, 83], ["DNA", "CELLULAR_COMPONENT", 84, 87], ["C owpox virus", "ORGANISM", 205, 218], ["cowpox virus", "ORGANISM", 279, 291], ["felids", "ORGANISM", 336, 342], ["virus-specifi c DNA", "DNA", 68, 87], ["antibodies", "PROTEIN", 91, 101], ["virus-specifi", "SPECIES", 68, 81], ["rodent", "SPECIES", 180, 186], ["C owpox virus", "SPECIES", 205, 218], ["C owpox virus", "SPECIES", 205, 218], ["cowpox virus", "SPECIES", 279, 291], ["virus", "PROBLEM", 68, 73], ["DNA", "PROBLEM", 84, 87], ["antibodies in carnivores", "PROBLEM", 91, 115], ["C owpox virus (family Poxviridae", "TREATMENT", 205, 237], ["genus Orthopoxvirus", "TREATMENT", 239, 258], ["cowpox virus case", "PROBLEM", 279, 296]]], ["To evaluate the possibility that cowpox virus may cause disease among Eurasian lynx, we searched for evidence of OPV infection in this large, free-ranging felid in Sweden.", [["cowpox virus", "DISEASE", 33, 45], ["OPV infection", "DISEASE", 113, 126], ["cowpox virus", "ORGANISM", 33, 45], ["OPV", "ORGANISM", 113, 116], ["cowpox virus", "SPECIES", 33, 45], ["Eurasian lynx", "SPECIES", 70, 83], ["OPV", "SPECIES", 113, 116], ["cowpox virus", "PROBLEM", 33, 45], ["disease", "PROBLEM", 56, 63], ["OPV infection", "PROBLEM", 113, 126], ["cowpox virus", "OBSERVATION", 33, 45], ["Eurasian lynx", "OBSERVATION", 70, 83], ["OPV", "OBSERVATION_MODIFIER", 113, 116], ["infection", "OBSERVATION", 117, 126], ["large", "OBSERVATION_MODIFIER", 135, 140]]], ["We used PCR to detect OPV DNA in tissue samples and compared these data with pathological fi ndings.", [["tissue samples", "ANATOMY", 33, 47], ["OPV", "ORGANISM", 22, 25], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["tissue samples", "CANCER", 33, 47], ["OPV DNA", "DNA", 22, 29], ["OPV", "SPECIES", 22, 25], ["PCR", "TEST", 8, 11], ["OPV DNA in tissue samples", "PROBLEM", 22, 47], ["these data", "TEST", 61, 71], ["pathological fi ndings", "TEST", 77, 99]]], ["In addition, to address the possible effects of such viruses in the ecosystems, we searched for phylogenetic relationships between the virus infecting lynx and viruses causing clinical cowpox cases in Scandinavia.AnimalsLynx samples were collected as part of a large study assessing the health of the free-ranging lynx population in Sweden from 1989 through 1999 and providing baseline data on diseases and parasites of the Eurasian lynx.", [["samples", "ANATOMY", 225, 232], ["cowpox", "DISEASE", 185, 191], ["lynx", "ORGANISM", 151, 155], ["cowpox", "ORGANISM", 185, 191], ["lynx", "ORGANISM", 314, 318], ["Eurasian lynx", "SPECIES", 424, 437], ["such viruses", "PROBLEM", 48, 60], ["the virus infecting lynx", "PROBLEM", 131, 155], ["AnimalsLynx samples", "TEST", 213, 232], ["a large study", "TEST", 259, 272], ["diseases", "PROBLEM", 394, 402], ["Eurasian lynx", "OBSERVATION", 424, 437]]], ["Complete necropsy was performed on all animals shipped to the National Veterinary Institute, Uppsala, Sweden, during the study period.", [["necropsy", "OBSERVATION", 9, 17]]], ["Samples of lung, kidney, and spleen were collected during necropsy and stored at -20\u00b0C until analysis.", [["Samples", "ANATOMY", 0, 7], ["lung", "ANATOMY", 11, 15], ["kidney", "ANATOMY", 17, 23], ["spleen", "ANATOMY", 29, 35], ["lung", "ORGAN", 11, 15], ["kidney", "ORGAN", 17, 23], ["spleen", "ORGAN", 29, 35], ["Samples of lung, kidney, and spleen", "TEST", 0, 35], ["necropsy", "TEST", 58, 66], ["analysis", "TEST", 93, 101], ["lung", "ANATOMY", 11, 15], ["kidney", "ANATOMY", 17, 23], ["spleen", "ANATOMY", 29, 35]]], ["The main causes of death were traffi c accidents and sarcoptic mange (Sarcoptes scabiei infestation) (27) .", [["death", "DISEASE", 19, 24], ["traffi c accidents", "DISEASE", 30, 48], ["Sarcoptes scabiei infestation", "DISEASE", 70, 99], ["Sarcoptes scabiei", "ORGANISM", 70, 87], ["Sarcoptes scabiei", "SPECIES", 70, 87], ["Sarcoptes scabiei", "SPECIES", 70, 87], ["death", "PROBLEM", 19, 24], ["sarcoptic mange (Sarcoptes scabiei infestation", "PROBLEM", 53, 99], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Infections with common feline viruses were rare (28) , and seropositivity to Toxoplasma gondii was more common among lynx from central Sweden than from farther north, where the climate is more harsh and the human population less dense (29) .", [["Infections", "DISEASE", 0, 10], ["feline viruses", "DISEASE", 23, 37], ["Toxoplasma gondii", "DISEASE", 77, 94], ["feline", "ORGANISM", 23, 29], ["Toxoplasma gondii", "ORGANISM", 77, 94], ["human", "ORGANISM", 207, 212], ["feline", "SPECIES", 23, 29], ["Toxoplasma gondii", "SPECIES", 77, 94], ["human", "SPECIES", 207, 212], ["Toxoplasma gondii", "SPECIES", 77, 94], ["human", "SPECIES", 207, 212], ["Infections", "PROBLEM", 0, 10], ["common feline viruses", "PROBLEM", 16, 37], ["seropositivity to Toxoplasma gondii", "PROBLEM", 59, 94], ["Toxoplasma gondii", "OBSERVATION", 77, 94], ["central", "OBSERVATION_MODIFIER", 127, 134], ["Sweden", "OBSERVATION_MODIFIER", 135, 141], ["more harsh", "OBSERVATION_MODIFIER", 188, 198], ["dense", "OBSERVATION_MODIFIER", 229, 234]]], ["A total of 263 lynx, sampled during 1995-1999, were included in the present study.AnimalsLynx originated from all over Sweden.", [["the present study", "TEST", 64, 81], ["AnimalsLynx", "PROBLEM", 82, 93], ["total", "OBSERVATION_MODIFIER", 2, 7], ["all", "OBSERVATION_MODIFIER", 110, 113]]], ["We differentiated 3 main geographic regions according to human population density ( Figure 1 ).", [["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["main", "OBSERVATION_MODIFIER", 20, 24], ["geographic", "OBSERVATION_MODIFIER", 25, 35], ["human population", "OBSERVATION_MODIFIER", 57, 73], ["density", "OBSERVATION", 74, 81]]], ["Northern Sweden, apart from the mountain chain bordering Norway, is part of the circumpolar northern coniferous forest belt, the taiga.", [["forest belt", "OBSERVATION", 112, 123]]], ["It is sparsely populated by humans; human populations increase toward the south and gradually decline farther from the coast.", [["humans", "ORGANISM", 28, 34], ["human", "ORGANISM", 36, 41], ["humans", "SPECIES", 28, 34], ["human", "SPECIES", 36, 41], ["humans", "SPECIES", 28, 34], ["human", "SPECIES", 36, 41], ["sparsely", "OBSERVATION_MODIFIER", 6, 14], ["populated", "OBSERVATION", 15, 24], ["populations", "OBSERVATION_MODIFIER", 42, 53], ["increase", "OBSERVATION_MODIFIER", 54, 62]]], ["The southernmost part of Sweden belongs to the broad-leaf forest region of central Europe but is mainly cultivated.", [["leaf forest", "OBSERVATION", 53, 64], ["central Europe", "OBSERVATION", 75, 89], ["mainly", "OBSERVATION_MODIFIER", 97, 103], ["cultivated", "OBSERVATION", 104, 114]]], ["They may come close to human settlements.", [["human", "ORGANISM", 23, 28], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28]]], ["Although their main prey are roe deer, they also prey on reindeer and sheep.", [["roe deer", "ORGANISM", 29, 37], ["reindeer", "ORGANISM_SUBDIVISION", 57, 65], ["sheep", "ORGANISM_SUBDIVISION", 70, 75], ["roe deer", "SPECIES", 29, 37], ["sheep", "SPECIES", 70, 75], ["roe deer", "SPECIES", 29, 37], ["reindeer", "SPECIES", 57, 65], ["sheep", "SPECIES", 70, 75], ["main", "OBSERVATION_MODIFIER", 15, 19]]], ["Furthermore, debilitated lynx affected by sarcoptic mange and orphans searching for easily accessible food are often found around human settlements.", [["human", "ORGANISM", 130, 135], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 130, 135], ["debilitated lynx", "PROBLEM", 13, 29], ["sarcoptic mange", "PROBLEM", 42, 57], ["debilitated", "OBSERVATION_MODIFIER", 13, 24], ["lynx", "OBSERVATION", 25, 29], ["sarcoptic mange", "OBSERVATION", 42, 57]]], ["Interactions between diseased lynx and domestic cats and dogs have been documented (30, 31) .AnimalsMost (245) animals submitted were apparently healthy (225 killed by hunters, 19 died of traumatic injury, 1 died of acute circulatory failure during anesthesia), 15 had sarcoptic mange, and 3 died of starvation caused by noninfectious or unclear etiology.", [["circulatory", "ANATOMY", 222, 233], ["traumatic injury", "DISEASE", 188, 204], ["circulatory failure", "DISEASE", 222, 241], ["mange", "DISEASE", 279, 284], ["lynx", "ORGANISM", 30, 34], ["cats", "ORGANISM", 48, 52], ["dogs", "ORGANISM", 57, 61], ["animals", "ORGANISM", 111, 118], ["cats", "SPECIES", 48, 52], ["dogs", "SPECIES", 57, 61], ["traumatic injury", "PROBLEM", 188, 204], ["acute circulatory failure", "PROBLEM", 216, 241], ["sarcoptic mange", "PROBLEM", 269, 284], ["starvation", "PROBLEM", 300, 310], ["diseased", "OBSERVATION_MODIFIER", 21, 29], ["lynx", "OBSERVATION", 30, 34], ["acute", "OBSERVATION_MODIFIER", 216, 221], ["circulatory failure", "OBSERVATION", 222, 241], ["noninfectious", "OBSERVATION", 321, 334]]], ["Body condition was evaluated by body weight, fat deposits in the abdomen and on the heart, and appearance of the bone marrow of the femur.", [["Body", "ANATOMY", 0, 4], ["body", "ANATOMY", 32, 36], ["fat deposits", "ANATOMY", 45, 57], ["abdomen", "ANATOMY", 65, 72], ["heart", "ANATOMY", 84, 89], ["bone marrow", "ANATOMY", 113, 124], ["femur", "ANATOMY", 132, 137], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["fat", "TISSUE", 45, 48], ["abdomen", "ORGAN", 65, 72], ["heart", "ORGAN", 84, 89], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 113, 124], ["femur", "ORGAN", 132, 137], ["Body condition", "PROBLEM", 0, 14], ["body weight", "TEST", 32, 43], ["fat deposits in the abdomen and on the heart, and appearance of the bone marrow of the femur", "PROBLEM", 45, 137], ["fat deposits", "OBSERVATION", 45, 57], ["abdomen", "ANATOMY", 65, 72], ["heart", "ANATOMY", 84, 89], ["bone marrow", "ANATOMY", 113, 124], ["femur", "ANATOMY", 132, 137]]], ["The animals were categorized into 3 groups: normal body condition (normal to fat, n = 230), poor body condition (low amount of fat in abdomen and on heart, n = 15), and emaciated (no abdominal fat, serous atrophy of fat deposits on heart and of bone marrow, n = 18, i.e., all diseased animals).AnimalsFor 228 animals, age was determined by counting cementum annuli of a canine tooth (Matson's Laboratory, Milltown, MT, USA); for the others, it was estimated on OPV DNA was amplifi ed by PCR from 24 animals (9%; red circles).", [["body", "ANATOMY", 51, 55], ["fat", "ANATOMY", 77, 80], ["body", "ANATOMY", 97, 101], ["fat", "ANATOMY", 127, 130], ["abdomen", "ANATOMY", 134, 141], ["heart", "ANATOMY", 149, 154], ["abdominal fat", "ANATOMY", 183, 196], ["serous", "ANATOMY", 198, 204], ["fat deposits", "ANATOMY", 216, 228], ["heart", "ANATOMY", 232, 237], ["bone marrow", "ANATOMY", 245, 256], ["cementum annuli", "ANATOMY", 349, 364], ["tooth", "ANATOMY", 377, 382], ["atrophy", "DISEASE", 205, 212], ["animals", "ORGANISM", 4, 11], ["body", "ORGANISM_SUBDIVISION", 51, 55], ["fat", "TISSUE", 77, 80], ["body", "ORGANISM_SUBDIVISION", 97, 101], ["fat", "TISSUE", 127, 130], ["abdomen", "ORGANISM_SUBDIVISION", 134, 141], ["heart", "ORGAN", 149, 154], ["abdominal fat", "TISSUE", 183, 196], ["fat", "TISSUE", 216, 219], ["heart", "ORGAN", 232, 237], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 245, 256], ["cementum annuli", "TISSUE", 349, 364], ["canine", "ORGANISM", 370, 376], ["tooth", "ORGAN", 377, 382], ["DNA", "CELLULAR_COMPONENT", 465, 468], ["OPV DNA", "DNA", 461, 468], ["canine", "SPECIES", 370, 376], ["OPV", "SPECIES", 461, 464], ["poor body condition", "PROBLEM", 92, 111], ["abdominal fat", "PROBLEM", 183, 196], ["serous atrophy of fat deposits", "PROBLEM", 198, 228], ["bone marrow", "TEST", 245, 256], ["a canine tooth", "PROBLEM", 368, 382], ["OPV DNA", "TEST", 461, 468], ["PCR", "TEST", 487, 490], ["low amount", "OBSERVATION_MODIFIER", 113, 123], ["abdomen", "ANATOMY", 134, 141], ["heart", "ANATOMY", 149, 154], ["no", "UNCERTAINTY", 180, 182], ["abdominal fat", "ANATOMY", 183, 196], ["serous", "OBSERVATION_MODIFIER", 198, 204], ["atrophy", "OBSERVATION", 205, 212], ["fat deposits", "OBSERVATION", 216, 228], ["heart", "ANATOMY", 232, 237], ["bone marrow", "ANATOMY", 245, 256], ["canine tooth", "ANATOMY", 370, 382]]], ["Light blue areas represent sparsely populated (<5 inhabitants/km 2 ) mountainous counties; medium blue areas represent more densely populated counties (10-41 inhabitants/km 2 ) farther south; and dark blue areas represent counties with the highest human population densities (>50 inhabitants/km 2 ). the basis of body size and weight, tooth wear, development of genital organs, and, if appropriate, morphologic characteristics and ossifi cation of the skull.", [["body", "ANATOMY", 313, 317], ["tooth", "ANATOMY", 335, 340], ["genital organs", "ANATOMY", 362, 376], ["skull", "ANATOMY", 452, 457], ["tooth wear", "DISEASE", 335, 345], ["human", "ORGANISM", 248, 253], ["body", "ORGANISM_SUBDIVISION", 313, 317], ["tooth", "ORGAN", 335, 340], ["genital organs", "ORGAN", 362, 376], ["skull", "ORGAN", 452, 457], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 248, 253], ["Light blue areas", "PROBLEM", 0, 16], ["medium blue areas", "PROBLEM", 91, 108], ["dark blue areas", "PROBLEM", 196, 211], ["the highest human population densities", "PROBLEM", 236, 274], ["development of genital organs", "PROBLEM", 347, 376], ["ossifi cation of the skull", "PROBLEM", 431, 457], ["blue", "OBSERVATION_MODIFIER", 6, 10], ["areas", "OBSERVATION_MODIFIER", 11, 16], ["sparsely", "OBSERVATION_MODIFIER", 27, 35], ["more", "OBSERVATION_MODIFIER", 119, 123], ["densely", "OBSERVATION_MODIFIER", 124, 131], ["dark blue", "OBSERVATION_MODIFIER", 196, 205], ["body", "OBSERVATION_MODIFIER", 313, 317], ["size", "OBSERVATION_MODIFIER", 318, 322], ["tooth wear", "OBSERVATION", 335, 345], ["genital organs", "ANATOMY", 362, 376], ["ossifi cation", "OBSERVATION", 431, 444], ["skull", "ANATOMY", 452, 457]]], ["Numbers of males and females were equal in the juvenile and adult age classes, but within subadults there were more males (n = 68) than females (n = 27).", [["males", "OBSERVATION", 11, 16], ["juvenile", "OBSERVATION_MODIFIER", 47, 55]]], ["According to the time of death, animals were grouped into seasons relevant to the biology of the lynx: delivery (May-July, n = 6); small kittens and lactation (August-October; n = 7); large kittens hunting with the dam (November-January, n = 24); and breeding season, separation of kittens from dam, and main hunting season (February-April, n = 224).PCR, Electrophoresis, and SequencingFrom each sampled lynx, 25 mg lung (n = 262), 25 mg kidney (n = 263), and 10 mg spleen (n = 261) were cut in small pieces and homogenized in phosphate-buffered saline.", [["lung", "ANATOMY", 416, 420], ["kidney", "ANATOMY", 438, 444], ["spleen", "ANATOMY", 466, 472], ["death", "DISEASE", 25, 30], ["phosphate", "CHEMICAL", 527, 536], ["phosphate", "CHEMICAL", 527, 536], ["kittens", "ORGANISM", 282, 289], ["lung", "ORGAN", 416, 420], ["kidney", "ORGAN", 438, 444], ["spleen", "ORGAN", 466, 472], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 527, 552], ["kittens", "SPECIES", 190, 197], ["PCR", "TEST", 350, 353], ["Electrophoresis", "TEST", 355, 370], ["Sequencing", "TEST", 376, 386], ["phosphate", "TREATMENT", 527, 536], ["buffered saline", "TREATMENT", 537, 552], ["lynx", "ANATOMY", 97, 101], ["lung", "ANATOMY", 416, 420], ["kidney", "ANATOMY", 438, 444], ["spleen", "ANATOMY", 466, 472], ["small pieces", "OBSERVATION_MODIFIER", 495, 507]]], ["DNA was extracted by using a QIAamp tissue kit (QIAGEN GmbH, D\u00fcsseldorf, Germany); mean DNA concentration was 39.7 \u03bcg/mL \u00b1 23.8 SD for lung, 99.0 \u03bcg/ mL \u00b1 46.4 SD for kidney, and 101.0 \u03bcg/mL \u00b1 49.0 SD for spleen.", [["tissue", "ANATOMY", 36, 42], ["lung", "ANATOMY", 135, 139], ["kidney", "ANATOMY", 167, 173], ["spleen", "ANATOMY", 205, 211], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["tissue", "TISSUE", 36, 42], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["lung", "ORGAN", 135, 139], ["kidney", "ORGAN", 167, 173], ["spleen", "ORGAN", 205, 211], ["mean DNA concentration", "TEST", 83, 105], ["lung", "TEST", 135, 139], ["kidney", "TEST", 167, 173], ["spleen", "PROBLEM", 205, 211], ["lung", "ANATOMY", 135, 139], ["kidney", "ANATOMY", 167, 173], ["spleen", "ANATOMY", 205, 211]]], ["Five \u03bcL of the DNA eluate was used as template for the PCR.PCR, Electrophoresis, and SequencingPCR primers (MedProbe AS, Oslo, Norway) from the thymidine kinase gene (tk) were used as described (21), generating an expected PCR amplicon of 339 bp.", [["thymidine", "CHEMICAL", 144, 153], ["thymidine", "CHEMICAL", 144, 153], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 144, 160], ["SequencingPCR primers", "DNA", 85, 106], ["thymidine kinase gene", "DNA", 144, 165], ["tk", "DNA", 167, 169], ["PCR amplicon", "DNA", 223, 235], ["the DNA eluate", "TREATMENT", 11, 25], ["the PCR", "TEST", 51, 58], ["PCR", "TEST", 59, 62], ["Electrophoresis", "TEST", 64, 79], ["the thymidine kinase gene", "TREATMENT", 140, 165], ["an expected PCR amplicon", "TEST", 211, 235], ["bp", "TEST", 243, 245]]], ["DNA from vaccinia virus (Western Reserve; VR-119), cowpox virus (Brighton; VR-302) (both from American Type Culture Collection, Rockville, MD, USA), and cowpox virus isolated from a felid with clinical disease (16) was used as positive control.", [["felid", "ANATOMY", 182, 187], ["VR-302", "CHEMICAL", 75, 81], ["cowpox virus", "DISEASE", 153, 165], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["vaccinia virus", "ORGANISM", 9, 23], ["VR-119", "ORGANISM", 42, 48], ["cowpox virus", "ORGANISM", 51, 63], ["cowpox virus", "ORGANISM", 153, 165], ["vaccinia virus", "SPECIES", 9, 23], ["cowpox virus", "SPECIES", 51, 63], ["cowpox virus", "SPECIES", 153, 165], ["vaccinia virus", "SPECIES", 9, 23], ["cowpox virus (Brighton; VR-302", "SPECIES", 51, 81], ["cowpox virus", "SPECIES", 153, 165], ["DNA", "PROBLEM", 0, 3], ["vaccinia virus", "PROBLEM", 9, 23], ["VR", "TEST", 42, 44], ["cowpox virus", "PROBLEM", 51, 63], ["VR", "TEST", 75, 77], ["cowpox virus", "PROBLEM", 153, 165], ["clinical disease", "PROBLEM", 193, 209], ["vaccinia virus", "OBSERVATION", 9, 23], ["cowpox virus", "OBSERVATION", 153, 165]]], ["PCR was performed with a Gene Amp PCR System 9700 (PerkinElmer Corp., Norwalk, CT, USA).", [["PCR", "TEST", 0, 3], ["a Gene Amp PCR System", "TEST", 23, 44], ["CT", "TEST", 79, 81]]], ["Reaction volume was 50 \u03bcL and contained 5 \u03bcL of the DNA eluate from the lynx tissue, 1 \u03bcL of each primer (25 \u03bcM), 4 \u03bcL dNTP (10 mmol/L), 5 \u03bcL MgCl 2 (25 mmol/L), 5 \u03bcL GeneAmp 10X Gold Buffer (Applied Biosystems, Oslo, Norway), 2.5 U AmpliTaq Gold polymerase (Applied Biosystems), and 19 \u03bcL water.", [["tissue", "ANATOMY", 77, 83], ["dNTP", "CHEMICAL", 119, 123], ["dNTP", "CHEMICAL", 119, 123], ["MgCl 2", "CHEMICAL", 142, 148], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["lynx tissue", "TISSUE", 72, 83], ["Reaction volume", "TEST", 0, 15], ["the DNA eluate", "TEST", 48, 62], ["dNTP", "TEST", 119, 123], ["2.5 U AmpliTaq Gold polymerase (Applied Biosystems", "TREATMENT", 227, 277], ["lynx tissue", "ANATOMY", 72, 83]]], ["The tubes were placed in a preheated block (95\u00b0C) and held for 5 min before cycling.", [["tubes", "ANATOMY", 4, 9], ["tubes", "TISSUE", 4, 9], ["The tubes", "TREATMENT", 0, 9], ["a preheated block", "TREATMENT", 25, 42], ["tubes", "OBSERVATION", 4, 9]]], ["Five cycles of denaturation (95\u00b0C for 30 s), annealing (53\u00b0C for 2 min), and primer extension (72\u00b0C for 30 s) were followed by 35 cycles with 30 s annealing time.", [["denaturation", "TEST", 15, 27], ["primer extension", "TEST", 77, 93]]], ["After the last cycle, the temperature was held at 72\u00b0C for 10 min.PCR, Electrophoresis, and SequencingPCR amplicons were analyzed by using the Gibco BRL Horizon 11-14 Gel Electrophoresis System (Life Technologies, Paisly, Scotland) in a 2% agarose gel (UltraPure agarose gel; Life Technologies) with TAE buffer (0.04 M Tris-acetate, 1.0 mmol/L EDTA) and ethidium bromide for DNA staining.", [["Tris-acetate", "CHEMICAL", 319, 331], ["ethidium bromide", "CHEMICAL", 354, 370], ["TAE", "CHEMICAL", 300, 303], ["Tris-acetate", "CHEMICAL", 319, 331], ["EDTA", "CHEMICAL", 344, 348], ["ethidium bromide", "CHEMICAL", 354, 370], ["agarose", "SIMPLE_CHEMICAL", 240, 247], ["Tris-acetate", "SIMPLE_CHEMICAL", 319, 331], ["mmol/L EDTA", "SIMPLE_CHEMICAL", 337, 348], ["ethidium bromide", "SIMPLE_CHEMICAL", 354, 370], ["DNA", "CELLULAR_COMPONENT", 375, 378], ["SequencingPCR amplicons", "DNA", 92, 115], ["the temperature", "TEST", 22, 37], ["PCR", "TEST", 66, 69], ["Electrophoresis", "TEST", 71, 86], ["SequencingPCR amplicons", "TREATMENT", 92, 115], ["the Gibco BRL Horizon", "TREATMENT", 139, 160], ["Gel Electrophoresis System (Life Technologies", "TREATMENT", 167, 212], ["Paisly, Scotland)", "TREATMENT", 214, 231], ["a 2% agarose gel (UltraPure agarose gel", "TREATMENT", 235, 274], ["Life Technologies", "TREATMENT", 276, 293], ["TAE buffer", "TREATMENT", 300, 310], ["Tris-acetate", "TREATMENT", 319, 331], ["mmol/L EDTA)", "TREATMENT", 337, 349], ["ethidium bromide", "TREATMENT", 354, 370], ["DNA staining", "PROBLEM", 375, 387]]], ["Fifteen \u03bcL of PCR product mixed with 3 \u03bcL 6X loading buffer (0.25% [wt/vol] bromphenol blue and 40% [wt/vol] sucrose) were loaded in each well.", [["bromphenol blue", "CHEMICAL", 76, 91], ["sucrose", "CHEMICAL", 109, 116], ["bromphenol blue", "CHEMICAL", 76, 91], ["sucrose", "CHEMICAL", 109, 116], ["bromphenol blue", "SIMPLE_CHEMICAL", 76, 91], ["vol] sucrose", "SIMPLE_CHEMICAL", 104, 116], ["PCR product", "TREATMENT", 14, 25], ["3 \u03bcL 6X loading buffer", "TREATMENT", 37, 59], ["bromphenol blue", "TREATMENT", 76, 91], ["wt/vol] sucrose)", "TREATMENT", 101, 117], ["mixed", "OBSERVATION_MODIFIER", 26, 31]]], ["The gels were run in TAE buffer at 150 V for 1.5 h and examined by using a Gel Doc 2000 Documentation System (Bio-Rad Laboratories, Oslo, Norway).", [["TAE", "CHEMICAL", 21, 24], ["The gels", "TREATMENT", 0, 8], ["TAE buffer", "TREATMENT", 21, 31]]], ["Primers and dNTP were removed from amplicons by using ExoSapIT reagent (Amersham Pharmacia, Uppsala, Sweden), adding 1 \u03bcL/5\u03bcL PCR product, incubating 45 min at 37\u00baC, and by conducting enzyme inactivation for 20 min at 80\u00baC.", [["dNTP", "CHEMICAL", 12, 16], ["dNTP", "CHEMICAL", 12, 16], ["dNTP", "SIMPLE_CHEMICAL", 12, 16], ["Primers and dNTP", "TREATMENT", 0, 16]]], ["Cycle sequencing was conducted in both directions by using Big Dye 3.1 reagents (ABI BigDye Terminator version 3.1, Applied Biosystems).", [["Cycle sequencing", "TEST", 0, 16], ["Big Dye", "TREATMENT", 59, 66], ["ABI BigDye Terminator version", "TREATMENT", 81, 110]]], ["Two microliters EDTA (125 mmol/L), 2 \u03bcL sodium acetate (3 mol/L), and 50 \u03bcL of ethanol were added to the 20 \u03bcL sequencing product.", [["EDTA", "CHEMICAL", 16, 20], ["sodium acetate", "CHEMICAL", 40, 54], ["ethanol", "CHEMICAL", 79, 86], ["EDTA", "CHEMICAL", 16, 20], ["sodium acetate", "CHEMICAL", 40, 54], ["ethanol", "CHEMICAL", 79, 86], ["EDTA", "SIMPLE_CHEMICAL", 16, 20], ["\u03bcL sodium acetate", "SIMPLE_CHEMICAL", 37, 54], ["ethanol", "SIMPLE_CHEMICAL", 79, 86], ["Two microliters EDTA", "TREATMENT", 0, 20], ["2 \u03bcL sodium acetate", "TREATMENT", 35, 54], ["ethanol", "TREATMENT", 79, 86]]], ["Electrophoresis of the cycle sequencing extension products was conducted in an ABI Prism 377 DNA Analyzer (Applied Biosystems).", [["DNA", "CELLULAR_COMPONENT", 93, 96], ["Electrophoresis", "TEST", 0, 15], ["the cycle sequencing extension products", "TREATMENT", 19, 58], ["an ABI Prism", "TEST", 76, 88], ["DNA Analyzer", "TEST", 93, 105]]], ["Raw sequence data were edited by Chromas Pro software version 1.41 (Technelysium Pty Ltd., Tewantin, Queensland, Australia) and BioEdit Sequence Alignment Editor version 7.0.4 (www.mbio.ncsu.edu/ BioEdit/bioedit.html).", [["Raw sequence data", "TEST", 0, 17]]], ["Multiple sequence alignment was performed by using ClustalX 1.181 (32) .", [["Multiple sequence alignment", "TEST", 0, 27], ["ClustalX", "TEST", 51, 59]]], ["The phylogenetic tree was generated with the neighbor-joining method by using MEGA 3.1 (www.megasoftware.net).", [["phylogenetic tree", "OBSERVATION", 4, 21]]], ["The lynx orthopoxvirus DNA sequences obtained in this study have been submitted to the GenBank nucelotide sequence database (Table) .Statistical AnalysesStatistical calculations regarding differences in prevalence were performed by using NCSS 2007 Statistical Software (www.ncss.com).", [["DNA", "CELLULAR_COMPONENT", 23, 26], ["lynx orthopoxvirus DNA sequences", "DNA", 4, 36], ["GenBank nucelotide sequence", "DNA", 87, 114], ["lynx orthopoxvirus", "SPECIES", 4, 22], ["The lynx orthopoxvirus DNA sequences", "TEST", 0, 36], ["this study", "TEST", 49, 59]]], ["Statistical signifi cance of differences was analyzed by using the 2-tailed Fisher exact test; level of signifi cance was set at p<0.05.ResultsIn contrast to what has been reported for domestic cats and exotic felids in zoos (11, 12, 33) , no macroscopic lesions in the skin or lungs could be ascribed to a cowpox virus infection.", [["lesions", "ANATOMY", 255, 262], ["skin", "ANATOMY", 270, 274], ["lungs", "ANATOMY", 278, 283], ["cowpox virus infection", "DISEASE", 307, 329], ["cats", "ORGANISM", 194, 198], ["lesions", "PATHOLOGICAL_FORMATION", 255, 262], ["skin", "ORGAN", 270, 274], ["lungs", "ORGAN", 278, 283], ["cowpox virus", "ORGANISM", 307, 319], ["cats", "SPECIES", 194, 198], ["cowpox virus", "SPECIES", 307, 319], ["domestic cats", "TREATMENT", 185, 198], ["macroscopic lesions in the skin or lungs", "PROBLEM", 243, 283], ["a cowpox virus infection", "PROBLEM", 305, 329], ["no", "UNCERTAINTY", 240, 242], ["macroscopic", "OBSERVATION_MODIFIER", 243, 254], ["lesions", "OBSERVATION", 255, 262], ["skin", "ANATOMY", 270, 274], ["lungs", "ANATOMY", 278, 283], ["cowpox virus", "OBSERVATION", 307, 319]]], ["OPV PCR amplifi cation products of expected size (\u2248339 bp) were detected in tissues from 24 lynx (9.1%, 95% confi dence interval [CI] 5.9%-13.3%).", [["tissues", "ANATOMY", 76, 83], ["tissues", "TISSUE", 76, 83], ["OPV PCR amplifi cation products", "TREATMENT", 0, 31], ["bp", "TEST", 55, 57], ["interval", "TEST", 120, 128], ["CI", "TEST", 130, 132], ["size", "OBSERVATION_MODIFIER", 44, 48]]], ["Mean age of the 24 lynx with positive results by PCR and exact age data was 2.5 years \u00b1 2.6 SD.", [["Mean age", "TEST", 0, 8], ["PCR", "TEST", 49, 52]]], ["Of the PCR-positive lynx, 18 were in normal body condition, 1 showed no visible signs of disease except for otodectic otoacariasis and being in poor condition, and 5 were emaciated and had sarcoptic mange (Table) .", [["body", "ANATOMY", 44, 48], ["otodectic otoacariasis", "DISEASE", 108, 130], ["body", "ORGANISM_SUBDIVISION", 44, 48], ["the PCR", "TEST", 3, 10], ["visible signs of disease", "PROBLEM", 72, 96], ["otodectic otoacariasis", "PROBLEM", 108, 130], ["positive lynx", "OBSERVATION", 11, 24], ["no visible", "UNCERTAINTY", 69, 79], ["disease", "OBSERVATION", 89, 96], ["otodectic otoacariasis", "OBSERVATION", 108, 130]]], ["Prevalence differed signifi cantly between apparently healthy (7.7%, 95% CI 4.7%-11.7%) and diseased (29.4%, 95% CI 10.3%-55.9%; p = 0.012) lynx and between lynx in normal body condition (7.8%, 95% CI 4.7-12.1) and those that were emaciated (33.3%, 95% CI 11.8%-61.6%; p = 0.007).", [["body", "ANATOMY", 172, 176], ["body", "ORGANISM_SUBDIVISION", 172, 176], ["CI", "TEST", 73, 75], ["diseased", "TEST", 92, 100], ["CI", "TEST", 113, 115], ["p", "TEST", 129, 130], ["lynx", "TEST", 140, 144], ["CI", "TEST", 198, 200], ["CI", "TEST", 253, 255], ["p", "TEST", 269, 270], ["diseased", "OBSERVATION", 92, 100], ["normal body", "OBSERVATION_MODIFIER", 165, 176], ["emaciated", "OBSERVATION_MODIFIER", 231, 240]]], ["Most diseased and emaciated lynx had sarcoptic mange, and difference in prevalence was most signifi cant between those with (33.3%, 95% CI 11.8%-61.6%) and without (7.7%, 95% CI 4.7%-11.7%; p = 0.007) sarcoptic mange.", [["lynx", "ORGANISM", 28, 32], ["Most diseased", "PROBLEM", 0, 13], ["sarcoptic mange", "PROBLEM", 37, 52], ["CI", "TEST", 136, 138], ["CI", "TEST", 175, 177], ["p", "TEST", 190, 191], ["sarcoptic mange", "PROBLEM", 201, 216], ["emaciated", "OBSERVATION_MODIFIER", 18, 27], ["lynx", "OBSERVATION", 28, 32], ["sarcoptic mange", "OBSERVATION", 37, 52]]], ["A signifi cant difference was also found between areas with sparse human inhabitants (5.3%, 95% CI 1.5-12.9) and areas with higher human density (14.3%, 95% CI 8.4-22.2; p = 0.016).", [["human", "ORGANISM", 67, 72], ["human", "ORGANISM", 131, 136], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 131, 136], ["A signifi cant difference", "PROBLEM", 0, 25], ["sparse human inhabitants", "PROBLEM", 60, 84], ["CI", "TEST", 96, 98], ["higher human density", "PROBLEM", 124, 144], ["CI", "TEST", 157, 159], ["p", "TEST", 170, 171], ["sparse", "OBSERVATION_MODIFIER", 60, 66], ["higher", "OBSERVATION_MODIFIER", 124, 130], ["human density", "OBSERVATION_MODIFIER", 131, 144]]], ["Yearly prevalence of animals having OPV DNA varied from 5.3% in 1997 (95% CI 1.5-12.9) to 20% in 1995 (95% CI 0.5-71.6), but differences were not signifi cant.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["OPV", "SPECIES", 36, 39], ["OPV DNA", "TEST", 36, 43], ["CI", "TEST", 74, 76], ["CI", "TEST", 107, 109]]], ["No signifi cant differences were observed between sexes, age classes, or seasons.ResultsSequence data were obtained from 21 of 24 samples positive by PCR (Figure 2 ).", [["samples", "ANATOMY", 130, 137], ["signifi cant differences", "PROBLEM", 3, 27], ["Sequence data", "TEST", 88, 101], ["PCR", "TEST", 150, 153]]], ["The partial tk gene sequences were identical for all 21 samples.", [["samples", "ANATOMY", 56, 63], ["tk", "GENE_OR_GENE_PRODUCT", 12, 14], ["partial tk gene sequences", "DNA", 4, 29], ["The partial tk gene sequences", "TEST", 0, 29]]], ["The obtained OPV tk gene sequences were also identical to that of a cowpox virus isolate from a person in Norway (No.H1) and differed by1 nt substitution from a cowpox virus isolate from a felid in Norway (No.F1) (Figure 2 ).", [["tk", "GENE_OR_GENE_PRODUCT", 17, 19], ["cowpox virus", "ORGANISM", 68, 80], ["cowpox virus", "ORGANISM", 161, 173], ["OPV tk gene sequences", "DNA", 13, 34], ["person", "SPECIES", 96, 102], ["cowpox virus", "SPECIES", 161, 173], ["cowpox virus", "SPECIES", 68, 80], ["cowpox virus", "SPECIES", 161, 173], ["The obtained OPV tk gene sequences", "TEST", 0, 34], ["a cowpox virus isolate", "TREATMENT", 66, 88], ["by1 nt substitution", "TREATMENT", 134, 153], ["a cowpox virus isolate", "TREATMENT", 159, 181], ["cowpox virus", "OBSERVATION", 161, 173]]], ["In addition, the generated OPV tk gene sequences differed from those of CPXV-BR and of cowpox virus isolates from Sweden (Swe.H1 and Swe.H2) by multiple nucleotide substitutions ( Figure 2 ).", [["H2", "CHEMICAL", 137, 139], ["nucleotide", "CHEMICAL", 153, 163], ["H2", "CHEMICAL", 137, 139], ["nucleotide", "CHEMICAL", 153, 163], ["tk", "GENE_OR_GENE_PRODUCT", 31, 33], ["CPXV-BR", "GENE_OR_GENE_PRODUCT", 72, 79], ["cowpox virus isolates", "ORGANISM", 87, 108], ["H2", "GENE_OR_GENE_PRODUCT", 137, 139], ["OPV tk gene sequences", "DNA", 27, 48], ["cowpox virus", "SPECIES", 87, 99], ["cowpox virus", "SPECIES", 87, 99], ["the generated OPV tk gene sequences", "TEST", 13, 48], ["CPXV", "TEST", 72, 76], ["cowpox virus isolates", "TREATMENT", 87, 108], ["multiple nucleotide substitutions", "PROBLEM", 144, 177]]], ["Phylogenetic analysis of the OPV tk gene sequences revealed that they clustered with the tk gene of cowpox virus No.H1 and cowpox virus GRI (30) but separated from that of cowpox virus isolates from Sweden (Swe.H1and Swe.H2) and from CPXV-BR ( Figure 3 ).DiscussionOn the basis of previous serologic investigations that found anti-OPV antibodies in lynx in Sweden (25) and our detection of OPV-specifi c DNA in lynx tissue samples, we conclude that the Eurasian lynx in Sweden are infected with OPV.", [["tissue samples", "ANATOMY", 416, 430], ["OPV tk", "GENE_OR_GENE_PRODUCT", 29, 35], ["tk", "GENE_OR_GENE_PRODUCT", 89, 91], ["cowpox virus", "ORGANISM", 100, 112], ["H1", "GENE_OR_GENE_PRODUCT", 116, 118], ["cowpox virus GRI", "ORGANISM", 123, 139], ["cowpox virus", "ORGANISM", 172, 184], ["CPXV-BR", "GENE_OR_GENE_PRODUCT", 234, 241], ["anti-OPV antibodies", "GENE_OR_GENE_PRODUCT", 326, 345], ["OPV-specifi c", "GENE_OR_GENE_PRODUCT", 390, 403], ["DNA", "CELLULAR_COMPONENT", 404, 407], ["lynx tissue samples", "CANCER", 411, 430], ["OPV tk gene sequences", "DNA", 29, 50], ["tk gene", "DNA", 89, 96], ["H1", "PROTEIN", 116, 118], ["anti-OPV antibodies", "PROTEIN", 326, 345], ["OPV-specifi c DNA", "DNA", 390, 407], ["cowpox virus", "SPECIES", 100, 112], ["cowpox virus", "SPECIES", 123, 135], ["OPV-specifi", "SPECIES", 390, 401], ["cowpox virus", "SPECIES", 100, 112], ["H1", "SPECIES", 116, 118], ["cowpox virus", "SPECIES", 123, 135], ["cowpox virus", "SPECIES", 172, 184], ["OPV-specifi", "SPECIES", 390, 401], ["Eurasian lynx", "SPECIES", 453, 466], ["OPV", "SPECIES", 495, 498], ["Phylogenetic analysis", "TEST", 0, 21], ["the OPV tk gene sequences", "TEST", 25, 50], ["cowpox virus", "PROBLEM", 100, 112], ["H1", "PROBLEM", 116, 118], ["cowpox virus GRI", "TEST", 123, 139], ["cowpox virus isolates", "PROBLEM", 172, 193], ["previous serologic investigations", "TEST", 281, 314], ["anti-OPV antibodies", "PROBLEM", 326, 345], ["our detection", "TEST", 373, 386], ["OPV", "TEST", 390, 393], ["specifi c DNA in lynx tissue samples", "PROBLEM", 394, 430], ["OPV", "TREATMENT", 495, 498], ["cowpox virus", "OBSERVATION", 100, 112], ["cowpox virus", "OBSERVATION", 172, 184], ["lynx tissue", "OBSERVATION", 411, 422], ["Eurasian lynx", "OBSERVATION", 453, 466]]], ["Thus, we report fi nding OPV in free-ranging, wild felids.DiscussionWe used the tk gene as a target for the PCR because it is highly conserved within species of the genus Orthopoxvirus (34), thus enabling DNA amplifi cation of different OPVs in the sample.", [["sample", "ANATOMY", 249, 255], ["OPV", "CHEMICAL", 25, 28], ["felids", "ORGANISM", 51, 57], ["tk", "GENE_OR_GENE_PRODUCT", 80, 82], ["DNA", "CELLULAR_COMPONENT", 205, 208], ["OPVs", "CANCER", 237, 241], ["tk gene", "DNA", 80, 87], ["the tk gene", "TREATMENT", 76, 87], ["the PCR", "TEST", 104, 111], ["DNA amplifi cation", "TREATMENT", 205, 223], ["different OPVs", "TREATMENT", 227, 241], ["genus Orthopoxvirus", "ANATOMY", 165, 184]]], ["We cannot rule out the possibility that the OPV tk sequences obtained from lynx were derived from other OPVs apart from cowpox virus; but although the phylogeny is based on a partial sequence of a single gene, which may have restrictions as a predictor of phylogenetic relationships (35) , we suggest that the tk OPV sequences obtained from the lynx in this study were probably derived from cowpox virus.", [["OPVs", "GENE_OR_GENE_PRODUCT", 104, 108], ["cowpox virus", "ORGANISM", 120, 132], ["tk OPV", "ORGANISM", 310, 316], ["cowpox virus", "ORGANISM", 391, 403], ["OPV tk sequences", "DNA", 44, 60], ["tk OPV sequences", "DNA", 310, 326], ["cowpox virus", "SPECIES", 120, 132], ["cowpox virus", "SPECIES", 391, 403], ["the OPV tk sequences", "TEST", 40, 60], ["cowpox virus", "PROBLEM", 120, 132], ["the tk OPV sequences", "TEST", 306, 326], ["this study", "TEST", 353, 363], ["cowpox virus", "PROBLEM", 391, 403], ["cowpox virus", "OBSERVATION", 120, 132], ["cowpox virus", "OBSERVATION", 391, 403]]], ["This assumption is based on the fact that the lynx tk sequences were 100% identical with the partial tk gene of several cowpox virus isolates ( Figure 2 and data not shown) and is also supported by the phylogenetic analysis, which showed that the lynx tk gene sequences formed a common clade with those of CPXV-GRI (strain GRI-90 isolated from a person infected by contact with a mole) (36) and of isolates from 1 person (No.H1) and 1 felid (No.F1) from Norway ( Figure 3 ).", [["cowpox virus", "ORGANISM", 120, 132], ["tk", "GENE_OR_GENE_PRODUCT", 252, 254], ["CPXV-GRI", "ORGANISM", 306, 314], ["GRI-90", "ORGANISM", 323, 329], ["lynx tk sequences", "DNA", 46, 63], ["tk gene", "DNA", 101, 108], ["lynx tk gene sequences", "DNA", 247, 269], ["person", "SPECIES", 346, 352], ["person", "SPECIES", 414, 420], ["cowpox virus", "SPECIES", 120, 132], ["lynx tk", "SPECIES", 247, 254], ["GRI-90", "SPECIES", 323, 329], ["the lynx tk sequences", "TEST", 42, 63], ["several cowpox virus isolates", "PROBLEM", 112, 141], ["the phylogenetic analysis", "TEST", 198, 223], ["the lynx tk gene sequences", "TEST", 243, 269], ["CPXV", "TEST", 306, 310]]], ["Given the general genetic heterogeneity of cowpox virus isolates (35, 37) , it is not surprising that the clade containing the OPV tk sequences from lynx diverged from that of some other cowpox virus isolates, such as CPXV-BR and the 2 isolates from persons in Sweden (Swe.HI and Swe.", [["cowpox virus isolates", "ORGANISM", 43, 64], ["OPV tk", "ORGANISM", 127, 133], ["cowpox virus", "ORGANISM", 187, 199], ["CPXV-BR", "ORGANISM", 218, 225], ["persons", "ORGANISM", 250, 257], ["OPV tk sequences", "DNA", 127, 143], ["persons", "SPECIES", 250, 257], ["cowpox virus", "SPECIES", 43, 55], ["cowpox virus", "SPECIES", 187, 199], ["cowpox virus isolates", "PROBLEM", 43, 64], ["the OPV tk sequences", "TEST", 123, 143], ["some other cowpox virus isolates", "PROBLEM", 176, 208], ["cowpox virus", "OBSERVATION", 43, 55]]], ["Unexpectedly, the OPV sequences obtained from the lynx in Sweden were similar to the 2 isolates from a person and a felid in Norway and less similar to 2 isolates from persons in Sweden.", [["persons", "ORGANISM", 168, 175], ["OPV sequences", "DNA", 18, 31], ["person", "SPECIES", 103, 109], ["persons", "SPECIES", 168, 175], ["the OPV sequences", "TEST", 14, 31]]], ["A potential explanation is that none of these 4 clinical cases occurred near the sites in which the lynx were sampled for this study.", [["this study", "TEST", 122, 132]]], ["In Sweden, the 2 human cases appeared in Sk\u00e5ne, the southernmost part of the country, 150-200 km from the southernmost region where the lynx were sampled.", [["human", "ORGANISM", 17, 22], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["lynx", "ANATOMY", 136, 140]]], ["In Norway, all feline cases and all but 1 human case occurred in the southwestern part of the country, far from the common mountainous Sweden-Norway border, the region where most lynx are found.", [["feline", "ORGANISM", 15, 21], ["human", "ORGANISM", 42, 47], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["most lynx", "OBSERVATION", 174, 183]]], ["Recently, only 1 case of cowpox virus in a human has been identifi ed in this region (Nordland County, Norway).DiscussionThe presence of OPV DNA in >1 internal organs of the lynx is evidence of a virus infection and indicates that the host most likely has entered a viremic phase.", [["internal organs", "ANATOMY", 151, 166], ["cowpox virus", "DISEASE", 25, 37], ["infection", "DISEASE", 202, 211], ["cowpox virus", "ORGANISM", 25, 37], ["human", "ORGANISM", 43, 48], ["OPV", "ORGANISM", 137, 140], ["DNA", "CELLULAR_COMPONENT", 141, 144], ["organs", "ORGAN", 160, 166], ["lynx", "ORGANISM", 174, 178], ["OPV DNA", "DNA", 137, 144], ["human", "SPECIES", 43, 48], ["cowpox virus", "SPECIES", 25, 37], ["human", "SPECIES", 43, 48], ["OPV", "SPECIES", 137, 140], ["cowpox virus", "PROBLEM", 25, 37], ["OPV DNA", "PROBLEM", 137, 144], ["a virus infection", "PROBLEM", 194, 211], ["cowpox virus", "OBSERVATION", 25, 37], ["lynx", "OBSERVATION", 174, 178], ["evidence of", "UNCERTAINTY", 182, 193], ["virus", "OBSERVATION", 196, 201]]], ["No specifi c pathologic lesions in skin or lungs were recorded, but only a limited number of skins were submitted with the carcasses.", [["lesions", "ANATOMY", 24, 31], ["skin", "ANATOMY", 35, 39], ["lungs", "ANATOMY", 43, 48], ["skins", "ANATOMY", 93, 98], ["lesions", "PATHOLOGICAL_FORMATION", 24, 31], ["skin", "ORGAN", 35, 39], ["lungs", "ORGAN", 43, 48], ["skins", "ORGAN", 93, 98], ["specifi c pathologic lesions in skin or lungs", "PROBLEM", 3, 48], ["pathologic", "OBSERVATION_MODIFIER", 13, 23], ["lesions", "OBSERVATION", 24, 31], ["skin", "ANATOMY", 35, 39], ["lungs", "ANATOMY", 43, 48], ["skins", "ANATOMY", 93, 98]]], ["This fi nding calls for increased efforts to document possible clinical signs, pathologic changes, and the effects of cowpox virus infection in lynx, taking into account the clinical signs and organ lesions documented in domestic cats and in large felid species in zoos (11, 12) .DiscussionWild rodents such as bank voles, wood mice, and fi eld voles have been suggested as the main cowpox virus reservoirs in Finland (23), Great Britain (19, 22) , and Norway (in addition to lemmings and common shrews) (20, 21) .", [["organ lesions", "ANATOMY", 193, 206], ["cowpox virus infection", "DISEASE", 118, 140], ["cowpox virus", "ORGANISM", 118, 130], ["organ lesions", "PATHOLOGICAL_FORMATION", 193, 206], ["cats", "ORGANISM", 230, 234], ["bank voles", "ORGANISM", 311, 321], ["wood mice", "ORGANISM", 323, 332], ["fi eld voles", "ORGANISM", 338, 350], ["cowpox", "ORGANISM", 383, 389], ["cats", "SPECIES", 230, 234], ["mice", "SPECIES", 328, 332], ["cowpox virus", "SPECIES", 118, 130], ["bank voles", "SPECIES", 311, 321], ["mice", "SPECIES", 328, 332], ["fi eld voles", "SPECIES", 338, 350], ["cowpox virus", "SPECIES", 383, 395], ["clinical signs", "PROBLEM", 63, 77], ["pathologic changes", "PROBLEM", 79, 97], ["cowpox virus infection", "PROBLEM", 118, 140], ["the clinical signs", "PROBLEM", 170, 188], ["organ lesions", "PROBLEM", 193, 206], ["domestic cats", "TEST", 221, 234], ["large felid species", "PROBLEM", 242, 261], ["pathologic", "OBSERVATION", 79, 89], ["cowpox virus", "OBSERVATION", 118, 130], ["organ", "ANATOMY", 193, 198], ["lesions", "OBSERVATION", 199, 206], ["large", "OBSERVATION_MODIFIER", 242, 247], ["felid species", "OBSERVATION", 248, 261], ["main", "OBSERVATION_MODIFIER", 378, 382], ["cowpox virus", "OBSERVATION", 383, 395]]], ["Cowpox virus is considered to be endemic in these species in certain regions, circulating in several host species at the same time.", [["Cowpox virus", "ORGANISM", 0, 12], ["Cowpox virus", "SPECIES", 0, 12], ["Cowpox virus", "PROBLEM", 0, 12], ["endemic", "PROBLEM", 33, 40], ["considered to be", "UNCERTAINTY", 16, 32], ["endemic", "OBSERVATION_MODIFIER", 33, 40], ["species", "OBSERVATION", 50, 57], ["several", "OBSERVATION_MODIFIER", 93, 100], ["host species", "OBSERVATION", 101, 113]]], ["In a previous examination of stomach contents of Norwegian lynx, which are part of the common lynx population inhabiting Norway and Sweden, remnants of small rodents were found in 8% of the individuals (38) , demonstrating that rodents are part of their prey.DiscussionDomestic cats may also act as source of infection for lynx, as a potential prey species.", [["stomach", "ANATOMY", 29, 36], ["infection", "DISEASE", 309, 318], ["stomach", "ORGAN", 29, 36], ["cats", "ORGANISM", 278, 282], ["cats", "SPECIES", 278, 282], ["Norwegian lynx", "SPECIES", 49, 63], ["a previous examination", "TEST", 3, 25], ["small rodents", "PROBLEM", 152, 165], ["DiscussionDomestic cats", "TREATMENT", 259, 282], ["infection", "PROBLEM", 309, 318], ["lynx", "PROBLEM", 323, 327], ["stomach", "ANATOMY", 29, 36], ["Norwegian lynx", "OBSERVATION", 49, 63], ["common lynx", "ANATOMY", 87, 98], ["small", "OBSERVATION_MODIFIER", 152, 157], ["rodents", "OBSERVATION_MODIFIER", 158, 165], ["infection", "OBSERVATION", 309, 318]]], ["Lynx from areas with high human density, and thus a presumably larger domestic cat population, were more often infected than lynx from less populated areas, indicating a possible relationship between domestic cats and lynx.", [["human", "ORGANISM", 26, 31], ["cat", "ORGANISM", 79, 82], ["cats", "ORGANISM", 209, 213], ["human", "SPECIES", 26, 31], ["cats", "SPECIES", 209, 213], ["human", "SPECIES", 26, 31], ["high human density", "PROBLEM", 21, 39], ["a presumably larger domestic cat population", "PROBLEM", 50, 93], ["areas", "OBSERVATION_MODIFIER", 10, 15], ["high human", "OBSERVATION_MODIFIER", 21, 31], ["density", "OBSERVATION", 32, 39], ["presumably", "UNCERTAINTY", 52, 62], ["larger", "OBSERVATION_MODIFIER", 63, 69], ["domestic", "OBSERVATION_MODIFIER", 70, 78], ["cat population", "OBSERVATION", 79, 93], ["more often", "OBSERVATION_MODIFIER", 100, 110], ["infected", "OBSERVATION_MODIFIER", 111, 119], ["less", "OBSERVATION_MODIFIER", 135, 139], ["populated", "OBSERVATION_MODIFIER", 140, 149], ["lynx", "OBSERVATION", 218, 222]]], ["A similar association with human presence has already been observed with regard to seropositivity to T. gondii in some lynx in this study (29) .", [["T. gondii", "DISEASE", 101, 110], ["human", "ORGANISM", 27, 32], ["T. gondii", "ORGANISM", 101, 110], ["human", "SPECIES", 27, 32], ["T. gondii", "SPECIES", 101, 110], ["human", "SPECIES", 27, 32], ["T. gondii", "SPECIES", 101, 110], ["T. gondii", "TEST", 101, 110], ["this study", "TEST", 127, 137]]], ["In contrast, previous studies (1999) of other pathogens in some of the lynx (n = 70) included in this study suggested that contacts between lynx and domestic cats are uncommon; seroprevalence of antibodies against feline parvovirus was low; and feline leukemia virus antigen and antibodies against feline coronavirus, calicivirus, herpesvirus, and feline immunodefi ciency virus were absent (28) .", [["feline parvovirus", "DISEASE", 214, 231], ["feline leukemia", "DISEASE", 245, 260], ["feline coronavirus", "DISEASE", 298, 316], ["calicivirus", "DISEASE", 318, 329], ["lynx", "ORGANISM", 140, 144], ["domestic cats", "ORGANISM", 149, 162], ["feline parvovirus", "ORGANISM", 214, 231], ["feline leukemia virus", "ORGANISM", 245, 266], ["feline coronavirus", "ORGANISM", 298, 316], ["calicivirus", "ORGANISM", 318, 329], ["herpesvirus", "ORGANISM", 331, 342], ["feline immunodefi ciency virus", "ORGANISM", 348, 378], ["antibodies", "PROTEIN", 195, 205], ["feline leukemia virus antigen", "PROTEIN", 245, 274], ["antibodies", "PROTEIN", 279, 289], ["cats", "SPECIES", 158, 162], ["feline parvovirus", "SPECIES", 214, 231], ["feline leukemia virus", "SPECIES", 245, 266], ["feline coronavirus, calicivirus", "SPECIES", 298, 329], ["feline immunodefi ciency virus", "SPECIES", 348, 378], ["feline parvovirus", "SPECIES", 214, 231], ["feline leukemia virus", "SPECIES", 245, 266], ["feline coronavirus", "SPECIES", 298, 316], ["feline immunodefi ciency virus", "SPECIES", 348, 378], ["previous studies", "TEST", 13, 29], ["other pathogens", "PROBLEM", 40, 55], ["this study", "TEST", 97, 107], ["seroprevalence of antibodies", "TEST", 177, 205], ["feline parvovirus", "PROBLEM", 214, 231], ["feline leukemia virus antigen", "PROBLEM", 245, 274], ["antibodies", "TEST", 279, 289], ["feline coronavirus", "PROBLEM", 298, 316], ["calicivirus", "PROBLEM", 318, 329], ["herpesvirus", "PROBLEM", 331, 342], ["feline immunodefi ciency virus", "TEST", 348, 378], ["pathogens", "OBSERVATION", 46, 55], ["leukemia virus", "OBSERVATION", 252, 266]]], ["Assuming that lynx are susceptible to these feline pathogens, this difference may be explained by the fact that domestic cats are commonly vaccinated against these viral infections but not against T. gondii and OPVs.", [["feline pathogens", "DISEASE", 44, 60], ["viral infections", "DISEASE", 164, 180], ["feline", "ORGANISM", 44, 50], ["cats", "ORGANISM", 121, 125], ["T. gondii", "ORGANISM", 197, 206], ["OPVs", "CANCER", 211, 215], ["cats", "SPECIES", 121, 125], ["T. gondii", "SPECIES", 197, 206], ["T. gondii", "SPECIES", 197, 206], ["these feline pathogens", "PROBLEM", 38, 60], ["these viral infections", "PROBLEM", 158, 180], ["T. gondii", "PROBLEM", 197, 206], ["lynx", "OBSERVATION", 14, 18]]], ["Nevertheless, these results may suggest only limited contact between domestic cats and lynx, pointing at wild rodents and possibly shrews as the direct source of the OPV infection for lynx.", [["infection", "DISEASE", 170, 179], ["cats", "ORGANISM", 78, 82], ["OPV", "ORGANISM", 166, 169], ["cats", "SPECIES", 78, 82], ["limited contact between domestic cats and lynx", "PROBLEM", 45, 91], ["the OPV infection", "PROBLEM", 162, 179], ["infection", "OBSERVATION", 170, 179]]], ["Among the 24 animals that were OPV-positive by PCR, 5 (21%) had sarcoptic mange, whereas the total prevalence of mange among the 264 animals included in this study was 6.4%; this fi nding indicates a possible relationship between OPV infection and infestation with S. scabiei.", [["mange", "DISEASE", 74, 79], ["mange", "DISEASE", 113, 118], ["OPV infection", "DISEASE", 230, 243], ["infestation", "DISEASE", 248, 259], ["OPV", "ORGANISM", 230, 233], ["S. scabiei", "ORGANISM", 265, 275], ["S. scabiei", "SPECIES", 265, 275], ["S. scabiei", "SPECIES", 265, 275], ["OPV", "TEST", 31, 34], ["PCR", "TEST", 47, 50], ["sarcoptic mange", "TEST", 64, 79], ["this study", "TEST", 153, 163], ["OPV infection", "PROBLEM", 230, 243], ["infestation", "PROBLEM", 248, 259], ["S. scabiei", "PROBLEM", 265, 275], ["infection", "OBSERVATION", 234, 243]]], ["The severe epidermal lesions and breakage of the skin barrier might predispose the animals to infection by OPVs, such as cowpox virus, and such viruses might contribute to the severity of sarcoptic mange in lynx.", [["epidermal lesions", "ANATOMY", 11, 28], ["skin", "ANATOMY", 49, 53], ["epidermal lesions", "DISEASE", 11, 28], ["infection", "DISEASE", 94, 103], ["OPVs", "DISEASE", 107, 111], ["cowpox virus", "DISEASE", 121, 133], ["epidermal lesions", "PATHOLOGICAL_FORMATION", 11, 28], ["skin barrier", "TISSUE", 49, 61], ["OPVs", "GENE_OR_GENE_PRODUCT", 107, 111], ["cowpox virus", "ORGANISM", 121, 133], ["cowpox virus", "SPECIES", 121, 133], ["The severe epidermal lesions", "PROBLEM", 0, 28], ["the skin barrier", "TREATMENT", 45, 61], ["infection", "PROBLEM", 94, 103], ["OPVs", "TREATMENT", 107, 111], ["cowpox virus", "PROBLEM", 121, 133], ["such viruses", "PROBLEM", 139, 151], ["sarcoptic mange in lynx", "PROBLEM", 188, 211], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["epidermal", "OBSERVATION_MODIFIER", 11, 20], ["lesions", "OBSERVATION", 21, 28], ["breakage", "OBSERVATION_MODIFIER", 33, 41], ["skin", "ANATOMY", 49, 53], ["infection", "OBSERVATION", 94, 103], ["cowpox virus", "OBSERVATION", 121, 133], ["sarcoptic mange", "OBSERVATION", 188, 203]]], ["Alternatively, altered behavior in diseased lynx could infl uence exposure to infection.", [["infection", "DISEASE", 78, 87], ["lynx", "ORGANISM", 44, 48], ["altered behavior in diseased lynx", "PROBLEM", 15, 48], ["infection", "PROBLEM", 78, 87], ["altered", "OBSERVATION_MODIFIER", 15, 22], ["behavior", "OBSERVATION_MODIFIER", 23, 31], ["diseased lynx", "OBSERVATION", 35, 48], ["infection", "OBSERVATION", 78, 87]]], ["In contrast to healthy lynx, those with mange are commonly found in human settlements, where they sometimes prey on domestic animals, including cats and dogs (30) .DiscussionWe found no seasonal differences in OPV prevalence, although one could assume that autumn, with peak populations of rodents and shrews, would be when contact rate between these animals and lynx is highest.", [["human", "ORGANISM", 68, 73], ["cats", "ORGANISM", 144, 148], ["human", "SPECIES", 68, 73], ["cats", "SPECIES", 144, 148], ["dogs", "SPECIES", 153, 157], ["human", "SPECIES", 68, 73], ["no", "UNCERTAINTY", 183, 185], ["autumn", "OBSERVATION", 257, 263]]], ["It could also be expected that the presence of OPVs such as cowpox virus would fl uctuate between years, refl ecting the fl uctuations of rodent populations, but we found no signifi cant differences in prevalence between the years in this study.", [["OPVs", "GENE_OR_GENE_PRODUCT", 47, 51], ["cowpox virus", "ORGANISM", 60, 72], ["rodent", "SPECIES", 138, 144], ["cowpox virus", "SPECIES", 60, 72], ["OPVs", "TREATMENT", 47, 51], ["cowpox virus", "PROBLEM", 60, 72], ["signifi cant differences", "PROBLEM", 174, 198], ["this study", "TEST", 234, 244]]], ["These fi ndings could be the result of the low number of samples that were included from the nonhunting seasons and from some of the years represented in the study.DiscussionCowpox virus infection is a zoonosis, capable of being transmitted from rodents to humans, often by domestic cats.", [["DiscussionCowpox virus infection", "DISEASE", 164, 196], ["zoonosis", "DISEASE", 202, 210], ["DiscussionCowpox virus", "ORGANISM", 164, 186], ["humans", "ORGANISM", 257, 263], ["cats", "ORGANISM", 283, 287], ["humans", "SPECIES", 257, 263], ["cats", "SPECIES", 283, 287], ["DiscussionCowpox virus", "SPECIES", 164, 186], ["humans", "SPECIES", 257, 263], ["the low number of samples", "PROBLEM", 39, 64], ["the study", "TEST", 154, 163], ["DiscussionCowpox virus infection", "PROBLEM", 164, 196], ["a zoonosis", "PROBLEM", 200, 210], ["low", "OBSERVATION_MODIFIER", 43, 46], ["infection", "OBSERVATION", 187, 196]]], ["Cowpox virus infection in humans is usually characterized by single lesions on the infection site (face, hands, arms), but it sometimes spreads and cause secondary lesions and complications and can be especially severe in immunocompromised persons (6, 16, 23) .", [["lesions", "ANATOMY", 68, 75], ["site", "ANATOMY", 93, 97], ["face", "ANATOMY", 99, 103], ["lesions", "ANATOMY", 164, 171], ["Cowpox virus infection", "DISEASE", 0, 22], ["infection", "DISEASE", 83, 92], ["Cowpox virus", "ORGANISM", 0, 12], ["humans", "ORGANISM", 26, 32], ["lesions", "PATHOLOGICAL_FORMATION", 68, 75], ["face", "ORGANISM_SUBDIVISION", 99, 103], ["hands", "ORGANISM_SUBDIVISION", 105, 110], ["lesions", "PATHOLOGICAL_FORMATION", 164, 171], ["persons", "ORGANISM", 240, 247], ["humans", "SPECIES", 26, 32], ["persons", "SPECIES", 240, 247], ["Cowpox virus", "SPECIES", 0, 12], ["humans", "SPECIES", 26, 32], ["Cowpox virus infection", "PROBLEM", 0, 22], ["single lesions", "PROBLEM", 61, 75], ["the infection site", "PROBLEM", 79, 97], ["secondary lesions", "PROBLEM", 154, 171], ["complications", "PROBLEM", 176, 189], ["virus", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 13, 22], ["single", "OBSERVATION_MODIFIER", 61, 67], ["lesions", "OBSERVATION", 68, 75], ["infection", "OBSERVATION", 83, 92], ["face", "ANATOMY_MODIFIER", 99, 103], ["hands", "ANATOMY", 105, 110], ["arms", "ANATOMY", 112, 116], ["secondary", "OBSERVATION_MODIFIER", 154, 163], ["lesions", "OBSERVATION", 164, 171], ["severe", "OBSERVATION_MODIFIER", 212, 218], ["immunocompromised", "OBSERVATION", 222, 239]]], ["To our knowledge, however, only 2 verifi ed cowpox cases in humans have been recorded from Sweden (16, 26) .DiscussionIn conclusion, our results support the hypothesis that carnivores that prey on OPV reservoir species can be used as indicator species for the presence of such viruses in the ecosystem (25) .", [["cowpox", "ORGANISM", 44, 50], ["humans", "ORGANISM", 60, 66], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66], ["OPV reservoir species", "TREATMENT", 197, 218], ["such viruses", "PROBLEM", 272, 284], ["cowpox", "OBSERVATION", 44, 50]]], ["This study also provides further evidence that OPV, presumably cowpox virus, is widely distributed in ecosystems in Sweden.", [["OPV", "CHEMICAL", 47, 50], ["OPV", "ORGANISM", 47, 50], ["cowpox virus", "ORGANISM", 63, 75], ["cowpox virus", "SPECIES", 63, 75], ["This study", "TEST", 0, 10], ["OPV", "PROBLEM", 47, 50], ["cowpox virus", "PROBLEM", 63, 75], ["presumably", "UNCERTAINTY", 52, 62], ["cowpox virus", "OBSERVATION", 63, 75], ["widely", "OBSERVATION_MODIFIER", 80, 86], ["distributed", "OBSERVATION_MODIFIER", 87, 98], ["ecosystems", "OBSERVATION_MODIFIER", 102, 112]]], ["This fi nding may be relevant for vaccination strategies (39) , especially when considering the use of OPVs as vectors in genetically recombinant vaccines and their ability to undergo spontaneous genetic recombinations with virus relatives when replicating in the same cells of a host.", [["cells", "ANATOMY", 269, 274], ["OPVs", "GENE_OR_GENE_PRODUCT", 103, 107], ["cells", "CELL", 269, 274], ["vaccination strategies", "TREATMENT", 34, 56], ["OPVs as vectors", "TREATMENT", 103, 118], ["genetically recombinant vaccines", "TREATMENT", 122, 154]]], ["Moreover, our fi ndings indicate that the role of OPVs, such as cowpox virus, as potential human pathogens may increase, considering their broad distribution in ecosystems, the cessation of smallpox vaccination of humans, and an increasing number of immunocompromised persons.", [["OPVs", "GENE_OR_GENE_PRODUCT", 50, 54], ["cowpox virus", "ORGANISM", 64, 76], ["human", "ORGANISM", 91, 96], ["humans", "ORGANISM", 214, 220], ["persons", "ORGANISM", 268, 275], ["human", "SPECIES", 91, 96], ["humans", "SPECIES", 214, 220], ["persons", "SPECIES", 268, 275], ["cowpox virus", "SPECIES", 64, 76], ["human", "SPECIES", 91, 96], ["humans", "SPECIES", 214, 220], ["our fi ndings", "TEST", 10, 23], ["OPVs", "TREATMENT", 50, 54], ["cowpox virus", "PROBLEM", 64, 76], ["potential human pathogens", "PROBLEM", 81, 106], ["smallpox vaccination of humans", "TREATMENT", 190, 220], ["increasing", "OBSERVATION_MODIFIER", 229, 239], ["number", "OBSERVATION_MODIFIER", 240, 246], ["immunocompromised", "OBSERVATION", 250, 267]]], ["Thus, targeted surveillance of rodent species, and the carnivores that prey on them, is necessary for monitoring the emergence or reemergence of these viruses as potential human pathogens.", [["human", "ORGANISM", 172, 177], ["rodent", "SPECIES", 31, 37], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["rodent species", "PROBLEM", 31, 45], ["these viruses", "PROBLEM", 145, 158], ["potential human pathogens", "PROBLEM", 162, 187]]], ["Further genetic studies are needed to determine whether the detected virus in the free-ranging lynx population in Scandinavia is indeed cowpox virus.", [["lynx", "ORGANISM", 95, 99], ["cowpox virus", "ORGANISM", 136, 148], ["cowpox virus", "SPECIES", 136, 148], ["Further genetic studies", "TEST", 0, 23], ["the detected virus", "PROBLEM", 56, 74], ["cowpox virus", "PROBLEM", 136, 148], ["cowpox virus", "OBSERVATION", 136, 148]]]], "ff7f8110edb69b52b069ed8969e4f9d6d54bc23f": [["1Food protein-induced enterocolitis syndrome (FPIES) is a non IgE-mediated food 1 allergy that manifests with predominantly gastrointestinal symptoms characterized 2 by repetitive emesis, starting 1-4 hours (typically 2 hours) after food ingestion with 3 or without watery diarrhea that may follow within 6-10 hours.", [["gastrointestinal", "ANATOMY", 124, 140], ["enterocolitis syndrome", "DISEASE", 22, 44], ["FPIES", "DISEASE", 46, 51], ["food 1 allergy", "DISEASE", 75, 89], ["gastrointestinal symptoms", "DISEASE", 124, 149], ["repetitive emesis", "DISEASE", 169, 186], ["diarrhea", "DISEASE", 273, 281], ["gastrointestinal", "ORGAN", 124, 140], ["IgE", "PROTEIN", 62, 65], ["Food protein-induced enterocolitis syndrome", "PROBLEM", 1, 44], ["predominantly gastrointestinal symptoms", "PROBLEM", 110, 149], ["repetitive emesis", "PROBLEM", 169, 186], ["watery diarrhea", "PROBLEM", 266, 281], ["enterocolitis syndrome", "OBSERVATION", 22, 44], ["gastrointestinal", "ANATOMY", 124, 140], ["emesis", "OBSERVATION", 180, 186]]], ["(1) FPIES usually 4 starts in the first year of life; the most commonly reported triggers in infants 5 include cow's milk, soy, rice, and oat, followed by fruits, vegetables, egg, and fish 6 (Mediterranean countries).", [["milk", "ANATOMY", 117, 121], ["fruits", "ANATOMY", 155, 161], ["vegetables", "ANATOMY", 163, 173], ["egg", "ANATOMY", 175, 178], ["soy, rice, and oat", "CHEMICAL", 123, 141], ["infants", "ORGANISM", 93, 100], ["cow", "ORGANISM", 111, 114], ["milk", "ORGANISM_SUBSTANCE", 117, 121], ["soy", "ORGANISM_SUBSTANCE", 123, 126], ["rice", "ORGANISM_SUBDIVISION", 128, 132], ["oat", "ORGANISM_SUBDIVISION", 138, 141], ["fruits", "ORGANISM_SUBDIVISION", 155, 161], ["vegetables", "ORGANISM_SUBDIVISION", 163, 173], ["egg", "ORGANISM_SUBDIVISION", 175, 178], ["infants", "SPECIES", 93, 100], ["cow", "SPECIES", 111, 114], ["milk", "SPECIES", 117, 121], ["soy", "SPECIES", 123, 126], ["rice", "SPECIES", 128, 132], ["oat", "SPECIES", 138, 141], ["cow", "SPECIES", 111, 114], ["rice", "SPECIES", 128, 132]]], ["71While FPIES is traditionally regarded as a rare food allergy, recent population-based 8 study estimated prevalence in the US as 0.51% under 18 years, in line with 91previously reported cumulative incidence rates of FPIES in infancy between 0.34% 10 (Israel) and 0.7% (Spain).", [["food allergy", "DISEASE", 50, 62], ["FPIES", "CHEMICAL", 217, 222], ["a rare food allergy", "PROBLEM", 43, 62], ["FPIES in infancy", "PROBLEM", 217, 233]]], ["(2) 11 FPIES can be associated with systemic manifestations such as lethargy, hypotension 12 and hypovolemic shock.", [["lethargy", "DISEASE", 68, 76], ["hypotension", "DISEASE", 78, 89], ["hypovolemic shock", "DISEASE", 97, 114], ["systemic manifestations", "PROBLEM", 36, 59], ["lethargy", "PROBLEM", 68, 76], ["hypotension", "PROBLEM", 78, 89], ["hypovolemic shock", "PROBLEM", 97, 114], ["lethargy", "OBSERVATION", 68, 76], ["hypovolemic shock", "OBSERVATION", 97, 114]]], ["Because of the potential for severe symptoms, acute FPIES 13 is recognized as a medical emergency that may require prompt management with 14 intravenous fluids, anti-emetics and anti-inflammatories (e.g., methylprednisolone) 15 in the medical setting.", [["intravenous", "ANATOMY", 141, 152], ["methylprednisolone", "CHEMICAL", 205, 223], ["methylprednisolone", "CHEMICAL", 205, 223], ["anti-inflammatories", "SIMPLE_CHEMICAL", 178, 197], ["methylprednisolone", "SIMPLE_CHEMICAL", 205, 223], ["severe symptoms", "PROBLEM", 29, 44], ["acute FPIES", "PROBLEM", 46, 57], ["prompt management", "TREATMENT", 115, 132], ["14 intravenous fluids", "TREATMENT", 138, 159], ["anti-emetics", "TREATMENT", 161, 173], ["anti-inflammatories", "TREATMENT", 178, 197], ["methylprednisolone)", "TREATMENT", 205, 224], ["acute", "OBSERVATION_MODIFIER", 46, 51]]], ["Rarely, life support including intubation, ventilation and 16 vasopressors may be necessary.", [["life support", "TREATMENT", 8, 20], ["intubation", "TREATMENT", 31, 41], ["ventilation", "TREATMENT", 43, 54], ["16 vasopressors", "TREATMENT", 59, 74]]], ["Under regular circumstances, acute FPIES reactions 17 are preferably managed in the medical facility, unless symptoms are mild, and the 18 patient can be effectively monitored and rehydrated at home.", [["patient", "ORGANISM", 139, 146], ["patient", "SPECIES", 139, 146], ["acute FPIES reactions", "PROBLEM", 29, 50], ["symptoms", "PROBLEM", 109, 117], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["FPIES", "OBSERVATION", 35, 40]]], ["(1) 191The unprecedented circumstances of the COVID-19 pandemic present unique 20 challenges for patients with food allergy, including FPIES. shown in Figure 1 .", [["food allergy", "DISEASE", 111, 123], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["the COVID", "TREATMENT", 42, 51], ["food allergy", "PROBLEM", 111, 123]]], ["The implementation of these recommendations will vary based 31 on the local circumstances and the access to care due to COVID-19 burden.", [["COVID", "TEST", 120, 125]]], ["For 32 patients with past ssevere reactions, it is prudent to proactively discuss 33 management via telemedicine, if feasible.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["past ssevere reactions", "PROBLEM", 21, 43]]], ["341Consider providing patients with FPIES older than 6 months and without known 35 cardiac problems and no family history of syncope suggestive of prolonged QT 36 syndrome with a prescription for oral ondansetron to be used at home in case of an 37 acute reaction.", [["cardiac", "ANATOMY", 83, 90], ["oral", "ANATOMY", 196, 200], ["cardiac problems", "DISEASE", 83, 99], ["syncope", "DISEASE", 125, 132], ["QT 36 syndrome", "DISEASE", 157, 171], ["ondansetron", "CHEMICAL", 201, 212], ["ondansetron", "CHEMICAL", 201, 212], ["patients", "ORGANISM", 22, 30], ["oral", "ORGANISM_SUBDIVISION", 196, 200], ["ondansetron", "SIMPLE_CHEMICAL", 201, 212], ["patients", "SPECIES", 22, 30], ["known 35 cardiac problems", "PROBLEM", 74, 99], ["syncope", "PROBLEM", 125, 132], ["prolonged QT 36 syndrome", "PROBLEM", 147, 171], ["oral ondansetron", "TREATMENT", 196, 212], ["an 37 acute reaction", "PROBLEM", 243, 263], ["acute", "OBSERVATION_MODIFIER", 249, 254], ["reaction", "OBSERVATION", 255, 263]]], ["Ondansetron is a serotonin 5-HT receptor antagonist.", [["Ondansetron", "CHEMICAL", 0, 11], ["serotonin 5-HT", "CHEMICAL", 17, 31], ["Ondansetron", "CHEMICAL", 0, 11], ["serotonin", "CHEMICAL", 17, 26], ["Ondansetron", "SIMPLE_CHEMICAL", 0, 11], ["serotonin 5-HT", "SIMPLE_CHEMICAL", 17, 31], ["Ondansetron", "TREATMENT", 0, 11], ["a serotonin", "TREATMENT", 15, 26], ["HT receptor antagonist", "TREATMENT", 29, 51]]], ["Ondansetron is 38 available in oral forms (tablet, rapidly disintegrating tablet, oral film, and liqui).", [["oral", "ANATOMY", 31, 35], ["oral", "ANATOMY", 82, 86], ["Ondansetron", "CHEMICAL", 0, 11], ["Ondansetron", "CHEMICAL", 0, 11], ["Ondansetron", "SIMPLE_CHEMICAL", 0, 11], ["oral", "ORGANISM_SUBDIVISION", 31, 35], ["oral", "ORGANISM_SUBDIVISION", 82, 86], ["Ondansetron", "TREATMENT", 0, 11], ["oral film", "TREATMENT", 82, 91]]], ["391Ondansetron is indicated for prevention and treatment of chemotherapy -induced 40 nausea and emesis in patients older than 6 months.", [["391Ondansetron", "CHEMICAL", 0, 14], ["nausea", "DISEASE", 85, 91], ["emesis", "DISEASE", 96, 102], ["391Ondansetron", "CHEMICAL", 0, 14], ["391Ondansetron", "SIMPLE_CHEMICAL", 0, 14], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["391Ondansetron", "TREATMENT", 0, 14], ["chemotherapy", "TREATMENT", 60, 72], ["nausea", "PROBLEM", 85, 91], ["emesis", "PROBLEM", 96, 102]]], ["Ondansetron is recognized to 41 be associated with prolongation of the QT interval on electrocardiogram, but is 42 considered safe and is widely used in pediatric emergency departments to 43 symptomatically manage emesis.", [["Ondansetron", "CHEMICAL", 0, 11], ["emesis", "DISEASE", 214, 220], ["Ondansetron", "CHEMICAL", 0, 11], ["Ondansetron", "SIMPLE_CHEMICAL", 0, 11], ["Ondansetron", "TREATMENT", 0, 11], ["the QT interval", "PROBLEM", 67, 82], ["electrocardiogram", "TEST", 86, 103], ["emesis", "PROBLEM", 214, 220]]], ["There is limited experience with ondansetron in 44 FPIES, suggesting that it may be useful in alleviating emesis in mild and moderate The telephone number to activate emergency medical services in the USA and Canada is 911, in UK-999, in the countries of the European Union-112 and in Japan and South Korea-119.", [["ondansetron", "CHEMICAL", 33, 44], ["FPIES", "DISEASE", 51, 56], ["emesis", "DISEASE", 106, 112], ["ondansetron", "CHEMICAL", 33, 44], ["ondansetron", "SIMPLE_CHEMICAL", 33, 44], ["ondansetron", "TREATMENT", 33, 44], ["alleviating emesis in mild and moderate", "PROBLEM", 94, 133], ["mild", "OBSERVATION_MODIFIER", 116, 120], ["moderate", "OBSERVATION_MODIFIER", 125, 133]]]], "dfe3e0bb96147cbc06e4cf7b5f3635cda8d13106": [["52The coronavirus disease 2019 (COVID-19), caused by a novel virus-the severe acute respiratory This retrospective study was notified to the Institutional Ethical Committee.", [["coronavirus disease", "DISEASE", 6, 25], ["coronavirus disease 2019 (COVID-19", "SPECIES", 6, 40], ["The coronavirus disease", "PROBLEM", 2, 25], ["COVID", "TEST", 32, 37], ["a novel virus", "PROBLEM", 53, 66], ["the severe acute respiratory", "PROBLEM", 67, 95], ["This retrospective study", "TEST", 96, 120], ["coronavirus disease", "OBSERVATION", 6, 25], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["respiratory", "OBSERVATION", 84, 95]]], ["Given the retrospective 83 design of the study, the need for informed consent was waived.84To investigate significant differences between recovered and dead patients, we selected nine 85 independent variables that were presumed to influence the final outcome (Table 1) .", [["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["the study", "TEST", 37, 46], ["significant", "OBSERVATION_MODIFIER", 106, 117]]], ["These variables 86 were analyzed using Chi-square test or the Mann-Whitney U test.", [["Chi-square test", "TEST", 39, 54]]], ["The significant variables were 87 subsequently included in a multivariable logistic regression model to extract the predictive factors92We identified 302 Caucasian patients who were hospitalized for COVID-19 (Table 1) conditions that induced immunosuppression were significant predictive factors for in-hospital 96 mortality, and therefore, were included in the predictive model (Table 2) .", [["patients", "ORGANISM", 164, 172], ["predictive factors", "PROTEIN", 116, 134], ["patients", "SPECIES", 164, 172], ["the predictive factors", "PROBLEM", 112, 134], ["COVID", "TEST", 199, 204], ["immunosuppression", "TREATMENT", 242, 259], ["significant", "OBSERVATION_MODIFIER", 4, 15]]], ["With regard to 97 immunosuppressive conditions, most patients had advanced renal failure (42%), hematological 98 disorders (20%), or were treated with corticosteroids (18%).99On receiver operating characteristic curve analyses, the optimal cutoff values for Brixia score and 100 patient age were 8 points and 71 years, respectively.", [["renal", "ANATOMY", 75, 80], ["hematological", "ANATOMY", 96, 109], ["renal failure", "DISEASE", 75, 88], ["hematological 98 disorders", "DISEASE", 96, 122], ["corticosteroids", "CHEMICAL", 151, 166], ["patients", "ORGANISM", 53, 61], ["renal", "ORGAN", 75, 80], ["patient", "ORGANISM", 279, 286], ["patients", "SPECIES", 53, 61], ["patient", "SPECIES", 279, 286], ["immunosuppressive conditions", "TREATMENT", 18, 46], ["advanced renal failure", "PROBLEM", 66, 88], ["hematological 98 disorders", "PROBLEM", 96, 122], ["corticosteroids", "TREATMENT", 151, 166], ["characteristic curve analyses", "TEST", 197, 226], ["the optimal cutoff values", "TEST", 228, 253], ["Brixia score", "TEST", 258, 270], ["renal", "ANATOMY", 75, 80], ["failure", "OBSERVATION", 81, 88]]], ["Three different models that included the Brixia 101 score showed excellent predictive power (Figure 1 ).99to assess the effectiveness of a CXR scoring system for predicting in-hospital mortality in infected 123 patients.", [["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["the Brixia 101 score", "TEST", 37, 57], ["a CXR scoring system", "TEST", 137, 157]]], ["The main limitations of this study include the retrospective study design and lack of 124 laboratory parameters included in the predictive models because currently, these data were collected 125 from a limited number of cases.126In conclusion, this study demonstrated for the first time that high Brixia score and at least one other 127 predictive factor-patient age and conditions that induced immunosuppression-conferred the 128 highest risk of death due to COVID-19.", [["death", "DISEASE", 447, 452], ["patient", "ORGANISM", 355, 362], ["patient", "SPECIES", 355, 362], ["this study", "TEST", 24, 34], ["the retrospective study", "TEST", 43, 66], ["laboratory parameters", "TEST", 90, 111], ["these data", "TEST", 165, 175], ["this study", "TEST", 244, 254], ["high Brixia score", "PROBLEM", 292, 309], ["immunosuppression", "TREATMENT", 395, 412], ["death", "PROBLEM", 447, 452], ["COVID", "TEST", 460, 465], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["This information may help clinicians with patient 129 management and treatment planning, and additionally, would help them to be prepared for possible", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["treatment planning", "TREATMENT", 69, 87]]]], "6908a089fea0a7345e066dfd10462507601d88eb": [["rhea, vomiting, and dehydration, which lead to high mortality in suckling piglets.", [["rhea", "DISEASE", 0, 4], ["vomiting", "DISEASE", 6, 14], ["dehydration", "DISEASE", 20, 31], ["piglets", "ORGANISM", 74, 81], ["piglets", "SPECIES", 74, 81], ["rhea", "PROBLEM", 0, 4], ["vomiting", "PROBLEM", 6, 14], ["dehydration", "PROBLEM", 20, 31], ["high mortality in suckling piglets", "PROBLEM", 47, 81], ["vomiting", "OBSERVATION", 6, 14], ["dehydration", "OBSERVATION", 20, 31], ["high", "OBSERVATION_MODIFIER", 47, 51], ["mortality", "OBSERVATION_MODIFIER", 52, 61]]], ["In 1973, a transmissible gastroenteritis (TGE)-like outbreak of acute diarrhea caused by PEDV was first recorded in China (2) .", [["transmissible gastroenteritis", "DISEASE", 11, 40], ["TGE", "DISEASE", 42, 45], ["diarrhea", "DISEASE", 70, 78], ["PEDV", "CHEMICAL", 89, 93], ["PEDV", "SPECIES", 89, 93], ["a transmissible gastroenteritis", "PROBLEM", 9, 40], ["acute diarrhea", "PROBLEM", 64, 78], ["PEDV", "PROBLEM", 89, 93], ["transmissible", "OBSERVATION_MODIFIER", 11, 24], ["gastroenteritis", "OBSERVATION", 25, 40], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["diarrhea", "OBSERVATION", 70, 78]]], ["Since 2010, severe outbreaks with high mortality among suckling piglets have been widely reported both in Asia and North America (3) (4) (5) (6) (7) (8) .", [["piglets", "ORGANISM", 64, 71], ["piglets", "SPECIES", 64, 71], ["severe outbreaks", "PROBLEM", 12, 28], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["outbreaks", "OBSERVATION", 19, 28]]], ["During May 2014 to January 2015, outbreaks of diarrhea in fattening pigs on German and Belgian farms were confirmed to be caused by two strains both genetically close to U.S. prototype strain OH851 (9, 10) .", [["diarrhea", "DISEASE", 46, 54], ["pigs", "ORGANISM", 68, 72], ["pigs", "SPECIES", 68, 72], ["pigs", "SPECIES", 68, 72], ["diarrhea", "PROBLEM", 46, 54], ["two strains", "PROBLEM", 132, 143], ["diarrhea", "OBSERVATION", 46, 54]]]], "551995b1d6e1285a28eef0f2c582f70824214cbd": [["During the last decade viral epidemics have become a prevalent global health threat requiring techniques for rapid vaccine development [2] .", [["rapid vaccine development", "TREATMENT", 109, 134]]], ["Radiation has long been used to inactivate virions [3] although the uncorrelated nature of the ionization produced by gamma rays means that the protective outer envelope of the virus is highly damaged.", [["outer envelope", "ANATOMY", 155, 169], ["Radiation", "TREATMENT", 0, 9], ["the ionization", "PROBLEM", 91, 105], ["the protective outer envelope", "TREATMENT", 140, 169], ["the virus", "PROBLEM", 173, 182], ["virus", "OBSERVATION", 177, 182]]], ["High energy ion beams however produce long-thin (nanoscale) damage tracks which can be used for much more selective virion inactivation [4] .", [["High energy ion beams", "PROBLEM", 0, 21], ["long-thin (nanoscale) damage tracks", "PROBLEM", 38, 73], ["ion beams", "OBSERVATION_MODIFIER", 12, 21]]], ["Currently, in an important extension of this concept, a large-scale ion beam facility, is using beams of heavy, high energy ions to attempt to produce a vaccine for SARS-CoV-2 [5] .", [["SARS", "DISEASE", 165, 169], ["SARS-CoV", "SPECIES", 165, 173], ["a large-scale ion beam facility", "TREATMENT", 54, 85], ["a vaccine", "TREATMENT", 151, 160], ["SARS", "PROBLEM", 165, 169], ["large", "OBSERVATION_MODIFIER", 56, 61]]], ["Since the ions form long straight damage tracks, each of the ions interacting with a single virion will produce many ionizations or excitations in the nucleocapsid.", [["nucleocapsid", "CELLULAR_COMPONENT", 151, 163], ["long straight damage tracks", "PROBLEM", 20, 47], ["a single virion", "TREATMENT", 83, 98], ["excitations in the nucleocapsid", "PROBLEM", 132, 163], ["long straight damage", "OBSERVATION_MODIFIER", 20, 40], ["tracks", "OBSERVATION_MODIFIER", 41, 47]]], ["Each of these events has a chance to damage the RNA, rendering the virion inactive.", [["damage the RNA", "PROBLEM", 37, 51], ["virion inactive", "OBSERVATION", 67, 82]]], ["Damage to the envelope is typically limited to one or two locations, on the ion's 'way in' and on its 'way out', thus limiting the amount of structural damage to the surface spike proteins integral to activation of a host immune response.", [["surface", "ANATOMY", 166, 173], ["surface spike proteins", "PROTEIN", 166, 188], ["structural damage", "PROBLEM", 141, 158], ["damage", "OBSERVATION", 152, 158]]], ["RNA is a highly serial structure in its biological information expression; damage it in one or a few critical places and you probably render the virion inactive.", [["RNA", "RNA", 0, 3], ["a highly serial structure", "PROBLEM", 7, 32], ["highly", "OBSERVATION_MODIFIER", 9, 15], ["serial", "OBSERVATION_MODIFIER", 16, 22], ["structure", "OBSERVATION", 23, 32]]], ["In contrast the envelope proteins and phospholipid membrane are highly parallel structures so several of them can be radio-damaged without affecting the structure of the envelope significantly, leaving its function unchanged.", [["phospholipid membrane", "ANATOMY", 38, 59], ["phospholipid membrane", "CELLULAR_COMPONENT", 38, 59], ["envelope proteins", "PROTEIN", 16, 33], ["envelope proteins", "OBSERVATION", 16, 33], ["phospholipid membrane", "OBSERVATION", 38, 59], ["highly", "OBSERVATION_MODIFIER", 64, 70], ["parallel", "OBSERVATION_MODIFIER", 71, 79], ["unchanged", "OBSERVATION_MODIFIER", 215, 224]]], ["This assertion points to an informatic aspect of the problem, one we will investigate in this paper -there are two structures involved, the structure of the virion being irradiated and the structure of the radiation tracks doing the irradiation.", [["virion", "CELLULAR_COMPONENT", 157, 163], ["the irradiation", "TREATMENT", 229, 244], ["virion", "OBSERVATION_MODIFIER", 157, 163], ["radiation", "OBSERVATION_MODIFIER", 206, 215], ["tracks", "OBSERVATION_MODIFIER", 216, 222]]], ["As we show below, the interplay between these two structural forms is a governing factors determining the predicted dose inactivation curve for any given virion.IntroductionIf one can thus inactivate sufficient numbers of virions, they could be used as the key component for developing viral vaccines in a universal manner.", [["virions", "ANATOMY", 222, 229], ["virion", "CELLULAR_COMPONENT", 154, 160], ["the predicted dose inactivation curve", "TREATMENT", 102, 139], ["developing viral vaccines", "TREATMENT", 275, 300], ["viral vaccines", "OBSERVATION", 286, 300]]], ["The inactivation process, perhaps uniquely, produces little or no apparent change to the structure of the virions' envelopes.", [["virions", "ANATOMY", 106, 113], ["The inactivation process", "PROBLEM", 0, 24], ["inactivation process", "OBSERVATION", 4, 24], ["no apparent", "UNCERTAINTY", 63, 74], ["change", "OBSERVATION", 75, 81], ["virions", "OBSERVATION", 106, 113]]], ["Hence, they can be expected to enter a host in the usual way, including, in the case of SARS-CoV-2, using angiotensin-converting enzyme 2 (ACE2)-mediated cellular entry [6] .", [["cellular", "ANATOMY", 154, 162], ["SARS", "DISEASE", 88, 92], ["angiotensin", "CHEMICAL", 106, 117], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 106, 137], ["ACE2", "GENE_OR_GENE_PRODUCT", 139, 143], ["cellular", "CELL", 154, 162], ["angiotensin-converting enzyme 2", "PROTEIN", 106, 137], ["ACE2", "PROTEIN", 139, 143], ["SARS-CoV", "SPECIES", 88, 96], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96], ["angiotensin-converting enzyme", "TREATMENT", 106, 135]]], ["Upon encountering host immune cells, these inactivated antigenic virions would stimulate an immune response in the usual manner, but critically would lack reproductive capability.", [["immune cells", "ANATOMY", 23, 35], ["virions", "ANATOMY", 65, 72], ["host immune cells", "CELL", 18, 35], ["immune cells", "CELL_TYPE", 23, 35], ["host immune cells", "TREATMENT", 18, 35], ["these inactivated antigenic virions", "TREATMENT", 37, 72], ["host immune cells", "OBSERVATION", 18, 35]]], ["Hence, we call virions modified in this way Structurally Intact Radiation Inactivated Virions (SIRI-Vs).IntroductionIt is worth asking the question \"What would the specifications of an ion beam facility designed to produce sufficient quantities of SIRI-Vs look like?\".", [["an ion beam facility", "TREATMENT", 182, 202]]], ["High-energy, large scale ion facilities such as the one currently being used [5] are rare and very expensive.", [["large scale ion facilities", "TREATMENT", 13, 39]]], ["However, we believe it is also possible to use midrange ion facilities, such as those more traditionally associated with nuclear energy research [7] .IntroductionIn order to support such endeavors, it is important to have a set of predictive tools able to determine doseinactivation curves reliably.", [["nuclear", "ANATOMY", 121, 128], ["midrange ion facilities", "TREATMENT", 47, 70], ["predictive tools", "TEST", 231, 247]]], ["Here we show rapid prediction of inactivation responses and discuss some of the barriers which must be overcome to produce reliable predictions.", [["inactivation responses", "PROBLEM", 33, 55]]], ["We believe it is currently premature to rely on radiation transport simulations such as those in [5] or those presented here.", [["radiation transport simulations", "TREATMENT", 48, 79]]], ["It is in this spirit that several new approaches are offered in this paper.IntroductionEven before the current coronavirus disease 2019 (COVID-19) pandemic, total human vaccine business was projected to be worth ~$60 Bn annually by 2024 [8] whilst that for animals is projected to reach ~$11Bn by 2025 [9] .", [["coronavirus disease", "DISEASE", 111, 130], ["human", "ORGANISM", 163, 168], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["the current coronavirus disease", "PROBLEM", 99, 130], ["total human vaccine business", "TREATMENT", 157, 185], ["several", "OBSERVATION_MODIFIER", 26, 33], ["new", "OBSERVATION_MODIFIER", 34, 37]]], ["Clearly then there would be commercial benefit in developing mid-range ion facilities similar to [7] but designed specifically for purpose.Fast ion irradiation of the SARS-CoV virionA putative model of the SARS-CoV virion was developed using available structural biology information [10] [11] [12] [13] .", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 206, 214], ["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 283, 302], ["SARS-CoV virion", "PROTEIN", 206, 221], ["SARS-CoV", "SPECIES", 167, 175], ["SARS-CoV", "SPECIES", 206, 214], ["Fast ion irradiation", "TREATMENT", 139, 159], ["the SARS", "PROBLEM", 163, 171], ["the SARS", "PROBLEM", 202, 210], ["CoV virion", "TREATMENT", 211, 221]]], ["We chose to do this for SARS-CoV rather than the more topical SARS-CoV-2 since the structural biology database is more mature, allowing us to work with a realistic putative geometry.", [["SARS", "DISEASE", 24, 28], ["SARS", "DISEASE", 62, 66], ["SARS-CoV", "ORGANISM", 24, 32], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "PROBLEM", 24, 28]]], ["There is important information about the tertiary structure of at least part of the RNA in the nucleocapsid [10, 11] .", [["RNA", "RNA", 84, 87], ["RNA", "OBSERVATION", 84, 87]]], ["The two virions are very similar so general conclusions reached should also apply to SARS-CoV-2.Figure 1.Geometry of the SARS-CoV virion and its interaction with six randomly generated 3 MeV He 2+ ions shown from two different viewpoints.", [["virions", "ANATOMY", 8, 15], ["SARS", "DISEASE", 85, 89], ["SARS", "DISEASE", 121, 125], ["He 2+", "CHEMICAL", 191, 196], ["SARS-CoV virion", "PROTEIN", 121, 136], ["SARS-CoV", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 121, 129], ["The two virions", "TREATMENT", 0, 15], ["the SARS", "PROBLEM", 117, 125], ["CoV virion", "TREATMENT", 126, 136], ["two", "OBSERVATION_MODIFIER", 4, 7], ["virions", "OBSERVATION", 8, 15], ["SARS", "OBSERVATION", 121, 125]]], ["Tracks 1 and 6 completely miss the virion, whilst the core of track 2 misses but one of the child electrons produces an ionisation event in one of the spike proteins.", [["spike proteins", "PROTEIN", 151, 165], ["an ionisation event", "PROBLEM", 117, 136], ["the spike proteins", "PROBLEM", 147, 165], ["ionisation", "OBSERVATION", 120, 130]]], ["The cores of tracks 3 and 4 pass through a spike protein, whilst 5 passes through the nucleocapsid causing RNA-candidate damage events (red dots), envelope damage events (green dots) and spike-damage events (magenta dots).", [["spike protein", "PROTEIN", 43, 56], ["a spike protein", "PROBLEM", 41, 56], ["the nucleocapsid", "PROBLEM", 82, 98], ["damage events", "PROBLEM", 121, 134], ["red dots", "PROBLEM", 136, 144], ["envelope damage events", "PROBLEM", 147, 169], ["green dots", "PROBLEM", 171, 181], ["spike-damage events", "PROBLEM", 187, 206], ["magenta dots", "TREATMENT", 208, 220], ["cores", "OBSERVATION_MODIFIER", 4, 9], ["tracks", "OBSERVATION_MODIFIER", 13, 19]]], ["It is necessary to include tracks such as 1 and 6 with cores far from the nucleocapsid to ensure a correct weighting of the spike-damage, i.e through tracks like 2.", [["the nucleocapsid", "TREATMENT", 70, 86], ["the spike", "PROBLEM", 120, 129], ["damage", "PROBLEM", 130, 136]]], ["Full details of the geometry and how it was derived are given in the Methods section.Figure 1.The full details of the RNA tertiary/quaternary structure within the nucleocapsid are unknown.", [["nucleocapsid", "CELLULAR_COMPONENT", 163, 175], ["quaternary structure", "OBSERVATION", 131, 151], ["nucleocapsid", "ANATOMY", 163, 175]]], ["To test the importance of this unknown structure we considered three extreme forms of RNA arrangement, without making reference to any published structural forms.", [["RNA arrangement", "TREATMENT", 86, 101]]], ["These structural forms were i) all RNA concentrated in a small sphere at the centre of the nucleocapsid, ii) all RNA concentrated in a spherical shell at the inner surface of the nucleocapsid shell and iii) all RNA uniformly and randomly distributed throughout the entire volume of the nucleocapsid and with no persistence from ion to ion.", [["inner surface", "ANATOMY", 158, 171], ["inner surface", "CELLULAR_COMPONENT", 158, 171], ["nucleocapsid", "PROTEIN", 91, 103], ["all RNA", "PROBLEM", 31, 38], ["a small sphere", "PROBLEM", 55, 69], ["a spherical shell", "TREATMENT", 133, 150], ["small sphere", "OBSERVATION_MODIFIER", 57, 69], ["nucleocapsid", "OBSERVATION", 91, 103], ["spherical shell", "OBSERVATION", 135, 150], ["inner", "ANATOMY_MODIFIER", 158, 163], ["surface", "ANATOMY_MODIFIER", 164, 171], ["nucleocapsid shell", "OBSERVATION", 179, 197], ["RNA", "OBSERVATION_MODIFIER", 211, 214], ["uniformly", "OBSERVATION_MODIFIER", 215, 224], ["randomly", "OBSERVATION_MODIFIER", 229, 237], ["distributed", "OBSERVATION_MODIFIER", 238, 249], ["entire", "OBSERVATION_MODIFIER", 265, 271], ["volume", "OBSERVATION_MODIFIER", 272, 278], ["nucleocapsid", "OBSERVATION", 286, 298], ["no", "UNCERTAINTY", 308, 310], ["persistence", "OBSERVATION_MODIFIER", 311, 322]]], ["Indeed, this form has been implicitly assumed in modelling inactivation of SARS-CoV-2 [5] .", [["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "ORGANISM", 75, 85], ["SARS-CoV", "SPECIES", 75, 83]]], ["However, this form represents an extreme when viewed informatically as it places the tertiary/quaternary structure of RNA in its highest entropic state, something not typically found in biology.", [["the tertiary/quaternary structure of RNA", "PROBLEM", 81, 121], ["quaternary structure", "OBSERVATION", 94, 114]]], ["Furthermore, it is known that much of the RNA-protein complex of the SARS-CoV virion is highly ordered [10, 11] .", [["SARS", "DISEASE", 69, 73], ["SARS-CoV", "ORGANISM", 69, 77], ["RNA-protein complex", "PROTEIN", 42, 61], ["SARS-CoV virion", "PROTEIN", 69, 84], ["SARS-CoV", "SPECIES", 69, 77], ["the RNA", "TEST", 38, 45], ["the SARS", "PROBLEM", 65, 73], ["CoV virion", "TREATMENT", 74, 84]]], ["Accordingly, SARS-CoV-2 cannot have its RNA in such a high entropic state.Figure 1.For the geometry shown in figure 1, many 3 MeV He 2+ ions were successively passed through the virion each entering the simulation at a different random location.", [["He 2+", "CHEMICAL", 130, 135], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["He 2+ ions", "SIMPLE_CHEMICAL", 130, 140], ["SARS", "PROBLEM", 13, 17], ["its RNA", "PROBLEM", 36, 43], ["a high entropic state", "PROBLEM", 52, 73], ["high entropic", "OBSERVATION", 54, 67]]], ["The location of ionisation events were recorded, with ~42% of events being direct He 2+ ion-interactions with the remaining ~58% being due to child electrons produced upstream.", [["ionisation events", "PROBLEM", 16, 33], ["ionisation events", "OBSERVATION", 16, 33]]], ["The range of initial positions of the ion trajectories was chosen to be significantly bigger than the area of the virion presented to the ion beam so that roughly 50% of the ions had no interaction with the virion, properly mimicking the effect of ions passing in close proximity to the virion causing damage to the membrane or spike proteins.", [["membrane", "ANATOMY", 316, 324], ["virion", "CELLULAR_COMPONENT", 287, 293], ["membrane", "CELLULAR_COMPONENT", 316, 324], ["spike proteins", "PROTEIN", 328, 342], ["the virion", "TREATMENT", 203, 213], ["spike proteins", "PROBLEM", 328, 342], ["range", "OBSERVATION_MODIFIER", 4, 9], ["significantly", "OBSERVATION_MODIFIER", 72, 85], ["bigger", "OBSERVATION_MODIFIER", 86, 92], ["virion", "OBSERVATION", 114, 120]]], ["This damage is generated through the creation of electrons which travel several nm from the main ion trajectory before causing an ionisation event.", [["This damage", "PROBLEM", 0, 11], ["an ionisation event", "PROBLEM", 127, 146], ["main", "OBSERVATION_MODIFIER", 92, 96], ["ionisation event", "OBSERVATION", 130, 146]]], ["An example of this phenomenon is track 2, figure 1.", [["this phenomenon", "PROBLEM", 14, 29]]], ["An ion was considered to have interacted with the virion if even a single ionisation process occurred anywhere in the virion geometry.", [["the virion", "TREATMENT", 46, 56], ["a single ionisation process", "PROBLEM", 65, 92], ["virion geometry", "OBSERVATION", 118, 133]]], ["Hence, proper weighting was given to the effect of peripheral ion trajectories on the outer parts of the virion structure.", [["outer parts", "ANATOMY", 86, 97], ["virion", "CELLULAR_COMPONENT", 105, 111], ["peripheral ion trajectories", "TREATMENT", 51, 78], ["outer", "ANATOMY_MODIFIER", 86, 91], ["virion structure", "OBSERVATION", 105, 121]]], ["Only ionisation events were used for this process, rather than energy deposition events as was done previously [5] .", [["ionisation events", "PROBLEM", 5, 22], ["this process", "PROBLEM", 37, 49], ["energy deposition events", "PROBLEM", 63, 87], ["ionisation events", "OBSERVATION", 5, 22]]], ["Although energy deposition approaches have been very successful in predicting biological outcomes in other nanoscale radiobiology contexts [15] [16] [17] , we argue in the discussion section that more of a targettheory inspired approach [3, 18] is appropriate, although we admit this is an open question and one worthy of further investigation.", [["energy deposition approaches", "TREATMENT", 9, 37], ["a targettheory inspired approach", "TREATMENT", 204, 236], ["further investigation", "TEST", 322, 343]]], ["However, none of the conclusions reached regarding the role of RNA tertiary/quaternary structure depend on the choice between energy deposition or target theory approaches.", [["quaternary structure", "OBSERVATION", 76, 96]]], ["There are clear differences in the probability of inflicting damage to the RNA.", [["inflicting damage to the RNA", "PROBLEM", 50, 78], ["clear", "OBSERVATION_MODIFIER", 10, 15], ["differences", "OBSERVATION_MODIFIER", 16, 27], ["inflicting", "OBSERVATION_MODIFIER", 50, 60], ["damage", "OBSERVATION", 61, 67], ["RNA", "ANATOMY", 75, 78]]], ["In case i), the RNA presents the smallest area to the incoming ion beam, so it is not surprising to find the probability of no ionisations in the RNA to be significantly larger than in the other two scenarios.", [["the RNA", "PROBLEM", 12, 19], ["ionisations in the RNA", "PROBLEM", 127, 149], ["smallest", "OBSERVATION_MODIFIER", 33, 41], ["RNA", "OBSERVATION", 146, 149], ["significantly", "OBSERVATION_MODIFIER", 156, 169], ["larger", "OBSERVATION", 170, 176]]], ["Although scenarios ii) and iii) have apparently similar histograms on a linear scale, there are noticeable differences.", [["a linear scale", "TREATMENT", 70, 84], ["noticeable", "OBSERVATION_MODIFIER", 96, 106], ["differences", "OBSERVATION_MODIFIER", 107, 118]]], ["When examined on the logarithmic scale the histogram of the number of hits to the RNA shows marked differences in all 3 cases.", [["the logarithmic scale", "TEST", 17, 38], ["the histogram", "TEST", 39, 52], ["marked differences in all 3 cases", "PROBLEM", 92, 125], ["marked", "OBSERVATION_MODIFIER", 92, 98]]], ["Assuming a single ionizing event to the RNA is sufficient to inactivate a virion, then the key parameter is the probability of no ionizing events occurring within the RNA per ion track interacting with the virion.", [["virion", "CELLULAR_COMPONENT", 206, 212], ["a virion", "TREATMENT", 72, 80], ["ionizing events", "PROBLEM", 130, 145], ["the virion", "TREATMENT", 202, 212]]], ["This probability has a value of 0.88, 0.50 and 0.52 for cases i) -iii) respectively.", [["a value", "TEST", 21, 28]]], ["From these probabilities one can deduce a dose-inactivation curve using Poisson statistics [5] .", [["a dose-inactivation curve", "TREATMENT", 40, 65]]], ["However, it is not yet clear how much of the RNA constitutes the critical target, another factor which will also affect this curve.", [["this curve", "TEST", 120, 130]]], ["Figure 3 shows histograms recording the average number of hits to spikes per ion track and the total number of spikes hit per ion track.", [["histograms recording", "TEST", 15, 35]]], ["These histograms are the same regardless of the RNA tertiary/quaternary structural form so only one set are shown.", [["These histograms", "TEST", 0, 16]]], ["Unsurprisingly, the forms of the histograms for number of hits per spike and number of hits to the RNA in case ii) are similar since they both involve the ion track interacting with a hollow, essentially spherical structure.", [["the histograms", "TEST", 29, 43], ["hits", "PROBLEM", 58, 62], ["spike", "PROBLEM", 67, 72], ["a hollow, essentially spherical structure", "PROBLEM", 182, 223], ["spherical structure", "OBSERVATION", 204, 223]]], ["This result confirms that shown in [5] and is encouraging for the field of ion-beam inactivation of virions.Radio-density scalingIn order to differentiate between RNA and proteins, one must account for the differences in their interactions when subject to fast charged particles.", [["virions", "ANATOMY", 100, 107], ["ion-beam inactivation of virions", "TREATMENT", 75, 107], ["Radio-density scaling", "PROBLEM", 108, 129], ["RNA and proteins", "PROBLEM", 163, 179], ["density", "OBSERVATION", 114, 121], ["scaling", "OBSERVATION_MODIFIER", 122, 129]]], ["Here, results of an analytical analysis of the scaling properties are presented and used to generate either scaled effective volumes or scaled effective densities for the biomolecules concerned.Radio-density scalingBecause there are not yet a good set of well curated charged-particle interaction cross sections for either proteins or RNA, one must rely on a well curated set for water.", [["sections", "ANATOMY", 303, 311], ["an analytical analysis", "TEST", 17, 39], ["scaled effective densities", "PROBLEM", 136, 162], ["Radio-density scaling", "PROBLEM", 194, 215], ["proteins or RNA", "PROBLEM", 323, 338], ["density", "OBSERVATION", 200, 207]]], ["One particularly useful and reliable set are those in Geant4 DNA.", [["DNA", "CELLULAR_COMPONENT", 61, 64], ["Geant4 DNA", "DNA", 54, 64]]], ["However, it is not a-priory clear that the mass-density is the appropriate parameter when scaling from water.", [["the mass-density", "PROBLEM", 39, 55], ["mass", "OBSERVATION", 43, 47], ["density", "OBSERVATION", 48, 55]]], ["The fast ions are really interacting with charge, not mass, as is evidenced by the Bethe formula [21, 22] , which for non-relativistic ion velocities reduces toRadio-density scalingHere is the velocity of the ion, is its change in multiples of the electron charge, is the electron density of the material through which the ion is passing and is the mean excitation potential.", [["electron", "SIMPLE_CHEMICAL", 248, 256], ["electron", "SIMPLE_CHEMICAL", 272, 280], ["mass", "PROBLEM", 54, 58], ["non-relativistic ion velocities", "PROBLEM", 118, 149], ["Radio-density scaling", "PROBLEM", 160, 181], ["mass", "OBSERVATION", 54, 58], ["density", "OBSERVATION", 166, 173], ["change", "OBSERVATION_MODIFIER", 221, 227], ["electron charge", "OBSERVATION", 248, 263], ["electron density", "OBSERVATION_MODIFIER", 272, 288]]], ["The electron density is given byRadio-density scalingwhere the material dependent parts are , its atomic number, , its mass density and , is its relative atoms mass.", [["electron", "SIMPLE_CHEMICAL", 4, 12], ["its mass density", "PROBLEM", 115, 131], ["its relative atoms mass", "PROBLEM", 141, 164], ["density", "OBSERVATION", 13, 20], ["density", "OBSERVATION", 38, 45], ["material dependent", "OBSERVATION_MODIFIER", 63, 81], ["parts", "OBSERVATION_MODIFIER", 82, 87], ["number", "OBSERVATION_MODIFIER", 105, 111], ["mass", "OBSERVATION_MODIFIER", 119, 123], ["density", "OBSERVATION", 124, 131], ["atoms", "OBSERVATION_MODIFIER", 154, 159], ["mass", "OBSERVATION", 160, 164]]], ["The other two symbols are 1 , the Avogadro number and 4 , the molar mass constant.", [["the molar mass", "PROBLEM", 58, 72], ["molar", "ANATOMY", 62, 67], ["mass", "OBSERVATION", 68, 72]]], ["One can calculate the electron density for a compound as if it was simply a mixture of the atoms, i.e. one sums over all of the atoms present, replacing the density by the density of that atom in the material.Radio-density scalingFor most light atoms the ratio \u2044 \u2248 1/2, allowing factorization of \u2044 out of the expression for the compound electron density, providing a scaling directly between charge and mass density.", [["electron", "SIMPLE_CHEMICAL", 22, 30], ["electron", "SIMPLE_CHEMICAL", 337, 345], ["Radio-density scaling", "PROBLEM", 209, 230], ["the compound electron density", "PROBLEM", 324, 353], ["mass density", "PROBLEM", 403, 415], ["density", "OBSERVATION", 31, 38], ["density", "OBSERVATION", 157, 164], ["density", "OBSERVATION_MODIFIER", 172, 179], ["atom", "OBSERVATION_MODIFIER", 188, 192], ["density", "OBSERVATION", 215, 222], ["electron density", "OBSERVATION", 337, 353], ["mass density", "OBSERVATION", 403, 415]]], ["However, hydrogen is a notable exception where the ratio \u2044 = 1.", [["hydrogen", "CHEMICAL", 9, 17], ["hydrogen", "CHEMICAL", 9, 17], ["hydrogen", "SIMPLE_CHEMICAL", 9, 17], ["the ratio", "TEST", 47, 56], ["hydrogen", "OBSERVATION", 9, 17], ["notable", "OBSERVATION_MODIFIER", 23, 30]]], ["Hence more hydrogen-rich materials will have proportionally greater electron densities and hence will interact with charged particle beams more intensely.Radio-density scalingThe other material-dependent term in equation (1)Radio-density scalingIt has been shown that a range of biomolecules including water, proteins and RNA all have a mean excitation energy of approximately 70 eV [23] .", [["hydrogen", "CHEMICAL", 11, 19], ["hydrogen", "CHEMICAL", 11, 19], ["electron", "SIMPLE_CHEMICAL", 68, 76], ["water", "SIMPLE_CHEMICAL", 302, 307], ["hydrogen-rich materials", "TREATMENT", 11, 34], ["proportionally greater electron densities", "PROBLEM", 45, 86], ["Radio-density scaling", "PROBLEM", 154, 175], ["Radio-density scaling", "PROBLEM", 224, 245], ["density", "OBSERVATION", 160, 167], ["scaling", "OBSERVATION_MODIFIER", 168, 175], ["material-dependent term", "OBSERVATION_MODIFIER", 185, 208], ["density scaling", "OBSERVATION_MODIFIER", 230, 245]]], ["This argument can also be applied to the child electrons; hence one can find a set of scaling densities which can be applied to water, so it has approximately the same interaction rate as the material of interest.", [["scaling densities", "PROBLEM", 86, 103], ["scaling", "OBSERVATION_MODIFIER", 86, 93], ["densities", "OBSERVATION", 94, 103]]], ["Taking known elemental compositions of biomolecules, it is then possible to generate a set of radio-equivalent densities such as those of table 1.", [["elemental compositions", "OBSERVATION_MODIFIER", 13, 35], ["densities", "OBSERVATION", 111, 120]]], ["These radio-equivalent densities are the density water would have to have to have the same electron density and hence the same rate of energy loss as per equation Table 1 showing the elemental compositions of various biomolecules, their densities and the resultant scaled radio-densities, i.e. the density water would have to have to produce the equivalent materialdependent term in equation 1.", [["electron", "SIMPLE_CHEMICAL", 91, 99], ["These radio-equivalent densities", "PROBLEM", 0, 32], ["energy loss", "PROBLEM", 135, 146], ["their densities", "PROBLEM", 231, 246], ["the resultant scaled radio-densities", "PROBLEM", 251, 287], ["densities", "OBSERVATION", 23, 32], ["density", "OBSERVATION", 41, 48], ["density", "OBSERVATION", 100, 107], ["various biomolecules", "OBSERVATION", 209, 229], ["densities", "OBSERVATION_MODIFIER", 237, 246], ["resultant", "OBSERVATION_MODIFIER", 255, 264], ["scaled", "OBSERVATION_MODIFIER", 265, 271], ["radio", "OBSERVATION_MODIFIER", 272, 277], ["densities", "OBSERVATION", 278, 287], ["density", "OBSERVATION", 298, 305], ["equivalent", "OBSERVATION_MODIFIER", 346, 356], ["materialdependent term", "OBSERVATION", 357, 379]]], ["Elemental compositions are taken from [24] .Radio-density scalingIf the density of the biomolecule is not known in the particular configuration of interest, usually both its elemental composition and total mass are known, e.g. from primary sequence information.", [["Elemental compositions", "TEST", 0, 22], ["Radio-density scaling", "PROBLEM", 44, 65], ["total mass", "PROBLEM", 200, 210], ["density", "OBSERVATION", 50, 57], ["scaling", "OBSERVATION_MODIFIER", 58, 65], ["density", "OBSERVATION", 72, 79], ["biomolecule", "OBSERVATION", 87, 98], ["total", "OBSERVATION_MODIFIER", 200, 205], ["mass", "OBSERVATION", 206, 210]]], ["The density of the biomolecule can then be estimated from atomic volumes to generate a mass-density.", [["a mass-density", "PROBLEM", 85, 99], ["density", "OBSERVATION", 4, 11], ["atomic volumes", "OBSERVATION", 58, 72], ["mass", "OBSERVATION", 87, 91], ["density", "OBSERVATION", 92, 99]]], ["Hence results like those of table 1 can be generated for many biomolecules as required.Radio-density scalingThe choice to scale the densities is somewhat ad hoc, indeed there is an assumption being made about the volumes of the objects which is used to determine their mass-densities.", [["many biomolecules", "TREATMENT", 57, 74], ["Radio-density scaling", "PROBLEM", 87, 108], ["their mass-densities", "PROBLEM", 263, 283], ["density", "OBSERVATION", 93, 100], ["scaling", "OBSERVATION_MODIFIER", 101, 108], ["densities", "OBSERVATION", 132, 141], ["mass", "OBSERVATION", 269, 273], ["densities", "OBSERVATION", 274, 283]]], ["Since these are small objects compared with the length-scales over which the ion slows down one could fix the densities of the objects representing the various biomolecules in a simulation and instead scale their volumes, i.e. instead of slightly perturbing the densities of objects in a simulation to account for their different interactions with charged particles, one could instead slightly perturb their volumes.", [["small objects", "PROBLEM", 16, 29], ["a simulation", "TREATMENT", 176, 188], ["charged particles", "TREATMENT", 348, 365], ["small", "OBSERVATION_MODIFIER", 16, 21], ["objects", "OBSERVATION", 22, 29], ["densities", "OBSERVATION", 110, 119], ["various", "OBSERVATION_MODIFIER", 152, 159], ["biomolecules", "OBSERVATION_MODIFIER", 160, 172], ["slightly", "OBSERVATION_MODIFIER", 238, 246], ["densities", "OBSERVATION_MODIFIER", 262, 271]]], ["This second approach has the advantage that the entire nanoscale radiation transport simulation can now be performed at a constant mass-density.", [["the entire nanoscale radiation transport simulation", "TREATMENT", 44, 95], ["a constant mass-density", "PROBLEM", 120, 143], ["mass", "OBSERVATION", 131, 135], ["density", "OBSERVATION", 136, 143]]], ["A set of ion tracks can be calculated for one density and then be 'replayed' many times with different starting positions and angles.", [["angles", "OBSERVATION_MODIFIER", 126, 132]]], ["Because the tracks do not pass through regions of different densities, the computationally expensive boundary-crossing checks are not required, instead one simply has to consider the volumes in which the transformed ionisations occur to determine the effects of the track.Radio-density scalingWe have explored both approaches (i.e. density and volume scaling) in the next section where we present results for ions passing through the RNA-protein nucleocomplex of the SARS-CoV virion.", [["SARS-CoV virion", "ORGANISM", 467, 482], ["RNA-protein nucleocomplex", "PROTEIN", 434, 459], ["SARS-CoV virion", "PROTEIN", 467, 482], ["SARS-CoV", "SPECIES", 467, 475], ["different densities", "PROBLEM", 50, 69], ["crossing checks", "TEST", 110, 125], ["the volumes", "TEST", 179, 190], ["volume scaling", "TEST", 344, 358], ["the RNA", "TEST", 430, 437], ["the SARS", "PROBLEM", 463, 471], ["different", "OBSERVATION_MODIFIER", 50, 59], ["densities", "OBSERVATION", 60, 69], ["density", "OBSERVATION", 278, 285], ["density", "OBSERVATION", 332, 339], ["volume", "OBSERVATION_MODIFIER", 344, 350], ["SARS", "OBSERVATION", 467, 471], ["CoV virion", "OBSERVATION", 472, 482]]], ["The scaled radio-density approach and the scaling of volumes instead of densities appear to be general procedures which can be applied in the calculation of radiation transport through nanoscale biological systems and they will be subject of a future publication.Simulations of the RNA-protein complexIn order to begin to assess the effect of RNA tertiary structure, we created a geometrical model of the RNA nucleocapsid complex for which there exists a putative RNA structure.", [["RNA nucleocapsid complex", "PROTEIN", 405, 429], ["The scaled radio-density approach", "TREATMENT", 0, 33], ["general procedures", "TREATMENT", 95, 113], ["radiation transport", "TREATMENT", 157, 176], ["the RNA-protein complexIn", "TREATMENT", 278, 303], ["RNA tertiary structure", "PROBLEM", 343, 365], ["the RNA nucleocapsid complex", "PROBLEM", 401, 429], ["a putative RNA structure", "PROBLEM", 453, 477], ["scaled", "OBSERVATION_MODIFIER", 4, 10], ["radio", "OBSERVATION_MODIFIER", 11, 16], ["density", "OBSERVATION", 17, 24], ["scaling", "OBSERVATION_MODIFIER", 42, 49], ["volumes", "OBSERVATION_MODIFIER", 53, 60], ["densities", "OBSERVATION", 72, 81], ["appear to be", "UNCERTAINTY", 82, 94], ["general", "OBSERVATION_MODIFIER", 95, 102], ["procedures", "OBSERVATION", 103, 113], ["RNA nucleocapsid complex", "OBSERVATION", 405, 429], ["RNA structure", "OBSERVATION", 464, 477]]], ["The geometry of the simulation was drawn from the putative structure for the RNA-protein complex [10, 11] .", [["RNA-protein complex", "PROTEIN", 77, 96], ["the simulation", "TEST", 16, 30], ["the RNA", "TEST", 73, 80], ["geometry", "OBSERVATION_MODIFIER", 4, 12]]], ["The RNA forms two helices separated and held in place by a protein complex, with the sugar-phosphate backbone lying on the inside of the helix and the RNA bases facing outwards.", [["phosphate", "CHEMICAL", 91, 100], ["sugar", "CHEMICAL", 85, 90], ["phosphate", "CHEMICAL", 91, 100], ["sugar", "SIMPLE_CHEMICAL", 85, 90], ["protein complex", "PROTEIN", 59, 74], ["the sugar-phosphate backbone", "TREATMENT", 81, 109], ["two", "OBSERVATION_MODIFIER", 14, 17], ["helices", "OBSERVATION_MODIFIER", 18, 25], ["helix", "ANATOMY_MODIFIER", 137, 142], ["RNA", "OBSERVATION", 151, 154], ["bases", "ANATOMY_MODIFIER", 155, 160]]], ["These two separate RNA strands are about 5 nm apart and their bases are not paired.", [["RNA strands", "RNA", 19, 30], ["RNA strands", "OBSERVATION", 19, 30], ["5 nm", "OBSERVATION_MODIFIER", 41, 45], ["bases", "ANATOMY_MODIFIER", 62, 67]]], ["The volumes and densities of the RNA bases were chosen in 3 ways.Simulations of the RNA-protein complexIn the first set of simulations the entire volume was treated as having a density of 1.40 g/cm 3 , close to the asymptotic value for large proteins [25] , and the volumes of the RNA bases and phosphate backbone were taken from [26] .", [["phosphate", "CHEMICAL", 295, 304], ["phosphate", "CHEMICAL", 295, 304], ["phosphate backbone", "SIMPLE_CHEMICAL", 295, 313], ["RNA-protein complexIn", "PROTEIN", 84, 105], ["RNA bases", "RNA", 281, 290], ["densities of the RNA bases", "PROBLEM", 16, 42], ["the RNA", "TEST", 80, 87], ["large proteins", "PROBLEM", 236, 250], ["the volumes", "TEST", 262, 273], ["phosphate backbone", "TREATMENT", 295, 313], ["volumes", "OBSERVATION_MODIFIER", 4, 11], ["densities", "OBSERVATION_MODIFIER", 16, 25], ["RNA", "ANATOMY", 33, 36], ["bases", "ANATOMY_MODIFIER", 37, 42], ["volumes", "ANATOMY_MODIFIER", 266, 273], ["RNA", "ANATOMY_MODIFIER", 281, 284], ["bases", "ANATOMY_MODIFIER", 285, 290]]], ["This is equivalent to transferring the assumption made in [5] and our simulations above that the density is the same across the entire capsid down to the scale of the RNA-protein complexclearly this is wrong but it serves as a useful starting point.Simulations of the RNA-protein complexSimulations were performed in two ways, one where a full Geant4 DNA calculation was performed, and the locations of the ionisations was recorded.", [["DNA", "CELLULAR_COMPONENT", 351, 354], ["RNA-protein", "PROTEIN", 167, 178], ["Geant4", "DNA", 344, 350], ["the RNA-protein complexSimulations", "TEST", 264, 298], ["a full Geant4 DNA calculation", "TEST", 337, 366], ["the ionisations", "TEST", 403, 418], ["density", "OBSERVATION", 97, 104]]], ["The locations of the ionisations were scored using Mathematica's geometry primitives.", [["Mathematica's geometry primitives", "TREATMENT", 51, 84]]], ["In both cases the density was set to 1.40 g/cm 3 throughout.Simulations of the RNA-protein complexIn a second pair of simulations the density for the RNA was calculated using appropriate atomic volumes [26] so that the RNA backbone had a density of 1.83 g/cm 3 and the bases had a density of 1.65 g/cm 3 .", [["RNA-protein complexIn", "PROTEIN", 79, 100], ["the RNA", "TEST", 75, 82], ["the RNA", "TEST", 146, 153], ["appropriate atomic volumes", "TEST", 175, 201], ["the RNA backbone", "TEST", 215, 231], ["density", "OBSERVATION", 18, 25], ["density", "OBSERVATION", 134, 141], ["density", "OBSERVATION_MODIFIER", 238, 245], ["1.83 g/cm", "OBSERVATION_MODIFIER", 249, 258], ["bases", "ANATOMY_MODIFIER", 269, 274], ["density", "OBSERVATION", 281, 288], ["1.65 g/cm", "OBSERVATION_MODIFIER", 292, 301]]], ["This simulation did not take account of the specific bases in the sequence as the motif being simulated is a repeating unit throughout the capsid, accounting for containment of more than half of the RNA complex [10, 13] .", [["RNA complex", "PROTEIN", 199, 210], ["a repeating unit throughout the capsid", "TREATMENT", 107, 145], ["containment", "OBSERVATION_MODIFIER", 162, 173]]], ["Instead the known RNA sequence [14] was used to calculate an average volume and density for the nucleobases.", [["nucleobases", "CHEMICAL", 96, 107], ["RNA sequence", "DNA", 18, 30], ["the known RNA sequence", "TEST", 8, 30], ["average", "OBSERVATION_MODIFIER", 61, 68], ["volume", "OBSERVATION_MODIFIER", 69, 75], ["density", "OBSERVATION", 80, 87], ["nucleobases", "ANATOMY_MODIFIER", 96, 107]]], ["These densities were used in a second Geant4 DNA simulation otherwise similar to the one described above, whilst the same densities were used to scale volumes in a simulation which again replayed many tracks and used Mathematica's geometry primitives to determine which ionisations occurred within the RNA backbone and base structures.", [["DNA", "CELLULAR_COMPONENT", 45, 48], ["a second Geant4 DNA simulation", "TREATMENT", 29, 59], ["Mathematica's geometry primitives", "TREATMENT", 217, 250], ["densities", "OBSERVATION", 6, 15], ["densities", "OBSERVATION", 122, 131], ["RNA backbone", "OBSERVATION", 302, 314], ["base", "ANATOMY_MODIFIER", 319, 323]]], ["Here the volumes of the bases and backbone elements were scaled by a factor of 1.65/1.40 and 1.83/1.40 respectively so that each element of the simulation had the same probability of interacting with the radiation.Simulations of the RNA-protein complexIn a third set of simulations, the same procedures were carried out using scaled radio-densities taken from table 1.", [["a factor", "TEST", 67, 75], ["the radiation", "TREATMENT", 200, 213], ["the RNA", "TEST", 229, 236], ["the same procedures", "TEST", 283, 302], ["volumes", "ANATOMY_MODIFIER", 9, 16], ["bases", "ANATOMY_MODIFIER", 24, 29], ["backbone elements", "ANATOMY", 34, 51]]], ["Again, this was used to scale the density in a full Monte Carlo simulation and also to scale the volumes in a simulation where many tracks were replayed.", [["a full Monte Carlo simulation", "TREATMENT", 45, 74], ["density", "OBSERVATION", 34, 41], ["tracks", "OBSERVATION_MODIFIER", 132, 138]]], ["The results of these simulations are presented in table 2.", [["these simulations", "TEST", 15, 32]]], ["These simulations were conducted with the ions only coming in from one direction.", [["the ions", "TREATMENT", 38, 46]]], ["In all cases, the fraction of ionisations found in simulation was greater than expected on purely geometrical grounds, suggesting the localised structure of the RNA does play a role, i.e. the probability is 5-10% greater than would be expected if transferring an approach like case iii) for the whole virion down to the scale of the RNA-protein complex.", [["RNA-protein complex", "PROTEIN", 333, 352], ["the localised structure of the RNA", "PROBLEM", 130, 164], ["the whole virion", "PROBLEM", 291, 307]]], ["Since this result shows it is not appropriate to apply the approximation used in case iii) to the RNA-protein complex shown in figure 4 and given that approximately half of the RNA is in these RNA-protein complexes, it follow that this approximation made by us in case iii) and also used in [5] is not valid.", [["RNA-protein complex", "PROTEIN", 98, 117], ["RNA", "RNA", 177, 180], ["RNA-protein complexes", "PROTEIN", 193, 214]]], ["Although they are generally in close agreement, the scaled volumes approach (scored using Mathematica) produces consistently smaller values than the scaled density approach calculated using Monte Carlo radiation transport.", [["Monte Carlo", "CHEMICAL", 190, 201], ["the scaled volumes approach", "TEST", 48, 75], ["the scaled density approach", "TREATMENT", 145, 172], ["Monte Carlo radiation transport", "TREATMENT", 190, 221], ["smaller", "OBSERVATION_MODIFIER", 125, 132]]], ["This could be due to differences in the volume-scoring algorithms when applied at sub-nm scale and will be the subject of further investigation.", [["sub-nm scale", "TREATMENT", 82, 94], ["further investigation", "TEST", 122, 143], ["could be due to", "UNCERTAINTY", 5, 20]]], ["Unlike the virion as a whole, the protein-RNA complex does not have quasi-spherical symmetry, so a full simulation should average irradiation over all orientations although this is computationally more expensive.", [["virion", "CELLULAR_COMPONENT", 11, 17], ["protein-RNA complex", "PROTEIN", 34, 53], ["the protein", "TEST", 30, 41], ["quasi-spherical symmetry", "PROBLEM", 68, 92], ["a full simulation", "TREATMENT", 97, 114], ["virion", "OBSERVATION", 11, 17]]], ["Using volume-scaling with scaled radio-densities, we performed another simulation.", [["scaling", "OBSERVATION_MODIFIER", 13, 20], ["densities", "OBSERVATION", 39, 48]]], ["Here we not only scored hits to the various RNA structures; we also stored the full track identification for each ionisation within any of the RNA structures.", [["RNA structures", "RNA", 143, 157], ["each ionisation", "TEST", 109, 124]]], ["These were then analysed for coincident events, i.e. when a single primary ion caused ionising events in two different parts of the RNA structure.", [["RNA structure", "RNA", 132, 145], ["ionising events", "PROBLEM", 86, 101], ["RNA structure", "OBSERVATION", 132, 145]]], ["Unsurprisingly, most of the coincidental ionisation events concern proximal backbone/base units, i.e. where the difference in index (explained in figure 5 's caption) is < 5.", [["the coincidental ionisation events", "PROBLEM", 24, 58], ["proximal backbone/base units", "TREATMENT", 67, 95], ["ionisation", "OBSERVATION", 41, 51], ["base units", "OBSERVATION_MODIFIER", 85, 95]]], ["However, it is interesting to note that there are persistent features in this map, even when structures are several nm apart.", [["this map", "TEST", 73, 81], ["persistent", "OBSERVATION_MODIFIER", 50, 60]]], ["The most prominent features are found when the difference in indexes is 32 or 53, which corresponds to the kinds of coincident events shown by the pink arrows in figure 5a ).", [["the pink arrows", "PROBLEM", 143, 158], ["most prominent", "OBSERVATION_MODIFIER", 4, 18]]], ["However, there is not a feature found corresponding to a difference in index of 44, i.e. a pair of events on directly opposite units of the two strands.", [["index", "TEST", 71, 76]]], ["There is also a weak shoulder on the same-strand distribution corresponding to a difference in index of about 17 although there is no immediately obvious cause of this feature.", [["shoulder", "ORGANISM_SUBDIVISION", 21, 29], ["a weak shoulder", "PROBLEM", 14, 29], ["a difference in index", "TEST", 79, 100], ["weak", "OBSERVATION_MODIFIER", 16, 20], ["shoulder", "ANATOMY", 21, 29], ["strand distribution", "OBSERVATION_MODIFIER", 42, 61], ["difference", "OBSERVATION_MODIFIER", 81, 91], ["no immediately obvious", "UNCERTAINTY", 131, 153]]], ["If each ionizing event corresponds to a chance to break the RNA strand where the ionisation took place, it follows that, depending on details of how the RNA is ordered within the nucleocapsid, the lengths of strands produced by multiple events from a single ion will reflect features of the map shown in figure 5b) , i.e. they will reflect the tertiary RNA structure.", [["nucleocapsid", "CELLULAR_COMPONENT", 179, 191], ["RNA strand", "RNA", 60, 70], ["RNA", "RNA", 153, 156], ["the map", "TEST", 287, 294], ["the tertiary RNA structure", "PROBLEM", 340, 366], ["tertiary RNA", "OBSERVATION", 344, 356]]], ["This idea is discussed in more detail in the Discussion section.Method of ionising lines (MoILs)Another fast analytical technique was developed, this time to account for the spectrum of coincident events from single ion tracks causing ionising events in two separate parts of the RNA structure, with a view to developing a framework for rapidly assessing the likely effect of tertiary structure on two-site damage to various RNA structures.", [["ionising lines", "CELL_LINE", 74, 88], ["MoILs", "CELL_LINE", 90, 95], ["Method of ionising lines (MoILs", "TREATMENT", 64, 95], ["Another fast analytical technique", "TREATMENT", 96, 129], ["coincident events", "PROBLEM", 186, 203], ["single ion tracks", "PROBLEM", 209, 226], ["ionising events", "PROBLEM", 235, 250], ["tertiary structure", "PROBLEM", 376, 394], ["ionising lines", "OBSERVATION", 74, 88], ["RNA structure", "OBSERVATION", 280, 293], ["tertiary structure", "OBSERVATION", 376, 394]]], ["Every pair of structures was considered in turn with a histogram constructed with the bins being the difference in position along the strand of the pair and the contribution to the height being 1 , \u2044 , where is the Euclidean distance between the two structural elements.", [["a histogram", "TEST", 53, 64], ["the bins", "TREATMENT", 82, 90], ["position", "OBSERVATION_MODIFIER", 115, 123], ["two", "OBSERVATION_MODIFIER", 246, 249], ["structural elements", "OBSERVATION", 250, 269]]], ["This factor acknowledges the fact that an ion track is long and narrow so that the chance of it interacting with two structures of fixed volume is proportional the solid angle one of the structures presents to the other and hence proportional to the inverse square of their separation.", [["fixed volume", "OBSERVATION", 131, 143], ["solid angle", "OBSERVATION_MODIFIER", 164, 175]]], ["As can be seen in figure 5c ) and d) this method is able to rapidly predict the distribution of coincident ionizing events as a function of index difference, i.e. for a suitable RNA ordering within the nucleocapsid it is able to rapidly predict the strand-length distribution for coincident single-strand breaks.", [["coincident ionizing events", "PROBLEM", 96, 122], ["index difference", "PROBLEM", 140, 156], ["a suitable RNA ordering within the nucleocapsid", "PROBLEM", 167, 214], ["strand breaks", "OBSERVATION", 298, 311]]], ["This concept is considered further in the discussion section.DiscussionThe histograms presented in figure 2 clearly show that 3D arrangement of the RNA (i.e. the tertiary/quaternary structure) within the virion is important.", [["virion", "CELLULAR_COMPONENT", 204, 210], ["The histograms", "TEST", 71, 85], ["the RNA", "PROBLEM", 144, 151], ["the tertiary/quaternary structure", "TREATMENT", 158, 191], ["quaternary structure", "OBSERVATION", 171, 191]]], ["Different assumed tertiary structures give different probabilities of delivering one or more ionisations to the RNA and hence give different probabilities of rendering a virion inactive per ion.", [["tertiary structures", "OBSERVATION", 18, 37]]], ["In coronavirus most of the viral RNA lies within ~25 nm of the inner face of the membrane [12] , making the arrangement similar to case ii).", [["inner face", "ANATOMY", 63, 73], ["membrane", "ANATOMY", 81, 89], ["coronavirus", "ORGANISM", 3, 14], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["viral RNA", "RNA", 27, 36], ["coronavirus", "PROBLEM", 3, 14], ["the viral RNA", "PROBLEM", 23, 36], ["coronavirus", "OBSERVATION", 3, 14], ["viral RNA", "OBSERVATION", 27, 36], ["25 nm", "OBSERVATION_MODIFIER", 50, 55], ["inner", "ANATOMY_MODIFIER", 63, 68], ["face", "ANATOMY_MODIFIER", 69, 73], ["membrane", "ANATOMY_MODIFIER", 81, 89]]], ["However, in this region it is believed to be largely in highly ordered RNA-protein complexes such as those shown in figure 4 [10] .", [["protein complexes", "PROTEIN", 75, 92], ["believed to be", "UNCERTAINTY", 30, 44]]], ["As table 2 and figure 5 show, the probability of hitting the RNA in such a configuration is roughly proportional to the fractional volume occupied by the RNA, although it is consistently higher by 5-10%something possibly related to the RNA's tertiary structure.", [["RNA", "RNA", 61, 64], ["hitting the RNA", "PROBLEM", 49, 64], ["the fractional volume", "TEST", 116, 137], ["RNA", "OBSERVATION", 61, 64], ["roughly", "OBSERVATION_MODIFIER", 92, 99], ["proportional", "OBSERVATION_MODIFIER", 100, 112], ["fractional volume", "OBSERVATION", 120, 137], ["RNA", "OBSERVATION", 154, 157], ["consistently", "OBSERVATION_MODIFIER", 174, 186], ["higher", "OBSERVATION_MODIFIER", 187, 193]]], ["The separate RNA-protein complexes will keep RNA far apart meaning that the coincident damage probability across two of these complexes will be small.", [["RNA-protein complexes", "PROTEIN", 13, 34], ["The separate RNA-protein complexes", "TEST", 0, 34], ["the coincident damage probability", "PROBLEM", 72, 105], ["coincident", "OBSERVATION_MODIFIER", 76, 86], ["damage", "OBSERVATION", 87, 93], ["small", "OBSERVATION_MODIFIER", 144, 149]]], ["However, the predicted inactivation probability would be raised somewhat due of ionising events on the RNA due to the structure in the RNA-protein complex.", [["RNA-protein complex", "PROTEIN", 135, 154], ["the predicted inactivation probability", "PROBLEM", 9, 47], ["ionising events on the RNA", "PROBLEM", 80, 106]]], ["Hence, one might suggest that the actual dose inactivation curve might lie somewhere between that for cases ii) and iii) considered.DiscussionTo make more firm predictions, among other things, one would need a better knowledge of the RNA tertiary/quaternary structure, something which is considered a major challenge of structural biology.", [["the actual dose inactivation curve", "TREATMENT", 30, 64]]], ["However, it is not possible to deduce the tertiary/quaternary RNA structure from the dose-inactivation curve -there could be many different tertiary/quaternary structures which lead to the same doseinactivation curve.", [["the tertiary/quaternary RNA structure", "PROBLEM", 38, 75], ["inactivation curve", "TEST", 90, 108], ["many different tertiary/quaternary structures", "PROBLEM", 125, 170], ["the same doseinactivation curve", "TEST", 185, 216], ["not possible", "UNCERTAINTY", 15, 27], ["quaternary RNA", "OBSERVATION", 51, 65], ["many", "OBSERVATION_MODIFIER", 125, 129], ["different", "OBSERVATION_MODIFIER", 130, 139], ["tertiary", "OBSERVATION_MODIFIER", 140, 148], ["quaternary structures", "OBSERVATION", 149, 170]]], ["Furthermore, there is currently significant uncertainty in radiation transport crosssections, the probability of an RNA strand-break either per ionizing event (target theory) or the amount of energy required to make a break (energy deposition theory).", [["an RNA strand", "PROBLEM", 113, 126], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["uncertainty", "OBSERVATION", 44, 55], ["radiation transport", "OBSERVATION_MODIFIER", 59, 78], ["RNA strand", "OBSERVATION", 116, 126]]], ["These factors will need to be systematically addressed before meaningful dose-inactivation curves can be deduced, even for an assumed tertiary/quaternary RNA structure.DiscussionHistorically there have been broadly two approaches to relate physical radiation transport processes to biological outcome, target theory [3, 18] and energy deposition [15] [16] [17] .", [["[15] [16] [17]", "SIMPLE_CHEMICAL", 346, 360], ["inactivation curves", "PROBLEM", 78, 97], ["an assumed tertiary/quaternary RNA structure", "PROBLEM", 123, 167], ["physical radiation transport processes", "TREATMENT", 240, 278], ["quaternary RNA", "OBSERVATION", 143, 157]]], ["Although it is an open question and one requiring further research, we argue that a target theory-based approach is more appropriate.", [["a target theory-based approach", "TREATMENT", 82, 112]]], ["The energy deposition approach accounts for energy deposition by excitation (of water) as well as its ionisation.", [["The energy deposition approach", "TREATMENT", 0, 30], ["energy deposition", "PROBLEM", 44, 61], ["excitation (of water)", "TREATMENT", 65, 86], ["energy deposition", "OBSERVATION", 4, 21], ["energy deposition", "OBSERVATION", 44, 61], ["ionisation", "OBSERVATION", 102, 112]]], ["In liquid water both processes lead to the formation of reactive products which mediate biological damage.", [["reactive products", "TREATMENT", 56, 73], ["biological damage", "PROBLEM", 88, 105], ["liquid water both", "OBSERVATION_MODIFIER", 3, 20], ["reactive products", "OBSERVATION", 56, 73], ["biological", "OBSERVATION_MODIFIER", 88, 98], ["damage", "OBSERVATION", 99, 105]]], ["However, in biological structures such as proteins and RNA, there is a larger network of bonds through which electronic energy can be transferred to stabilise the system, hence reducing bond breaking.", [["proteins and RNA", "PROBLEM", 42, 58], ["RNA", "OBSERVATION_MODIFIER", 55, 58], ["larger", "OBSERVATION_MODIFIER", 71, 77], ["bond breaking", "OBSERVATION", 186, 199]]], ["In contrast, ionisation will almost inevitably lead to rapid bond breaking.", [["ionisation", "TREATMENT", 13, 23], ["rapid bond breaking", "PROBLEM", 55, 74], ["rapid", "OBSERVATION_MODIFIER", 55, 60], ["bond breaking", "OBSERVATION", 61, 74]]], ["Indeed, the system is more complex and might need an entirely new theory altogether.", [["more complex", "OBSERVATION_MODIFIER", 22, 34]]], ["For example, it is reasonable to consider a highly folded 3D biological structure to be more robust to effects of ionizing radiation than a more open one.DiscussionWe have presented some new tools for the rapid evaluation of the effects of ion beams on biological systems.", [["a highly folded 3D biological structure", "PROBLEM", 42, 81], ["ionizing radiation", "TREATMENT", 114, 132], ["the rapid evaluation", "TEST", 201, 221], ["ion beams on biological systems", "TREATMENT", 240, 271]]], ["The concept of volume-scaling rather than density-scaling needs further investigation although ultimately what is required is a set of cross-sections for atomic and molecular processes for RNA, DNA and proteins.", [["DNA", "CELLULAR_COMPONENT", 194, 197], ["RNA, DNA and proteins", "PROTEIN", 189, 210], ["further investigation", "TEST", 64, 85], ["cross-sections", "TEST", 135, 149], ["volume", "OBSERVATION_MODIFIER", 15, 21], ["scaling", "OBSERVATION_MODIFIER", 22, 29]]], ["The entire gamut of these biomolecules is clearly too large to study as a whole, representing the entire 'Holy Trinity' of structural biology.", [["biomolecules", "OBSERVATION", 26, 38], ["too large", "OBSERVATION_MODIFIER", 50, 59]]], ["However, the charge-density scaling approach leading to table 1 is general, only requiring primary sequence information and atomic volumes.", [["the charge-density scaling approach", "TREATMENT", 9, 44], ["density", "OBSERVATION", 20, 27]]], ["The approach, then, could form the basis of a new way of generating the required cross-section data as required.DiscussionIn figure 5 we showed that there are preferred differences along the sequence for locations of coincident strand-breaks produced by a single ion.", [["strand-breaks", "PROBLEM", 228, 241]]], ["Coincident ionisation events could lead to the RNA being broken in two places.", [["Coincident ionisation events", "PROBLEM", 0, 28], ["the RNA", "PROBLEM", 43, 50], ["ionisation", "OBSERVATION", 11, 21]]], ["Since the threading of the RNA through the SARS-CoV collection of RNA-protein complexes is not yet understood, it is impossible to say if these peaks in the differences of indexes will manifest as peaks in the differences of RNA strand-lengths observable after low dose irradiation (ensuring one or less ions ionise a given RNA strand) and disassembling of the capsid.", [["SARS", "DISEASE", 43, 47], ["capsid", "CELLULAR_COMPONENT", 361, 367], ["RNA-protein complexes", "PROTEIN", 66, 87], ["RNA strand", "RNA", 324, 334], ["the SARS", "PROBLEM", 39, 47], ["CoV collection of RNA-protein complexes", "TEST", 48, 87], ["low dose irradiation", "TREATMENT", 261, 281], ["the capsid", "PROBLEM", 357, 367], ["capsid", "OBSERVATION", 361, 367]]], ["If there were peaks in the strand-length distribution, this would then directly be informative of the RNA tertiary/quaternary structure in an entirely new fashion and in turn informative of the way the virion forms.", [["virion forms", "RNA", 202, 214], ["peaks", "OBSERVATION_MODIFIER", 14, 19], ["quaternary structure", "OBSERVATION", 115, 135]]], ["This idea then points to the idea of using coincident RNA strand-breaks induced under single-ion hit conditions as a new means of deducing tertiary/quaternary RNA structure.DiscussionThe method of ionizing lines (MoILs) presented here is completely general and allows for the rapid prediction of RNA strand-length distributions after irradiation in this manner.", [["ionizing lines", "CELL", 197, 211], ["ionizing lines", "CELL_LINE", 197, 211], ["MoILs", "CELL_LINE", 213, 218], ["deducing tertiary/quaternary RNA structure", "PROBLEM", 130, 172], ["ionizing lines (MoILs)", "TREATMENT", 197, 219], ["quaternary RNA", "OBSERVATION", 148, 162]]], ["To illustrate this, we show an example of a prediction taken from the RNA-Puzzles collection, as is shown in figure 6 .", [["a prediction", "TEST", 42, 54], ["Puzzles collection", "PROBLEM", 74, 92]]], ["This clearly shows that the ion beam induced coincident fragment pattern is able to critique the best computationally derived tertiary structure from within the RNA-Puzzles collaboration compared to the 'golden standard' crystallography structure.", [["the ion beam induced coincident fragment pattern", "PROBLEM", 24, 72], ["ion beam", "OBSERVATION_MODIFIER", 28, 36], ["coincident", "OBSERVATION_MODIFIER", 45, 55], ["fragment", "OBSERVATION", 56, 64], ["tertiary structure", "OBSERVATION", 126, 144]]], ["Hence ion-beam induced fragment length distributions can provide clear indications of RNA tertiary structure.", [["Hence ion-beam induced fragment length distributions", "TREATMENT", 0, 52], ["RNA tertiary structure", "PROBLEM", 86, 108], ["fragment", "OBSERVATION_MODIFIER", 23, 31], ["length", "OBSERVATION_MODIFIER", 32, 38], ["tertiary structure", "OBSERVATION", 90, 108]]], ["Essentially, the low-entropy pattern of ionisations induced by the ion beam is able to encode the tertiary structural information in the RNA in the fragmentation pattern.", [["low", "OBSERVATION_MODIFIER", 17, 20], ["fragmentation pattern", "OBSERVATION", 148, 169]]], ["Figure 6 . comparison of MoILs-predicted fragment length distributions of the best predicted (but not entirely correct) structure (blue dots on the histogram) and the 'gold standard' X-ray crystallographic structure (red dots on the histogram) for RNA puzzle #9 (a 71 nt RNA aptamer) from the RNA puzzles collection [27] .", [["MoILs", "PROTEIN", 25, 30], ["71 nt RNA aptamer", "RNA", 265, 282], ["the histogram", "TEST", 144, 157], ["X-ray crystallographic structure", "TEST", 183, 215], ["the histogram", "TEST", 229, 242], ["RNA puzzle", "TEST", 248, 258], ["a 71 nt RNA aptamer", "TREATMENT", 263, 282], ["fragment", "OBSERVATION_MODIFIER", 41, 49], ["length", "OBSERVATION_MODIFIER", 50, 56]]], ["The X-ray crystallographic structure was also used to make the space-filling model shown in the inset.", [["The X-ray crystallographic structure", "TEST", 0, 36], ["the space-filling model", "TREATMENT", 59, 82], ["filling model", "OBSERVATION", 69, 82]]], ["Note the peak at a fragment length of ~23 is indicative of incorrect structure prediction.DiscussionFeatures like this in the fragment length distribution could form the basis for critiquing and predicting RNA tertiary structures.ConclusionWe have shown that the interplay between radiation track structure and RNA's 3D arrangement in space (i.e. the tertiary/quaternary structure) has a significant effect on predicted dose-inactivation curves for virions and that this effect can be traced back to the localised, low-entropy/highly informatic fashion ion beams transfer energy to biological systems.", [["a fragment length", "TEST", 17, 34], ["incorrect structure prediction", "PROBLEM", 59, 89], ["critiquing", "PROBLEM", 180, 190], ["the tertiary/quaternary structure", "TREATMENT", 347, 380], ["inactivation curves", "TREATMENT", 425, 444], ["virions", "PROBLEM", 449, 456], ["peak", "OBSERVATION_MODIFIER", 9, 13], ["fragment", "OBSERVATION_MODIFIER", 19, 27], ["length", "OBSERVATION_MODIFIER", 28, 34], ["indicative of", "UNCERTAINTY", 45, 58], ["incorrect structure", "OBSERVATION", 59, 78], ["significant", "OBSERVATION_MODIFIER", 388, 399]]], ["Indeed, it is this localised transfer which offers the promise of structurally intact radition inactivated virions (SIRI-Vs).", [["virions", "ANATOMY", 107, 114]]], ["This informatic transfer can potentially encode tertiary/quaternary structure structural information in the lengths of ion-beam induced RNA fragments, pointing to a new field of radio-structural biology.", [["ion-beam induced RNA fragments", "DNA", 119, 149], ["ion-beam induced RNA fragments", "PROBLEM", 119, 149], ["RNA fragments", "OBSERVATION", 136, 149]]], ["Methods such as charge-density based volume scaling of targets and MoILs have been proposed as tools to help develop this field with its promise of ab-initio RNA tertiary structure determination, provision of constraints for hybrid methods, detection of quaternary interactions and signatures to identify or monitor structures in-situ.MethodsTOPAS [28] version 3.3p01 that wraps the geant4-10-05-patch-01version [29] was used to transport 3 MeV alpha particles through a volume of water with a density of 1.4 g/cc over a distance of 0.8 \u00b5m.", [["geant4-10-05-patch-01version", "CHEMICAL", 383, 411], ["MoILs", "SIMPLE_CHEMICAL", 67, 72], ["MoILs", "PROTEIN", 67, 72], ["geant4", "DNA", 383, 389], ["Methods", "TREATMENT", 0, 7], ["charge-density based volume scaling", "TREATMENT", 16, 51], ["hybrid methods", "TREATMENT", 225, 239], ["quaternary interactions", "PROBLEM", 254, 277], ["MethodsTOPAS [28] version", "TREATMENT", 335, 360], ["the geant4", "TREATMENT", 379, 389], ["a volume of water", "TREATMENT", 469, 486]]], ["The slowing down of the ion is negligible over this distance.", [["slowing", "OBSERVATION_MODIFIER", 4, 11], ["negligible", "OBSERVATION_MODIFIER", 31, 41]]], ["The vertices for ionization by either the primary ion or any child electrons were recorded on an ion-by-ion basis for future simulations.", [["ionization", "TREATMENT", 17, 27]]], ["For the simulations shown in figures 2 and 3, one of this set of tracks was chosen at random and a 150 nm long section of the track was extracted.", [["the simulations", "TEST", 4, 19], ["a 150 nm long section", "TREATMENT", 97, 118]]], ["The locations of the resulting ionization events were then recorded to produce the histograms shown in figures 2 and 3.", [["the resulting ionization events", "PROBLEM", 17, 48], ["the histograms", "TEST", 79, 93], ["ionization events", "OBSERVATION", 31, 48]]], ["For each of these, ionizations from 200, 000 independent ion tracks were recorded.MethodsThe geometry used for the Virion was derived from available structural biology information [10] [11] [12] [13] .", [["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 180, 199], ["Virion", "PROTEIN", 115, 121], ["ionizations", "TEST", 19, 30], ["the Virion", "TREATMENT", 111, 121]]], ["The inner and outer radii of the envelope were set to 40 and 44 nm respectively with the RNA being confined within a spherical region of radius 39 nm, subject to other conditions defining cases i) -iii) for the RNA secondary structure.", [["inner", "ANATOMY", 4, 9], ["inner", "TISSUE", 4, 9], ["The inner and outer radii of the envelope", "TREATMENT", 0, 41], ["the RNA", "TREATMENT", 85, 92], ["the RNA secondary structure", "PROBLEM", 207, 234], ["inner", "ANATOMY_MODIFIER", 4, 9], ["outer", "ANATOMY_MODIFIER", 14, 19], ["radii", "ANATOMY_MODIFIER", 20, 25], ["spherical", "OBSERVATION_MODIFIER", 117, 126], ["radius", "OBSERVATION_MODIFIER", 137, 143], ["39 nm", "OBSERVATION_MODIFIER", 144, 149]]], ["A total of 75 protein spike complexes were distributed penetrating outwards through the virion's envelope.", [["virion", "CELLULAR_COMPONENT", 88, 94], ["75 protein spike complexes", "PROTEIN", 11, 37], ["A total of 75 protein spike complexes", "TREATMENT", 0, 37]]], ["Each spike complex was represented by an 8 nm long 1.6 nm radius cylinder starting from the inside of the envelope and pointing radially outward.", [["spike complex", "PROTEIN", 5, 18], ["Each spike complex", "PROBLEM", 0, 18], ["an 8 nm long 1.6 nm radius cylinder", "TREATMENT", 38, 73], ["envelope", "OBSERVATION", 106, 114], ["radially", "OBSERVATION_MODIFIER", 128, 136], ["outward", "OBSERVATION_MODIFIER", 137, 144]]], ["The other end of the cylinder was joined to a truncated cone, exactly matching the 1.6 nm radius at the narrow end, widening 5 nm in radius at the wide end, also with its axis point away radially and also being 8 nm long.", [["widening 5 nm in radius", "PROBLEM", 116, 139], ["narrow", "OBSERVATION_MODIFIER", 104, 110], ["end", "OBSERVATION_MODIFIER", 111, 114], ["widening", "OBSERVATION_MODIFIER", 116, 124], ["5 nm", "OBSERVATION_MODIFIER", 125, 129], ["radius", "OBSERVATION_MODIFIER", 133, 139], ["wide", "OBSERVATION_MODIFIER", 147, 151], ["end", "OBSERVATION_MODIFIER", 152, 155], ["8 nm", "OBSERVATION_MODIFIER", 211, 215]]], ["These spike complexes were positioned so that the axis of each one pointed directly away from the centre of the virion so as to be approximately equally spaced on the envelope's surface.", [["surface", "ANATOMY", 178, 185], ["virion", "CELLULAR_COMPONENT", 112, 118], ["surface", "CELLULAR_COMPONENT", 178, 185], ["spike complexes", "PROTEIN", 6, 21], ["These spike complexes", "PROBLEM", 0, 21]]], ["Each of these objects was represented by a Mathematica geometrical region, using Mathematica 12.1 with the RegionMember function being used to determine if an ionisation vertex was within a region of interest.MethodsFor simulation of the RNA-protein complex, again structural information was taken from [10] [11] [12] [13] .", [["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 303, 322], ["RNA-protein complex", "PROTEIN", 238, 257], ["a Mathematica geometrical region", "TREATMENT", 41, 73], ["Mathematica", "TREATMENT", 81, 92], ["the RegionMember function", "TREATMENT", 103, 128], ["an ionisation vertex", "TREATMENT", 156, 176], ["the RNA", "TEST", 234, 241], ["objects", "OBSERVATION", 14, 21]]], ["The outside of the complex was constructed as a 30 nm long, 15 nm radius cylinder.", [["a 30 nm long, 15 nm radius cylinder", "TREATMENT", 46, 81]]], ["Spiralling around the axis of this cylinder were two strands of RNA, each nucleotide being represented by two spheres, one of radius 0.35 nm (backbone) and one of radius 0.31 nm (base).", [["nucleotide", "CHEMICAL", 74, 84], ["nucleotide", "CHEMICAL", 74, 84], ["RNA", "RNA", 64, 67], ["two strands of RNA", "PROBLEM", 49, 67], ["axis", "ANATOMY_MODIFIER", 22, 26], ["strands", "OBSERVATION_MODIFIER", 53, 60], ["RNA", "OBSERVATION_MODIFIER", 64, 67], ["two", "OBSERVATION_MODIFIER", 106, 109], ["spheres", "OBSERVATION_MODIFIER", 110, 117], ["one", "OBSERVATION_MODIFIER", 119, 122], ["radius", "ANATOMY_MODIFIER", 126, 132], ["0.35 nm", "OBSERVATION", 133, 140], ["radius", "ANATOMY_MODIFIER", 163, 169], ["0.31 nm", "OBSERVATION", 170, 177], ["base", "ANATOMY_MODIFIER", 179, 183]]], ["The backbone was constructed along a 4.35 nm radius helix of pitch 14 nm with two complete revolutions of the helix being included for each strand.MethodsThe bases were placed so as to just touch the backbone, with the axis joining them pointing directly outwards.", [["a 4.35 nm radius helix of pitch 14 nm", "TREATMENT", 35, 72], ["the helix", "TREATMENT", 106, 115], ["helix", "ANATOMY", 110, 115], ["bases", "ANATOMY_MODIFIER", 158, 163], ["backbone", "ANATOMY_MODIFIER", 200, 208]]], ["This geometry was used for all the Monte Carlo (Geant4 [29] ) simulations reported in table 1, with the RNA chain modelled as water spheres with densities as per table 1 and immersed in a protein environment modelled as a water with density of 1.4 g/cc.MethodsGeant4 DNA [19] was used to track alpha particles and all secondary particles produced down to 10 eV and all deexcitation processes were included, such as Fluorescence, Auger cascade, and PIXE.", [["DNA", "CELLULAR_COMPONENT", 267, 270], ["RNA chain", "PROTEIN", 104, 113], ["alpha particles", "CELL_TYPE", 294, 309], ["the RNA chain", "TREATMENT", 100, 113], ["MethodsGeant4 DNA", "TREATMENT", 253, 270], ["all deexcitation processes", "TREATMENT", 365, 391], ["Auger cascade", "TREATMENT", 429, 442], ["densities", "OBSERVATION", 145, 154]]], ["The beam consisted of a rectangular field of 30 by 30 nm 2 of 3 MeV mono-energetic alphas launched along an axis, perpendicular to the RNA chain.", [["RNA chain", "PROTEIN", 135, 144], ["3 MeV mono-energetic alphas", "TREATMENT", 62, 89], ["rectangular", "OBSERVATION_MODIFIER", 24, 35], ["RNA chain", "OBSERVATION", 135, 144]]], ["A TOPAS extension was implemented in order to retrieve all the pertinent information each time an ionization occurred such as position, energy deposited in the material, particle type that indicated the interaction, material where ionization took place, track ID, and event ID of the particle.", [["A TOPAS extension", "TREATMENT", 0, 17], ["an ionization", "TREATMENT", 95, 108]]], ["The last two parameters allow to associate the track of all secondary particles that were created in the same event.MethodsFor the volume-scaled simulations, the volumes of the spheres representing the backbone and bases were modified as per table 1 with the scoring being done by replaying ion tracks and using Mathematica's RegionMember function as described above.", [["all secondary particles", "PROBLEM", 56, 79], ["Methods", "TREATMENT", 116, 123], ["the volume", "TEST", 127, 137], ["the scoring", "TEST", 255, 266], ["Mathematica's RegionMember function", "TREATMENT", 312, 347], ["secondary particles", "OBSERVATION", 60, 79], ["volumes", "OBSERVATION_MODIFIER", 162, 169], ["spheres", "OBSERVATION_MODIFIER", 177, 184], ["backbone", "OBSERVATION_MODIFIER", 202, 210], ["bases", "ANATOMY_MODIFIER", 215, 220]]], ["For the simulation shown in figures 4 and 5, the same process was repeated but the ion trajectories were rotated as well as translated so the sphere shown in figure 4 was uniformly and isotropically irradiated.", [["the simulation", "TEST", 4, 18]]], ["The inner cylinder shown in figure 4 was used to speed up the simulations by using nested region checking since only ionisation events inside this cylinder can also be inside one of the spheres representing the RNA strands.", [["RNA strands", "RNA", 211, 222], ["The inner cylinder", "TREATMENT", 0, 18], ["nested region checking", "TEST", 83, 105], ["ionisation events", "PROBLEM", 117, 134], ["inner", "OBSERVATION_MODIFIER", 4, 9], ["cylinder", "OBSERVATION_MODIFIER", 10, 18], ["RNA strands", "OBSERVATION", 211, 222]]], ["3.5 million ion trajectories were used in this simulation.Data availabilityOnce the manuscript is accepted all of the data used to produce the figures will be placed in Manchester University's Institutional Repository as per the university's policies to be publicly available and searchable.", [["3.5 million ion trajectories", "TREATMENT", 0, 28]]]], "805c1ad2675b12fe2b8e18fa6240642527133789": [["is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint", [["med", "ANATOMY", 38, 41]]]], "426b249116b5c2a1ca64b5c815f9fc2d465f5321": [["IntroductionEarly cancer detection is central to improving outcomes [1] .", [["cancer", "ANATOMY", 18, 24], ["cancer", "DISEASE", 18, 24], ["cancer", "CANCER", 18, 24], ["IntroductionEarly cancer detection", "PROBLEM", 0, 34], ["cancer", "OBSERVATION", 18, 24]]], ["Most early-detection strategies focus on the timely recognition and investigation of people likely to have undiagnosed cancer [2] [3] [4] .", [["cancer", "ANATOMY", 119, 125], ["cancer", "DISEASE", 119, 125], ["people", "ORGANISM", 85, 91], ["cancer", "CANCER", 119, 125], ["people", "SPECIES", 85, 91], ["undiagnosed cancer", "PROBLEM", 107, 125], ["cancer", "OBSERVATION", 119, 125]]], ["As screening detects <6 % of cancer [5] , UK strategies focus on promptly recognising the symptoms, signs or test results associated with undiagnosed cancer (\"features of possible cancer\", or simply \"features\") [6] .", [["cancer", "ANATOMY", 29, 35], ["cancer", "ANATOMY", 150, 156], ["cancer", "ANATOMY", 180, 186], ["cancer", "DISEASE", 29, 35], ["cancer", "DISEASE", 150, 156], ["cancer", "DISEASE", 180, 186], ["cancer", "CANCER", 29, 35], ["cancer", "CANCER", 150, 156], ["cancer", "CANCER", 180, 186], ["As screening", "TEST", 0, 12], ["cancer", "PROBLEM", 29, 35], ["the symptoms", "PROBLEM", 86, 98], ["undiagnosed cancer", "PROBLEM", 138, 156], ["cancer\"", "PROBLEM", 180, 187], ["cancer", "OBSERVATION", 29, 35], ["cancer", "OBSERVATION", 150, 156], ["cancer", "OBSERVATION", 180, 186]]], ["In 2005, UK suspected-cancer guidance was published, listing features warranting cancer testing or investigation [7] .IntroductionThe guidance was revised in 2011 for ovarian cancer [8] , and in 2015 for remaining cancers [2] .", [["cancer", "ANATOMY", 22, 28], ["cancer", "ANATOMY", 81, 87], ["ovarian cancer", "ANATOMY", 167, 181], ["cancers", "ANATOMY", 214, 221], ["cancer", "DISEASE", 22, 28], ["cancer", "DISEASE", 81, 87], ["ovarian cancer", "DISEASE", 167, 181], ["cancers", "DISEASE", 214, 221], ["cancer", "CANCER", 22, 28], ["cancer", "CANCER", 81, 87], ["ovarian cancer", "CANCER", 167, 181], ["cancers", "CANCER", 214, 221], ["cancer testing", "TEST", 81, 95], ["ovarian cancer", "PROBLEM", 167, 181], ["remaining cancers", "PROBLEM", 204, 221], ["cancer", "OBSERVATION", 22, 28], ["ovarian", "ANATOMY", 167, 174], ["cancer", "OBSERVATION", 175, 181], ["cancers", "OBSERVATION", 214, 221]]], ["The aim was to expedite cancer diagnosis by lowering the risk of undiagnosed cancer warranting clinical action from \u22655 % to 3 % [2] , which was achieved by introducing more vague features into the guidance [2, 9] .", [["cancer", "ANATOMY", 24, 30], ["cancer", "ANATOMY", 77, 83], ["cancer", "DISEASE", 24, 30], ["cancer", "DISEASE", 77, 83], ["cancer", "CANCER", 24, 30], ["cancer", "CANCER", 77, 83], ["undiagnosed cancer", "PROBLEM", 65, 83], ["cancer", "OBSERVATION", 24, 30], ["undiagnosed", "OBSERVATION_MODIFIER", 65, 76], ["cancer", "OBSERVATION", 77, 83]]], ["The revised guidance is officially applicable in England, and endorsed in Wales and Northern Ireland [10] .IntroductionOur objective was to explore the timeliness of cancer diagnosis in England, Wales and Northern Ireland in 2006-2017 for 11 common internal cancers.", [["cancer", "ANATOMY", 166, 172], ["internal cancers", "ANATOMY", 249, 265], ["cancer", "DISEASE", 166, 172], ["internal cancers", "DISEASE", 249, 265], ["cancer", "CANCER", 166, 172], ["internal cancers", "CANCER", 249, 265], ["11 common internal cancers", "PROBLEM", 239, 265], ["cancer", "OBSERVATION", 166, 172], ["internal", "ANATOMY_MODIFIER", 249, 257], ["cancers", "OBSERVATION", 258, 265]]], ["We compared time from first feature to diagnosis between two groups: \"Old-NICE\" (with features of possible cancer in the original 2005 guidance) and \"New-NICE\" (only participants with features introduced during guidance revision).", [["cancer", "ANATOMY", 107, 113], ["cancer", "DISEASE", 107, 113], ["cancer", "CANCER", 107, 113], ["participants", "SPECIES", 166, 178], ["cancer", "PROBLEM", 107, 113], ["guidance revision", "TREATMENT", 211, 228], ["cancer", "OBSERVATION", 107, 113]]], ["We hypothesised that times to diagnosis would be longer for New-NICE than for Old-NICE participants, because diagnosing cancer is more challenging and may take longer when symptoms are vague [9, [11] [12] [13] [14] .", [["cancer", "ANATOMY", 120, 126], ["cancer", "DISEASE", 120, 126], ["cancer", "CANCER", 120, 126], ["participants", "SPECIES", 87, 99], ["diagnosing cancer", "PROBLEM", 109, 126], ["symptoms", "PROBLEM", 172, 180], ["vague", "PROBLEM", 185, 190], ["cancer", "OBSERVATION", 120, 126]]], ["We also hypothesised that the difference in time to diagnosis between New-NICE and Old-NICE groups would reduce over time, as evidence on vague cancer features emerged and was translated into practice by guidance revision [2, 15] .Study setting and designThis serial, cross-sectional, primary-care study used UK Clinical Practice Research Datalink (CPRD GOLD) with linked National Cancer Registration and Analysis Service (NCRAS, Set 15) data.", [["cancer", "ANATOMY", 144, 150], ["cancer", "DISEASE", 144, 150], ["Cancer", "DISEASE", 381, 387], ["cancer", "CANCER", 144, 150], ["Old-NICE groups", "TREATMENT", 83, 98], ["vague cancer features", "PROBLEM", 138, 159], ["vague", "OBSERVATION_MODIFIER", 138, 143], ["cancer", "OBSERVATION", 144, 150], ["Cancer", "OBSERVATION", 381, 387]]], ["The study examined participants in the year before their cancer diagnosis between 2006 and 2017.Inclusion and exclusion criteriaInclusion criteria: \u2022 Scotland, where separate guidance applies [17] .Inclusion and exclusion criteria\u2022 Multiple primary cancers.Inclusion and exclusion criteria\u2022 Cancer typical of the opposite sex; e.g. male breast cancer.Inclusion and exclusion criteria\u2022 Screen-detected cancer, identified from NCRAS or by CPRD screening codes in the year before diagnosis. \u2022 No primary care attendance or no recorded feature of the participant's cancer in the year before diagnosis.Variables and outcome measures2.3.1.", [["cancer", "ANATOMY", 57, 63], ["primary cancers", "ANATOMY", 241, 256], ["Cancer", "ANATOMY", 291, 297], ["breast cancer", "ANATOMY", 337, 350], ["cancer", "ANATOMY", 401, 407], ["cancer", "ANATOMY", 561, 567], ["cancer", "DISEASE", 57, 63], ["primary cancers", "DISEASE", 241, 256], ["Cancer", "DISEASE", 291, 297], ["breast cancer", "DISEASE", 337, 350], ["cancer", "DISEASE", 401, 407], ["cancer", "DISEASE", 561, 567], ["cancer", "CANCER", 57, 63], ["primary cancers", "CANCER", 241, 256], ["Cancer", "CANCER", 291, 297], ["breast cancer", "CANCER", 337, 350], ["cancer", "CANCER", 401, 407], ["cancer", "CANCER", 561, 567], ["NCRAS", "DNA", 425, 430], ["participants", "SPECIES", 19, 31], ["The study", "TEST", 0, 9], ["Multiple primary cancers", "PROBLEM", 232, 256], ["Cancer", "PROBLEM", 291, 297], ["breast cancer", "PROBLEM", 337, 350], ["cancer", "PROBLEM", 401, 407], ["the participant's cancer", "PROBLEM", 543, 567], ["cancer", "OBSERVATION", 57, 63], ["primary", "OBSERVATION_MODIFIER", 241, 248], ["cancers", "OBSERVATION", 249, 256], ["breast", "ANATOMY", 337, 343], ["cancer", "OBSERVATION", 344, 350], ["cancer", "OBSERVATION", 401, 407], ["cancer", "OBSERVATION", 561, 567]]], ["Features of possible cancer CPRD codes for features of possible cancer were collated [18] , based on the symptoms, signs or blood test results in the original or revised guidance (Table 1) [2, 7, 8] .", [["cancer", "ANATOMY", 21, 27], ["cancer", "ANATOMY", 64, 70], ["blood", "ANATOMY", 124, 129], ["cancer", "DISEASE", 21, 27], ["cancer", "DISEASE", 64, 70], ["cancer", "CANCER", 21, 27], ["cancer", "CANCER", 64, 70], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["cancer CPRD codes", "PROBLEM", 21, 38], ["cancer", "PROBLEM", 64, 70], ["the symptoms", "PROBLEM", 101, 113], ["blood test", "TEST", 124, 134], ["possible", "UNCERTAINTY", 12, 20], ["cancer", "OBSERVATION", 21, 27], ["possible", "UNCERTAINTY", 55, 63], ["cancer", "OBSERVATION", 64, 70]]], ["Occurrences of these codes, restricted to the relevant cancer site, identified participants presenting with these features in the year before diagnosis.", [["cancer site", "ANATOMY", 55, 66], ["cancer", "DISEASE", 55, 61], ["cancer", "CANCER", 55, 61], ["participants", "SPECIES", 79, 91], ["the relevant cancer site", "PROBLEM", 42, 66], ["cancer", "OBSERVATION", 55, 61]]], ["Separate generic \"suspected-cancer\" codes were identified to explore for changing recording practices.Milestone dates and diagnostic intervalThe cancer diagnosis date was the earliest CPRD or NCRAS diagnostic code.", [["cancer", "ANATOMY", 28, 34], ["cancer", "ANATOMY", 145, 151], ["cancer", "DISEASE", 28, 34], ["cancer", "DISEASE", 145, 151], ["cancer", "CANCER", 28, 34], ["cancer", "CANCER", 145, 151], ["NCRAS diagnostic code", "DNA", 192, 213], ["cancer", "OBSERVATION", 28, 34], ["cancer", "OBSERVATION", 145, 151]]], ["The first recorded feature of possible cancer (index feature) was identified, along with the index date.", [["cancer", "ANATOMY", 39, 45], ["cancer", "DISEASE", 39, 45], ["cancer", "CANCER", 39, 45], ["cancer (index feature", "PROBLEM", 39, 60], ["possible", "UNCERTAINTY", 30, 38], ["cancer", "OBSERVATION", 39, 45]]], ["Our outcome variable was \"diagnostic interval\": days from index date to diagnosis [19] .NICE groupingParticipants were grouped by their index feature(s) (Fig. 1 , Table 1 ):NICE grouping\u2022 Old-NICE: participants with \u22651 index feature from the 2005 guidance [7] . \u2022 New-NICE: limited to participants who only had index feature(s) introduced during guidance revision [2, 8] .NICE groupingParticipants whose only index feature was a generic \"suspectedcancer\" code were omitted from analyses.Other variablesAge and sex were identified from the CPRD year of birth, assigning a birthday of 1st July.AnalysesSimple descriptive statistics summarised age (mean and standard deviation), sex (male, n, %), NICE grouping (New-NICE group, n, %), and the index feature(s) (n, % of all index features).", [["Participants", "SPECIES", 101, 113], ["participants", "SPECIES", 198, 210], ["participants", "SPECIES", 285, 297], ["Participants", "SPECIES", 385, 397]]], ["Diagnostic interval has a skewed distribution and was log-transformed for analyses [13] .AnalysesSemiparametric varying-coefficient methods estimated coefficients representing the percentage difference in mean log-transformed diagnostic interval between New-NICE and Old-NICE groups (see accompanying methodological paper [20] ).", [["a skewed distribution", "PROBLEM", 24, 45], ["analyses", "TEST", 74, 82], ["AnalysesSemiparametric varying", "TREATMENT", 89, 119], ["New-NICE and Old-NICE groups", "TREATMENT", 254, 282], ["skewed", "OBSERVATION_MODIFIER", 26, 32], ["distribution", "OBSERVATION_MODIFIER", 33, 45]]], ["The coefficients are estimated on a daily basis, so cannot be reported using a single summary statistic, and are plotted (with 95 % confidence intervals, using bootstrapping, n = 1000 replications [21] ) to allow visualisation over 2006-17.", [["bootstrapping", "TEST", 160, 173], ["visualisation", "TEST", 213, 226]]], ["Analyses examined each cancer site separately, sample size permitting (package \"np\" in R) [22] .Table 2Numbers of potential inclusions (individual diagnoses), with Cancer Registry linkage, and exclusions, to give final sample sizes by cancer site.", [["cancer site", "ANATOMY", 23, 34], ["cancer site", "ANATOMY", 235, 246], ["cancer", "DISEASE", 23, 29], ["Cancer", "DISEASE", 164, 170], ["cancer", "DISEASE", 235, 241], ["cancer", "CANCER", 23, 29], ["cancer", "CANCER", 235, 241], ["each cancer site", "PROBLEM", 18, 34], ["potential inclusions", "PROBLEM", 114, 134], ["cancer site", "PROBLEM", 235, 246], ["size", "OBSERVATION_MODIFIER", 54, 58], ["inclusions", "OBSERVATION", 124, 134], ["Cancer", "OBSERVATION", 164, 170], ["cancer", "OBSERVATION", 235, 241]]], ["The final sample is described in terms of size (N), age (mean, SD), number (%) who are male, and number (%) with an index cancer feature introduced during guidance revision.Study sizeFor the descriptive statistics, we included all CPRD participants meeting our inclusion criteria.", [["cancer", "ANATOMY", 122, 128], ["cancer", "DISEASE", 122, 128], ["cancer", "CANCER", 122, 128], ["participants", "SPECIES", 236, 248], ["an index cancer feature", "PROBLEM", 113, 136], ["guidance revision", "TREATMENT", 155, 172], ["Study size", "TEST", 173, 183], ["size", "OBSERVATION_MODIFIER", 42, 46], ["cancer", "OBSERVATION", 122, 128], ["size", "OBSERVATION_MODIFIER", 179, 183]]], ["Semiparametric varying-coefficient analyses were limited to cancer sites with participant numbers providing \u226590 % power at the 5 % level to detect a 14-day difference in diagnostic interval between New-NICE and Old-NICE groups.", [["cancer sites", "ANATOMY", 60, 72], ["cancer", "DISEASE", 60, 66], ["cancer", "CANCER", 60, 66], ["Semiparametric varying-coefficient analyses", "TEST", 0, 43], ["cancer sites", "PROBLEM", 60, 72], ["participant numbers", "TEST", 78, 97], ["New-NICE and Old-NICE groups", "TREATMENT", 198, 226], ["varying", "OBSERVATION_MODIFIER", 15, 22]]], ["Assuming mean diagnostic intervals of 114 and 100 days, respectively, for the Old-NICE and New-NICE groups, a common standard deviation of 100 days and 10 % of participants classified as New-NICE requires 5980 total participants.", [["participants", "SPECIES", 160, 172], ["participants", "SPECIES", 216, 228], ["New-NICE groups", "TREATMENT", 91, 106]]], ["An effect size of 14 days matches the two-week-wait target for urgent investigation.", [["urgent investigation", "TEST", 63, 83], ["effect", "OBSERVATION_MODIFIER", 3, 9], ["size", "OBSERVATION_MODIFIER", 10, 14]]], ["We assessed uncertainty in the estimates by confidence interval width.Missing data and biasTo explore for potential bias associated with changing coding practice, we identified, for annual cohorts: (a) the percentages of participants excluded for having no coded features or only suspected-cancer codes; (b) the proportions of Old-NICE and New-NICE participants; (c) demographic characteristics of participants excluded because they lacked coded features.ParticipantsThe CPRD provided 147,106 participants, of whom 63,171 (42\u22c59%) were excluded, leaving 83,935 (57\u22c51%) entering the analyses, from 603 practices, of which 384 (63\u22c57%) had NCRAS linkage ( Table 2 ).", [["cancer", "ANATOMY", 290, 296], ["cancer", "DISEASE", 290, 296], ["cancer", "CANCER", 290, 296], ["participants", "SPECIES", 221, 233], ["participants", "SPECIES", 349, 361], ["participants", "SPECIES", 398, 410], ["Participants", "SPECIES", 455, 467], ["participants", "SPECIES", 493, 505], ["potential bias", "PROBLEM", 106, 120], ["width", "OBSERVATION_MODIFIER", 64, 69], ["cancer", "OBSERVATION", 290, 296]]], ["The main reasons for exclusion were lack of recorded features (n = 37,715), Scottish residence (n = 17,360) and detection following screening (n = 7757) (Fig. 2) .ParticipantsThe sex distributions indicate male dominance in bladder (3870/ 5243, 73\u22c58 %), oesophageal (2900/4272, 67\u22c59%) and stomach (1823/ 2788, 65\u22c54 %) cancers ( Table 2 ).", [["bladder", "ANATOMY", 224, 231], ["oesophageal", "ANATOMY", 254, 265], ["stomach", "ANATOMY", 289, 296], ["cancers", "ANATOMY", 318, 325], ["cancers", "DISEASE", 318, 325], ["bladder", "ORGAN", 224, 231], ["oesophageal", "ORGAN", 254, 265], ["stomach", "ORGAN", 289, 296], ["cancers", "CANCER", 318, 325], ["Participants", "SPECIES", 163, 175], ["screening", "TEST", 132, 141], ["male dominance in bladder", "PROBLEM", 206, 231], ["oesophageal", "TEST", 254, 265], ["cancers", "PROBLEM", 318, 325], ["main", "OBSERVATION_MODIFIER", 4, 8], ["male dominance", "OBSERVATION", 206, 220], ["bladder", "ANATOMY", 224, 231], ["oesophageal", "ANATOMY", 254, 265], ["stomach", "ANATOMY", 289, 296]]], ["The overall mean (SD) age at diagnosis (n = 83,935) was 69\u22c56 years (12\u22c58), ranging from 62\u22c59 years (16\u22c57) for breast to 73\u22c54 years (12\u22c52) for stomach (Table 2) .NICE groupingThe percentage of participants whose index feature was introduced during guidance revision (New-NICE group) varied by cancer, ranging from 1529/1534 (99\u22c57 %) for myeloma to 858/15,542 (5\u22c55%) for breast.", [["breast", "ANATOMY", 110, 116], ["stomach", "ANATOMY", 142, 149], ["cancer", "ANATOMY", 292, 298], ["myeloma", "ANATOMY", 336, 343], ["breast", "ANATOMY", 369, 375], ["cancer", "DISEASE", 292, 298], ["myeloma", "DISEASE", 336, 343], ["breast", "ORGAN", 110, 116], ["stomach", "ORGAN", 142, 149], ["participants", "ORGANISM", 192, 204], ["cancer", "CANCER", 292, 298], ["myeloma", "CANCER", 336, 343], ["breast", "CANCER", 369, 375], ["participants", "SPECIES", 192, 204], ["guidance revision", "TREATMENT", 247, 264], ["cancer", "PROBLEM", 292, 298], ["myeloma", "PROBLEM", 336, 343], ["breast", "ANATOMY", 110, 116], ["stomach", "ANATOMY", 142, 149], ["percentage", "OBSERVATION_MODIFIER", 178, 188], ["cancer", "OBSERVATION", 292, 298], ["breast", "ANATOMY", 369, 375]]], ["More even distributions were observed for colorectal (5017/ 11,842, 42\u22c54%), lung (3384/13,107, 25\u22c58 %), ovarian (614/2481, 24\u22c58%), and uterine (713/2506, 28\u22c55%) cancers (Table 2 ).", [["colorectal", "ANATOMY", 42, 52], ["lung", "ANATOMY", 76, 80], ["ovarian", "ANATOMY", 104, 111], ["uterine", "ANATOMY", 135, 142], ["cancers", "ANATOMY", 161, 168], ["cancers", "DISEASE", 161, 168], ["colorectal", "CANCER", 42, 52], ["lung", "ORGAN", 76, 80], ["ovarian", "CANCER", 104, 111], ["uterine", "CANCER", 135, 142], ["cancers", "CANCER", 161, 168], ["colorectal", "TEST", 42, 52], ["ovarian", "TEST", 104, 111], ["cancers", "PROBLEM", 161, 168], ["lung", "ANATOMY", 76, 80], ["ovarian", "ANATOMY", 104, 111], ["uterine", "ANATOMY", 135, 142]]], ["Postmenopausal bleeding accounted for nearly half of all index features of uterine cancer (1305/2619, 49\u22c58%), with lower frequencies for high blood glucose (300/2619, 11\u22c55%) and low haemoglobin (275/2619, 10\u22c55%).Diagnostic intervalOverall, the median diagnostic interval was 58 days (interquartile range (IQR) 23-158, N = 83,935).", [["uterine cancer", "ANATOMY", 75, 89], ["blood", "ANATOMY", 142, 147], ["bleeding", "DISEASE", 15, 23], ["uterine cancer", "DISEASE", 75, 89], ["glucose", "CHEMICAL", 148, 155], ["glucose", "CHEMICAL", 148, 155], ["uterine cancer", "CANCER", 75, 89], ["blood", "ORGANISM_SUBSTANCE", 142, 147], ["glucose", "SIMPLE_CHEMICAL", 148, 155], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 182, 193], ["Postmenopausal bleeding", "PROBLEM", 0, 23], ["uterine cancer", "PROBLEM", 75, 89], ["high blood glucose", "TEST", 137, 155], ["low haemoglobin", "PROBLEM", 178, 193], ["all index", "OBSERVATION_MODIFIER", 53, 62], ["uterine", "ANATOMY", 75, 82], ["cancer", "OBSERVATION", 83, 89], ["low haemoglobin", "OBSERVATION_MODIFIER", 178, 193]]], ["By cancer site, the shortest diagnostic interval was in breast (median, IQR: 20, 10-30 days, N = 15,542) and the longest in lung (median, IQR: 129, 46-263 days, N = 13,107) ( Table 4) .Diagnostic intervalMedian (interquartile range) diagnostic intervals by year and by NICE grouping are plotted in Fig. 3 Fig. 3 ).", [["cancer site", "ANATOMY", 3, 14], ["breast", "ANATOMY", 56, 62], ["lung", "ANATOMY", 124, 128], ["cancer", "DISEASE", 3, 9], ["cancer", "CANCER", 3, 9], ["breast", "ORGANISM_SUBDIVISION", 56, 62], ["lung", "ORGAN", 124, 128], ["cancer", "OBSERVATION", 3, 9], ["breast", "ANATOMY", 56, 62], ["lung", "ANATOMY", 124, 128]]], ["Median diagnostic intervals were longer for New-NICE than for Old-NICE participants for colorectal (70 vs 51 days), oesophageal (77 vs 55 days), and lung (139\u22c55 vs 124 days) cancers; however, this difference tended to decrease or disappear over time (Fig. 3) .", [["colorectal", "ANATOMY", 88, 98], ["oesophageal", "ANATOMY", 116, 127], ["lung", "ANATOMY", 149, 153], ["cancers", "ANATOMY", 174, 181], ["cancers", "DISEASE", 174, 181], ["colorectal", "MULTI-TISSUE_STRUCTURE", 88, 98], ["oesophageal", "ORGAN", 116, 127], ["lung", "ORGAN", 149, 153], ["cancers", "CANCER", 174, 181], ["participants", "SPECIES", 71, 83], ["colorectal", "TEST", 88, 98], ["cancers", "PROBLEM", 174, 181], ["oesophageal", "ANATOMY", 116, 127], ["lung", "ANATOMY", 149, 153], ["cancers", "OBSERVATION", 174, 181]]], ["In ovarian cancer, diagnostic intervals were shorter in the New-NICE than in the Old-NICE group overall (56 vs 72 days), notably in 2010-16 (Fig. 3) .Diagnostic intervalFor bladder, colorectal, oesophageal, pancreatic and uterine cancers, median Old-NICE diagnostic intervals remained constant over 2006-2017.", [["ovarian cancer", "ANATOMY", 3, 17], ["bladder", "ANATOMY", 173, 180], ["colorectal", "ANATOMY", 182, 192], ["oesophageal", "ANATOMY", 194, 205], ["pancreatic", "ANATOMY", 207, 217], ["uterine cancers", "ANATOMY", 222, 237], ["ovarian cancer", "DISEASE", 3, 17], ["bladder, colorectal, oesophageal, pancreatic and uterine cancers", "DISEASE", 173, 237], ["ovarian cancer", "CANCER", 3, 17], ["bladder", "ORGAN", 173, 180], ["colorectal", "MULTI-TISSUE_STRUCTURE", 182, 192], ["oesophageal", "CANCER", 194, 205], ["pancreatic", "CANCER", 207, 217], ["uterine cancers", "CANCER", 222, 237], ["ovarian cancer", "PROBLEM", 3, 17], ["bladder, colorectal, oesophageal, pancreatic and uterine cancers", "PROBLEM", 173, 237], ["ovarian", "ANATOMY", 3, 10], ["cancer", "OBSERVATION", 11, 17], ["bladder", "ANATOMY", 173, 180], ["colorectal", "OBSERVATION", 182, 192], ["oesophageal", "ANATOMY", 194, 205], ["pancreatic", "ANATOMY", 207, 217], ["uterine", "ANATOMY", 222, 229], ["cancers", "OBSERVATION", 230, 237]]], ["They were longer in 2017 compared with 2006 for breast (25 vs 16 days), lung (135 vs 103 days), ovarian (100 vs 65\u22c55 days), prostate (93 vs 80 days) and stomach (102 vs 72\u22c55 days) cancers (Fig. 3) .Semiparametric varying-coefficient analysesSemiparametric varying-coefficient analyses were powered for bladder, breast, colorectal, lung, prostate and uterine cancers.", [["breast", "ANATOMY", 48, 54], ["lung", "ANATOMY", 72, 76], ["ovarian", "ANATOMY", 96, 103], ["prostate", "ANATOMY", 124, 132], ["stomach", "ANATOMY", 153, 160], ["cancers", "ANATOMY", 180, 187], ["bladder", "ANATOMY", 302, 309], ["breast", "ANATOMY", 311, 317], ["colorectal", "ANATOMY", 319, 329], ["lung", "ANATOMY", 331, 335], ["prostate", "ANATOMY", 337, 345], ["uterine cancers", "ANATOMY", 350, 365], ["cancers", "DISEASE", 180, 187], ["bladder, breast, colorectal, lung, prostate and uterine cancers", "DISEASE", 302, 365], ["breast", "ORGAN", 48, 54], ["lung", "ORGAN", 72, 76], ["ovarian", "ORGAN", 96, 103], ["prostate", "CANCER", 124, 132], ["stomach", "ORGAN", 153, 160], ["cancers", "CANCER", 180, 187], ["bladder", "CANCER", 302, 309], ["breast", "CANCER", 311, 317], ["colorectal", "CANCER", 319, 329], ["lung", "CANCER", 331, 335], ["prostate", "CANCER", 337, 345], ["uterine cancers", "CANCER", 350, 365], ["ovarian", "TEST", 96, 103], ["prostate", "TEST", 124, 132], ["stomach", "TEST", 153, 160], ["cancers", "PROBLEM", 180, 187], ["Semiparametric varying", "TEST", 198, 220], ["coefficient analyses", "TEST", 264, 284], ["bladder, breast, colorectal, lung, prostate and uterine cancers", "PROBLEM", 302, 365], ["breast", "ANATOMY", 48, 54], ["lung", "ANATOMY", 72, 76], ["ovarian", "ANATOMY", 96, 103], ["prostate", "ANATOMY", 124, 132], ["stomach", "ANATOMY", 153, 160], ["cancers", "OBSERVATION", 180, 187], ["varying", "OBSERVATION_MODIFIER", 213, 220], ["bladder", "ANATOMY", 302, 309], ["breast", "ANATOMY", 311, 317], ["colorectal", "ANATOMY", 319, 329], ["lung", "ANATOMY", 331, 335], ["prostate", "ANATOMY", 337, 345], ["uterine", "ANATOMY", 350, 357], ["cancers", "OBSERVATION", 358, 365]]], ["The percentage differences (with 95 % confidence intervals) in mean logtransformed diagnostic interval between New-NICE and Old-NICE groups over time are plotted in Fig. 4 .Semiparametric varying-coefficient analysesAfter guidance revision on 23rd June 2015, New-NICE diagnostic intervals tended to shorten relative to those of the Old-NICE group in prostate (Fig. 4e) and uterine (Fig. 4f) cancers (note the downward trajectory towards the horizontal dashed line).Semiparametric varying-coefficient analysesFor colorectal cancer, the difference in diagnostic interval between the New-NICE and Old-NICE groups reduced over time.", [["prostate", "ANATOMY", 350, 358], ["uterine (Fig. 4f) cancers", "ANATOMY", 373, 398], ["colorectal cancer", "ANATOMY", 512, 529], ["cancers", "DISEASE", 391, 398], ["colorectal cancer", "DISEASE", 512, 529], ["prostate", "CANCER", 350, 358], ["uterine (Fig. 4f) cancers", "CANCER", 373, 398], ["colorectal cancer", "CANCER", 512, 529], ["New-NICE", "TREATMENT", 111, 119], ["Old-NICE groups", "TREATMENT", 124, 139], ["Semiparametric varying", "TEST", 173, 195], ["the Old-NICE group in prostate (Fig. 4e", "TREATMENT", 328, 367], ["uterine (Fig. 4f", "TREATMENT", 373, 389], ["cancers", "PROBLEM", 391, 398], ["the horizontal dashed line", "TREATMENT", 437, 463], ["Semiparametric varying", "TEST", 465, 487], ["colorectal cancer", "PROBLEM", 512, 529], ["the New-NICE and Old-NICE groups", "TREATMENT", 577, 609], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["prostate", "ANATOMY", 350, 358], ["uterine", "ANATOMY", 373, 380], ["cancers", "OBSERVATION", 391, 398], ["colorectal", "ANATOMY", 512, 522], ["cancer", "OBSERVATION", 523, 529]]], ["After guidance revision, New-NICE diagnostic intervals were shorter than Old-NICE intervals, as indicated by the trend dropping below the horizontal dashed line (Fig. 4c) .Semiparametric varying-coefficient analysesFor lung cancer, New-NICE were longer than Old-NICE diagnostic intervals in the years 2006-10.", [["lung cancer", "ANATOMY", 219, 230], ["lung cancer", "DISEASE", 219, 230], ["lung cancer", "CANCER", 219, 230], ["revision", "TREATMENT", 15, 23], ["the horizontal dashed line", "TREATMENT", 134, 160], ["Semiparametric varying", "TEST", 172, 194], ["lung cancer", "PROBLEM", 219, 230], ["revision", "OBSERVATION", 15, 23], ["New", "OBSERVATION_MODIFIER", 25, 28], ["lung", "ANATOMY", 219, 223], ["cancer", "OBSERVATION", 224, 230]]], ["In 2010-15, there was no difference between the groups.", [["no", "UNCERTAINTY", 22, 24]]], ["In 2016 (post guidance revision), New-NICE diagnostic intervals shortened relative to Old-NICE diagnostic intervals, but this was not sustained into 2017-18 (Fig. 4d) .Missing data and biasThe proportions of eligible participants excluded for lack of coded features increased over time for bladder, colorectal, lung, oesophageal, ovarian, pancreatic, stomach, and uterine cancers.", [["bladder", "ANATOMY", 290, 297], ["colorectal", "ANATOMY", 299, 309], ["lung", "ANATOMY", 311, 315], ["oesophageal", "ANATOMY", 317, 328], ["ovarian", "ANATOMY", 330, 337], ["pancreatic", "ANATOMY", 339, 349], ["stomach", "ANATOMY", 351, 358], ["uterine cancers", "ANATOMY", 364, 379], ["bladder, colorectal, lung, oesophageal, ovarian, pancreatic, stomach, and uterine cancers", "DISEASE", 290, 379], ["bladder", "ORGAN", 290, 297], ["colorectal", "MULTI-TISSUE_STRUCTURE", 299, 309], ["lung", "ORGAN", 311, 315], ["oesophageal", "CANCER", 317, 328], ["ovarian", "CANCER", 330, 337], ["pancreatic", "CANCER", 339, 349], ["stomach", "ORGAN", 351, 358], ["uterine cancers", "CANCER", 364, 379], ["participants", "SPECIES", 217, 229], ["revision", "TREATMENT", 23, 31], ["Missing data", "TEST", 168, 180], ["coded features", "PROBLEM", 251, 265], ["bladder, colorectal, lung, oesophageal, ovarian, pancreatic, stomach, and uterine cancers", "PROBLEM", 290, 379], ["bladder", "ANATOMY", 290, 297], ["colorectal", "OBSERVATION", 299, 309], ["lung", "ANATOMY", 311, 315], ["oesophageal", "ANATOMY", 317, 328], ["ovarian", "ANATOMY", 330, 337], ["pancreatic", "ANATOMY", 339, 349], ["stomach", "ANATOMY", 351, 358], ["uterine", "ANATOMY", 364, 371], ["cancers", "OBSERVATION", 372, 379]]], ["This coincided with increased use of suspected-cancer codes (Fig. S1) .", [["cancer", "ANATOMY", 47, 53], ["cancer", "DISEASE", 47, 53], ["cancer", "CANCER", 47, 53], ["S1", "GENE_OR_GENE_PRODUCT", 66, 68], ["S1", "PROTEIN", 66, 68], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["cancer", "OBSERVATION", 47, 53]]], ["The demographic details of excluded and included participants were similar (Table S1 and Table 2 ).", [["participants", "SPECIES", 49, 61]]], ["The proportions of Old-NICE and New-NICE participants were largely similar across time within cancer sites (Fig. S2 ).FindingsThis study examined diagnostic intervals for 11 cancers in England, Table 4 Diagnostic interval (25th, 50th, 75th, and 90th centiles, mean and standard deviation) by cancer site.", [["cancer sites", "ANATOMY", 94, 106], ["cancers", "ANATOMY", 174, 181], ["cancer site", "ANATOMY", 292, 303], ["cancer", "DISEASE", 94, 100], ["cancers", "DISEASE", 174, 181], ["cancer", "DISEASE", 292, 298], ["cancer", "CANCER", 94, 100], ["cancers", "CANCER", 174, 181], ["cancer", "CANCER", 292, 298], ["S2", "PROTEIN", 113, 115], ["participants", "SPECIES", 41, 53], ["This study", "TEST", 126, 136], ["11 cancers", "PROBLEM", 171, 181], ["cancer site", "PROBLEM", 292, 303], ["New", "OBSERVATION_MODIFIER", 32, 35], ["cancer", "OBSERVATION", 94, 100], ["cancer", "OBSERVATION", 292, 298]]], ["Wales and Northern Ireland over 2006-2017, a period including major revision of national suspected-cancer referral guidance.", [["cancer", "ANATOMY", 99, 105], ["cancer", "DISEASE", 99, 105], ["cancer", "CANCER", 99, 105], ["cancer", "OBSERVATION", 99, 105]]], ["As hypothesised, times to diagnosis were generally longer for \"New-NICE\" participants (with index feature(s) of cancer introduced during guidance revision) than for \"Old-NICE\" participants (with feature(s) in the original guidance).", [["cancer", "ANATOMY", 112, 118], ["cancer", "DISEASE", 112, 118], ["cancer", "CANCER", 112, 118], ["participants", "SPECIES", 73, 85], ["participants", "SPECIES", 176, 188], ["cancer", "PROBLEM", 112, 118], ["revision", "TREATMENT", 146, 154], ["cancer", "OBSERVATION", 112, 118]]], ["Importantly, for colorectal cancer, New-NICE diagnostic intervals were shorter than Old-NICE diagnostic intervals after guidance revision.", [["colorectal cancer", "ANATOMY", 17, 34], ["colorectal cancer", "DISEASE", 17, 34], ["colorectal cancer", "CANCER", 17, 34], ["colorectal cancer", "PROBLEM", 17, 34], ["guidance revision", "TREATMENT", 120, 137], ["colorectal", "ANATOMY", 17, 27], ["cancer", "OBSERVATION", 28, 34]]], ["The gap between New-and Old-NICE groups decreased for prostate and uterine cancers over time, consistent with decreasing New-NICE diagnostic intervals aided by increasing Old-NICE diagnostic intervals for prostate cancer.", [["prostate", "ANATOMY", 54, 62], ["uterine cancers", "ANATOMY", 67, 82], ["prostate cancer", "ANATOMY", 205, 220], ["prostate and uterine cancers", "DISEASE", 54, 82], ["prostate cancer", "DISEASE", 205, 220], ["prostate", "CANCER", 54, 62], ["uterine cancers", "CANCER", 67, 82], ["prostate cancer", "CANCER", 205, 220], ["The gap", "TEST", 0, 7], ["New-and Old-NICE groups", "TREATMENT", 16, 39], ["prostate and uterine cancers", "PROBLEM", 54, 82], ["prostate cancer", "PROBLEM", 205, 220], ["gap", "OBSERVATION_MODIFIER", 4, 7], ["New", "OBSERVATION_MODIFIER", 16, 19], ["prostate", "ANATOMY", 54, 62], ["uterine", "ANATOMY", 67, 74], ["cancers", "OBSERVATION", 75, 82], ["consistent with", "UNCERTAINTY", 94, 109], ["decreasing", "OBSERVATION_MODIFIER", 110, 120], ["New", "OBSERVATION_MODIFIER", 121, 124], ["prostate", "ANATOMY", 205, 213], ["cancer", "OBSERVATION", 214, 220]]], ["In conclusion, scope remains to reduce time to diagnosis for symptomatic cancers in England, Wales and Northern Ireland.Strengths and limitationsA considerable strength is the study's primary-care setting, where suspected-cancer guidance is implemented.", [["cancers", "ANATOMY", 73, 80], ["cancer", "ANATOMY", 222, 228], ["cancers", "DISEASE", 73, 80], ["cancer", "DISEASE", 222, 228], ["cancers", "CANCER", 73, 80], ["cancer", "CANCER", 222, 228], ["symptomatic cancers", "PROBLEM", 61, 80], ["the study", "TEST", 172, 181], ["symptomatic", "OBSERVATION_MODIFIER", 61, 72], ["cancers", "OBSERVATION", 73, 80], ["cancer", "OBSERVATION", 222, 228]]], ["The CPRD is the largest primary-care database worldwide and is recognised for its high-quality data [23] .", [["largest", "OBSERVATION_MODIFIER", 16, 23]]], ["We used established methods for case identification [18] , with validation of cancer diagnosis by NCRAS where linkage was available.", [["cancer", "ANATOMY", 78, 84], ["cancer", "DISEASE", 78, 84], ["cancer", "CANCER", 78, 84], ["case identification", "TEST", 32, 51], ["cancer", "OBSERVATION", 78, 84]]], ["Pre-2013 studies report a concordance rate of 83\u22c53% between CPRD and cancer registry information [25] .", [["cancer", "ANATOMY", 69, 75], ["cancer", "DISEASE", 69, 75], ["cancer", "CANCER", 69, 75], ["a concordance rate", "TEST", 24, 42]]], ["The CPRD diagnosis date was a median of 11 days (interquartile range -6 to 30 days) later than the registry date pre-2013 for colorectal, lung, gastrointestinal, and urological cancers [26] .", [["colorectal", "ANATOMY", 126, 136], ["lung", "ANATOMY", 138, 142], ["gastrointestinal", "ANATOMY", 144, 160], ["urological cancers", "ANATOMY", 166, 184], ["colorectal, lung, gastrointestinal, and urological cancers", "DISEASE", 126, 184], ["colorectal", "MULTI-TISSUE_STRUCTURE", 126, 136], ["lung", "ORGAN", 138, 142], ["gastrointestinal", "ORGAN", 144, 160], ["urological cancers", "CANCER", 166, 184], ["colorectal, lung, gastrointestinal, and urological cancers", "PROBLEM", 126, 184], ["colorectal", "OBSERVATION", 126, 136], ["lung", "ANATOMY", 138, 142], ["gastrointestinal", "ANATOMY", 144, 160]]], ["Reassuringly, no step-change in Newor Old-NICE diagnostic intervals were observed around 2013, suggesting that any associated bias is small.Strengths and limitationsWe studied diagnostic interval rather than the primary care (time from index date to referral) or secondary care (time from referral to treatment) interval to avoid restricting analyses to participants referred to secondary care [19] .", [["participants", "SPECIES", 354, 366], ["no", "UNCERTAINTY", 14, 16], ["bias", "OBSERVATION", 126, 130], ["small", "OBSERVATION_MODIFIER", 134, 139]]], ["A limitation was the inability to analyse diagnostic intervals separately for participants referred via the two-week-wait pathway [27] because robust data sources for identifying them were unavailable to us.", [["participants", "SPECIES", 78, 90]]], ["We found conflicting evidence of changes in GP recording practice over time.", [["conflicting evidence of", "UNCERTAINTY", 9, 32]]], ["The proportion excluded for lack of coded features increased over time for some cancers, often coinciding with increased use of \"suspected-cancer\" codes.", [["cancers", "ANATOMY", 80, 87], ["cancer", "ANATOMY", 139, 145], ["cancers", "DISEASE", 80, 87], ["cancer", "DISEASE", 139, 145], ["cancers", "CANCER", 80, 87], ["-cancer", "CANCER", 138, 145], ["coded features", "PROBLEM", 36, 50], ["some cancers", "PROBLEM", 75, 87], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["cancers", "OBSERVATION", 80, 87], ["cancer", "OBSERVATION", 139, 145]]], ["The proportions of Old-and New-NICE groups over time were constant and the similar demographic details for included and excluded participants suggests no marked selection bias.", [["participants", "SPECIES", 129, 141], ["New-NICE groups", "TREATMENT", 27, 42], ["marked selection bias", "PROBLEM", 154, 175], ["proportions", "OBSERVATION_MODIFIER", 4, 15], ["New", "OBSERVATION_MODIFIER", 27, 30], ["no", "UNCERTAINTY", 151, 153], ["marked", "OBSERVATION_MODIFIER", 154, 160], ["selection bias", "OBSERVATION", 161, 175]]], ["We excluded approximately 26 % of participants for lack of coded features, a proportion consistent with evidence that coded CPRD data identifies 80 % of visible haematuria or jaundice events, and 60-70 % of abdominal pain in patients with pancreatic or bladder cancers [28] .", [["abdominal", "ANATOMY", 207, 216], ["pancreatic", "ANATOMY", 239, 249], ["bladder cancers", "ANATOMY", 253, 268], ["haematuria", "DISEASE", 161, 171], ["jaundice", "DISEASE", 175, 183], ["abdominal pain", "DISEASE", 207, 221], ["pancreatic or bladder cancers", "DISEASE", 239, 268], ["abdominal", "ORGANISM_SUBDIVISION", 207, 216], ["patients", "ORGANISM", 225, 233], ["pancreatic", "CANCER", 239, 249], ["bladder cancers", "CANCER", 253, 268], ["participants", "SPECIES", 34, 46], ["patients", "SPECIES", 225, 233], ["coded CPRD data", "TEST", 118, 133], ["visible haematuria", "PROBLEM", 153, 171], ["jaundice events", "PROBLEM", 175, 190], ["abdominal pain", "PROBLEM", 207, 221], ["pancreatic or bladder cancers", "PROBLEM", 239, 268], ["haematuria", "OBSERVATION", 161, 171], ["jaundice", "OBSERVATION", 175, 183], ["abdominal", "ANATOMY", 207, 216], ["pain", "OBSERVATION", 217, 221], ["pancreatic", "ANATOMY", 239, 249], ["bladder", "ANATOMY", 253, 260], ["cancers", "OBSERVATION", 261, 268]]], ["Of participants without recorded features, some will have presented at Emergency Departments without prior primary-care consultations [5, 29, 30] , some will had the information recorded in \"free text\" [28] , and others may have presented with features outside NICE guidance.", [["participants", "SPECIES", 3, 15]]], ["Such features were deliberately omitted from our study, as irrelevant to our focus on guidance revision.Strengths and limitationsOur analytical method allowed us to explore trends in the difference in diagnostic interval between groups aligned by their index feature(s) to the revised (New-NICE) or original (Old-NICE) guidance [20] .", [["our study", "TEST", 45, 54], ["guidance revision", "TREATMENT", 86, 103], ["original (Old-NICE) guidance", "TREATMENT", 299, 327]]], ["The method was derived to explore the time-varying and gradual impact of emerging clinical evidence that is legitimised into clinical practice by official guidance revision and implementation [20] .Comparison with existing literatureOur findings build on previous analysis of the original 2005 NICE guideline's impact on diagnostic interval [13] .", [["previous analysis", "TEST", 255, 272]]], ["Mean diagnostic interval for 15 UK cancers reduced between 2001-2 and 2007-8 by 5\u22c54 days (95 % CI: 2\u22c54-8\u22c55 days) from an initial value of 125\u22c58 days.", [["cancers", "ANATOMY", 35, 42], ["cancers", "DISEASE", 35, 42], ["cancers", "CANCER", 35, 42], ["15 UK cancers", "PROBLEM", 29, 42]]], ["Similar to our study, median diagnostic intervals were shortest for cancers commonly presenting with lumps/masses (e.g. 26 days for breast) and longest for cancers often presenting with symptoms shared with other diseases (e.g. 112 days in lung cancer) [13] .", [["cancers", "ANATOMY", 68, 75], ["lumps", "ANATOMY", 101, 106], ["masses", "ANATOMY", 107, 113], ["breast", "ANATOMY", 132, 138], ["cancers", "ANATOMY", 156, 163], ["lung cancer", "ANATOMY", 240, 251], ["cancers", "DISEASE", 68, 75], ["cancers", "DISEASE", 156, 163], ["lung cancer", "DISEASE", 240, 251], ["cancers", "CANCER", 68, 75], ["breast", "CANCER", 132, 138], ["cancers", "CANCER", 156, 163], ["lung cancer", "CANCER", 240, 251], ["our study", "TEST", 11, 20], ["cancers", "PROBLEM", 68, 75], ["lumps/masses", "PROBLEM", 101, 113], ["cancers", "PROBLEM", 156, 163], ["symptoms", "PROBLEM", 186, 194], ["other diseases", "PROBLEM", 207, 221], ["lung cancer", "PROBLEM", 240, 251], ["masses", "OBSERVATION", 107, 113], ["breast", "ANATOMY", 132, 138], ["lung", "ANATOMY", 240, 244], ["cancer", "OBSERVATION", 245, 251]]], ["Our estimates of diagnostic interval for colorectal cancer are similar to those obtained by the International Cancer Benchmarking Partnership using different data sources [31] .", [["colorectal cancer", "ANATOMY", 41, 58], ["colorectal cancer", "DISEASE", 41, 58], ["Cancer", "DISEASE", 110, 116], ["colorectal cancer", "CANCER", 41, 58], ["colorectal cancer", "PROBLEM", 41, 58], ["colorectal", "ANATOMY", 41, 51], ["cancer", "OBSERVATION", 52, 58], ["Cancer", "OBSERVATION", 110, 116]]], ["Our findings are consistent with the taxonomy of cancer symptom \"signatures\" and diagnostic difficulty [9] .", [["cancer", "ANATOMY", 49, 55], ["cancer", "DISEASE", 49, 55], ["cancer", "CANCER", 49, 55], ["cancer symptom", "PROBLEM", 49, 63], ["consistent with", "UNCERTAINTY", 17, 32], ["cancer", "OBSERVATION", 49, 55]]], ["Breast cancer had a narrow signature of a single alarm feature (breast lump) highly predictive of undiagnosed cancer plus the shortest diagnostic interval.", [["Breast cancer", "ANATOMY", 0, 13], ["breast lump", "ANATOMY", 64, 75], ["cancer", "ANATOMY", 110, 116], ["Breast cancer", "DISEASE", 0, 13], ["breast lump", "DISEASE", 64, 75], ["cancer", "DISEASE", 110, 116], ["Breast cancer", "CANCER", 0, 13], ["breast lump", "CANCER", 64, 75], ["cancer", "CANCER", 110, 116], ["Breast cancer", "PROBLEM", 0, 13], ["a single alarm feature (breast lump", "PROBLEM", 40, 75], ["undiagnosed cancer", "PROBLEM", 98, 116], ["cancer", "OBSERVATION", 7, 13], ["narrow signature", "OBSERVATION_MODIFIER", 20, 36], ["breast", "ANATOMY", 64, 70], ["lump", "OBSERVATION", 71, 75], ["undiagnosed", "OBSERVATION_MODIFIER", 98, 109], ["cancer", "OBSERVATION", 110, 116]]], ["In contrast, lung cancer had a very broad signature and the longest diagnostic interval.Comparison with existing literatureJensen et al. [27] investigated the impact of implementing a standardised cancer patient pathway in Denmark in 2007-2009.", [["lung cancer", "ANATOMY", 13, 24], ["cancer", "ANATOMY", 197, 203], ["lung cancer", "DISEASE", 13, 24], ["cancer", "DISEASE", 197, 203], ["lung cancer", "CANCER", 13, 24], ["cancer", "CANCER", 197, 203], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 204, 211], ["lung cancer", "PROBLEM", 13, 24], ["lung", "ANATOMY", 13, 17], ["cancer", "OBSERVATION", 18, 24], ["cancer", "OBSERVATION", 197, 203]]], ["Post-implementation diagnostic intervals were 15 (12) (13) (14) (15) (16) (17) days shorter than peri-implementation values for the 37 % of patients actually referred via a cancer pathway, but were 4 (1-7) days longer for the 63 % of patients diagnosed via other routes.", [["cancer", "ANATOMY", 173, 179], ["cancer", "DISEASE", 173, 179], ["patients", "ORGANISM", 140, 148], ["cancer", "CANCER", 173, 179], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 234, 242], ["diagnostic intervals", "TEST", 20, 40], ["peri-implementation values", "TEST", 97, 123]]], ["The authors concluded that the cancer pathways expedited diagnosis for a minority of patients.Clinical interpretation and policy implications of the findingsThe relationship between diagnostic interval and mortality (and stage) is U-shaped, reflecting confounding by indication [32] [33] [34] .", [["cancer", "ANATOMY", 31, 37], ["cancer", "DISEASE", 31, 37], ["cancer", "CANCER", 31, 37], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["the cancer pathways", "PROBLEM", 27, 46], ["the findings", "TEST", 145, 157], ["cancer", "OBSERVATION", 31, 37], ["U-shaped", "OBSERVATION_MODIFIER", 231, 239]]], ["Patients with advanced tumours generally receive an expedited diagnosis (possibly as an emergency) and have poor outcomes because of their high inherent mortality: the so-called \"sick-quick\".", [["tumours", "ANATOMY", 23, 30], ["tumours", "DISEASE", 23, 30], ["Patients", "ORGANISM", 0, 8], ["tumours", "CANCER", 23, 30], ["Patients", "SPECIES", 0, 8], ["advanced tumours", "PROBLEM", 14, 30]]], ["Conversely, patients presenting with vague symptoms usually have longer diagnostic intervals, and higher mortalitythought to reflect the impact of diagnostic delay, particularly between referral and diagnosis [32] [33] [34] [35] .", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["vague symptoms", "PROBLEM", 37, 51]]], ["The revised guidance aimed to benefit patients by legitimising doctors to investigate at a lower risk of undiagnosed cancer.", [["cancer", "ANATOMY", 117, 123], ["cancer", "DISEASE", 117, 123], ["patients", "ORGANISM", 38, 46], ["cancer", "CANCER", 117, 123], ["patients", "SPECIES", 38, 46], ["undiagnosed cancer", "PROBLEM", 105, 123], ["undiagnosed", "OBSERVATION_MODIFIER", 105, 116], ["cancer", "OBSERVATION", 117, 123]]], ["In this study, for colorectal cancer, New-NICE diagnostic intervals reduced relative to Old-NICE interval after guidance revision.", [["colorectal cancer", "ANATOMY", 19, 36], ["colorectal cancer", "DISEASE", 19, 36], ["colorectal cancer", "CANCER", 19, 36], ["this study", "TEST", 3, 13], ["colorectal cancer", "PROBLEM", 19, 36], ["guidance revision", "TREATMENT", 112, 129], ["colorectal", "ANATOMY", 19, 29], ["cancer", "OBSERVATION", 30, 36]]], ["This is consistent with general practitioners acting on the vague (\"New-NICE\") features introduced during guidance revision.", [["guidance revision", "TREATMENT", 106, 123], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Indeed, the proportion diagnosed via the urgent cancer referral pathway increased from 30 % (95 %CI 29 %-30 %) in 2013 to 33 % (33 %-34 %) in 2016, spanning the period of guidance revision [36] .Clinical interpretation and policy implications of the findingsOur findings of increasing Old-NICE diagnostic intervals over time may reflect growing strain on NHS diagnostic-endoscopy and imaging services [37], as demand for all indications (not just cancer) rises [38] , particularly if CT-based targeted screening for lung cancer is introduced [39] .", [["cancer", "ANATOMY", 48, 54], ["cancer", "ANATOMY", 447, 453], ["lung cancer", "ANATOMY", 516, 527], ["cancer", "DISEASE", 48, 54], ["cancer", "DISEASE", 447, 453], ["lung cancer", "DISEASE", 516, 527], ["cancer", "CANCER", 48, 54], ["cancer", "CANCER", 447, 453], ["lung cancer", "CANCER", 516, 527], ["CI", "TEST", 97, 99], ["guidance revision", "TREATMENT", 171, 188], ["the findings", "TEST", 246, 258], ["growing strain", "PROBLEM", 337, 351], ["NHS diagnostic", "TEST", 355, 369], ["endoscopy", "TEST", 370, 379], ["imaging services", "TEST", 384, 400], ["CT", "TEST", 484, 486], ["targeted screening", "TEST", 493, 511], ["lung cancer", "PROBLEM", 516, 527], ["cancer", "OBSERVATION", 48, 54], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["increasing", "OBSERVATION_MODIFIER", 274, 284], ["lung", "ANATOMY", 516, 520], ["cancer", "OBSERVATION", 521, 527]]], ["In 2018, inadequate diagnostic capacity was considered a rate-limiting step in the diagnostic pathway [40] , and a negative impact of Covid-19 on diagnostic services is already becoming apparent [41] .ConclusionsWe conclude that scope remains to reduce time to cancer diagnosis.", [["cancer", "ANATOMY", 261, 267], ["cancer", "DISEASE", 261, 267], ["cancer", "CANCER", 261, 267], ["a rate", "TEST", 55, 61], ["Covid", "TEST", 134, 139], ["cancer", "OBSERVATION", 261, 267]]], ["The revised colorectal cancer diagnostic guidance may be exerting a downward pressure on time to diagnosis of this cancer, through impacts on the vague features of cancer introduced during guidance revision.", [["colorectal cancer", "ANATOMY", 12, 29], ["cancer", "ANATOMY", 115, 121], ["cancer", "ANATOMY", 164, 170], ["colorectal cancer", "DISEASE", 12, 29], ["cancer", "DISEASE", 115, 121], ["cancer", "DISEASE", 164, 170], ["colorectal cancer", "CANCER", 12, 29], ["cancer", "CANCER", 115, 121], ["cancer", "CANCER", 164, 170], ["The revised colorectal cancer", "PROBLEM", 0, 29], ["a downward pressure", "PROBLEM", 66, 85], ["this cancer", "PROBLEM", 110, 121], ["the vague features of cancer", "PROBLEM", 142, 170], ["guidance revision", "TREATMENT", 189, 206], ["colorectal", "ANATOMY", 12, 22], ["cancer", "OBSERVATION", 23, 29], ["downward", "OBSERVATION_MODIFIER", 68, 76], ["pressure", "OBSERVATION_MODIFIER", 77, 85], ["cancer", "OBSERVATION", 115, 121], ["vague", "OBSERVATION_MODIFIER", 146, 151], ["cancer", "OBSERVATION", 164, 170]]], ["Future studies using causal analysis should examine the impact of guidance revision on staging at diagnosis and survival for all cancers, and the possible downstream effects on investigative services.", [["cancers", "ANATOMY", 129, 136], ["cancers", "DISEASE", 129, 136], ["cancers", "CANCER", 129, 136], ["Future studies", "TEST", 0, 14], ["causal analysis", "TEST", 21, 36], ["guidance revision", "TREATMENT", 66, 83], ["staging", "TEST", 87, 94], ["all cancers", "PROBLEM", 125, 136], ["investigative services", "TREATMENT", 177, 199], ["cancers", "OBSERVATION", 129, 136]]], ["Policymakers are urged to enhance cancer diagnostic services so that they do not pose a rate-limiting step in the diagnostic pathway, and to protect them from the pressures of Covid-19.FundingThis study was funded by Cancer Research UK [C56843/A21550], who were not involved in any aspect of the conduct of the study, in writing the manuscript or in the decision to submit for publication.", [["cancer", "ANATOMY", 34, 40], ["cancer", "DISEASE", 34, 40], ["Cancer", "DISEASE", 217, 223], ["cancer", "CANCER", 34, 40], ["the pressures", "TEST", 159, 172], ["Covid", "TEST", 176, 181], ["This study", "TEST", 192, 202], ["the study", "TEST", 307, 316], ["Cancer", "OBSERVATION", 217, 223]]], ["This research is also linked to the CanTest Collaborative, which is funded by Cancer Research UK [C8640/A23385], of which WH is co-Director, GL is Associate Director, AS is Senior Faculty, and SP is an affiliated ResearchDeclaration of Competing InterestWH was clinical lead of the guideline development group which formulated the revised NICE suspected-cancer guidelines (NG12).", [["cancer", "ANATOMY", 354, 360], ["Cancer", "DISEASE", 78, 84], ["cancer", "DISEASE", 354, 360], ["cancer", "CANCER", 354, 360], ["Cancer", "OBSERVATION", 78, 84], ["cancer", "OBSERVATION", 354, 360]]]]}